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Abstract 
 
In this dissertation I assessed three distinct policy questions: the implications of introducing a 
new tuberculosis diagnostic in southern Africa, the potential value of research related to HIV 
treatment policy in South Africa, and the causal effect of state cigarette taxes imposed between 
1996 and 2013 on health outcomes in the United States.  
In Chapter 1 I investigated use of a new TB diagnostic, Xpert MTB/RIF, to replace sputum 
smear-based diagnostic algorithms in southern Africa. Analyses were undertaken using a dynamic 
mathematical model, taking account of TB transmission and natural history, HIV epidemiology, TB 
drug resistance, and disease control interventions. Results suggest Xpert may substantially reduce 
TB morbidity and mortality, and modestly reduce transmission, while significantly increasing 
demands on healthcare resources. Xpert adoption was estimated to cost $711 to $1,083 per DALY 
averted, representing good value for money according to conventional benchmarks.  
In Chapter 2 I estimated the value of new research on various targets relevant to HIV 
treatment policy in South Africa. I implemented the analysis with a mathematical model of HIV 
epidemiology, simulating HIV transmission, disease progression, and receipt of treatment. I used 
Value of Information (VOI) methods to identify priority research areas, based on the welfare gains 
possible by obtaining better information prior to decision-making. High priority research targets 
included issues of cost and implementation, relative infectiousness during late HIV, the reduction in iv 
 
infectiousness following treatment initiation, and the therapeutic benefits of early treatment 
initiation.  
In Chapter 3 I estimated how changes in state cigarette taxes over the period 1996-2013 
affected smoking behavior and health outcomes in the United States. The causal effect of tax 
changes were estimated in the context of a demographic model directly linking smoking behavior 
with subsequent mortality risks, using data from the Behavioral Risk Factor Surveillance System. 
Results suggest national cigarette consumption by 2013 was 4.0% lower (3.3, 4.6) compared to a 
counterfactual with no new state cigarette taxes after 1996, averting 27 thousand (22, 34) deaths 
and producing 119 thousand (92, 151) extra life-years lived. The health impact of these taxes was 
projected to be far greater in future years. 
 
 
 v 
 
Table of Contents  
List of Tables .......................................................................................................................................................... ix 
List of Figures ...........................................................................................................................................................x 
Acknowledgements  ............................................................................................................................................ xiv 
Chapter 1.  Dissertation Overview .................................................................................................................. 1 
1.1.  Chapter 2: Population health impact and cost-effectiveness of tuberculosis diagnosis with 
Xpert MTB/RIF, a dynamic simulation and economic evaluation ................................................. 3 
1.2.  Chapter 2: Value of new research to inform HIV control policy in South Africa ..................... 5 
1.3.  Chapter 3: Estimating the health impact of recent changes in state-level cigarette taxes .. 8 
1.4.  Citations ............................................................................................................................................................... 11 
Chapter 2.  Population health impact and cost-effectiveness of tuberculosis 
diagnosis with Xpert MTB/RIF, a dynamic simulation and 
economic evaluation ................................................................................................................... 16 
Abstract .......................................................................................................................................................................... 17 
2.1.  Introduction ....................................................................................................................................................... 19 
2.2.  Methods ............................................................................................................................................................... 20 
2.2.1.  Overview ................................................................................................................................................ 20 
2.2.2.  Diagnostic strategies ........................................................................................................................ 21 
2.2.3.  Modeling approach ............................................................................................................................ 23 
2.2.4.  TB diagnosis and treatment........................................................................................................... 27 
2.2.5.  Impact of diagnostic algorithms on TB epidemiology ........................................................ 28 
2.2.6.  Estimation approach......................................................................................................................... 28 
2.2.7.  Model parameter values.................................................................................................................. 29 
2.2.8.  Measurement of resource use and costs .................................................................................. 33 
2.2.9.  Outcomes ............................................................................................................................................... 34 
2.2.10.  Sensitivity analysis ............................................................................................................................ 35 
2.3.  Results .................................................................................................................................................................. 36 vi 
 
2.3.1.  Epidemiological projections under the current diagnostic algorithm ......................... 36 
2.3.2.  Performance of diagnostic algorithms ...................................................................................... 38 
2.3.3.  Population health impact of introducing Xpert ..................................................................... 39 
2.3.4.  Health system costs of introducing Xpert ................................................................................ 42 
2.3.5.  Cost-effectiveness of Xpert strategy versus the status quo .............................................. 43 
2.3.6.  Sensitivity analyses ........................................................................................................................... 46 
2.4.  Discussion ........................................................................................................................................................... 50 
2.5.  Citations ............................................................................................................................................................... 57 
2.6.  Additional information .................................................................................................................................. 68 
2.6.1.  Model overview and structure ..................................................................................................... 68 
2.6.2.  Transitions between model states and subdivisions .......................................................... 70 
2.6.3.  Model parameterization .................................................................................................................. 75 
2.6.4.  Model calibration ............................................................................................................................... 90 
2.6.5.  Sensitivity and uncertainty analyses ......................................................................................... 94 
2.6.6.  References .......................................................................................................................................... 124 
Chapter 3.  Value of new research to inform HIV control policy in South Africa ...................... 134 
Abstract ....................................................................................................................................................................... 135 
3.1.  Introduction .................................................................................................................................................... 137 
3.2.  Methods ............................................................................................................................................................ 142 
3.2.1.  General approach ............................................................................................................................ 142 
3.2.2.  Policy options ................................................................................................................................... 142 
3.2.3.  Model overview ............................................................................................................................... 144 
3.2.4.  Model structure ............................................................................................................................... 144 
3.2.5.  Sexual networks .............................................................................................................................. 145 
3.2.6.  HIV transmission ............................................................................................................................. 151 
3.2.7.  HIV progression ............................................................................................................................... 153 
3.2.8.  Model entry, aging, and mortality ............................................................................................ 153 
3.2.9.  HIV care and treatment ................................................................................................................ 154 
3.2.10.  Simulation .......................................................................................................................................... 155 
3.2.11.  Parameter estimates and calibration...................................................................................... 156 vii 
 
3.2.12.  Estimating costs ............................................................................................................................... 172 
3.2.13.  Estimating health outcomes ....................................................................................................... 174 
3.2.14.  Value function and decision rule .............................................................................................. 175 
3.2.15.  Value of information analysis .................................................................................................... 176 
3.2.16.  Sensitivity analyses ........................................................................................................................ 181 
3.3.  Results ............................................................................................................................................................... 182 
3.3.1.  Epidemiological estimates and projections ......................................................................... 182 
3.3.2.  Cost projections ............................................................................................................................... 190 
3.3.3.  Decision-making with no new information.......................................................................... 193 
3.3.4.  Decision uncertainty ...................................................................................................................... 202 
3.3.5.  Value of information ...................................................................................................................... 204 
3.4.  Discussion ........................................................................................................................................................ 217 
3.5.  Citations ............................................................................................................................................................ 225 
Chapter 4.  Estimating the health impact of recent changes in state-level 
cigarette taxes ............................................................................................................................ 236 
Abstract ....................................................................................................................................................................... 237 
4.1.  Background ..................................................................................................................................................... 239 
4.2.  Methods ............................................................................................................................................................ 241 
4.2.1.  General approach ............................................................................................................................ 241 
4.2.2.  Identification strategy ................................................................................................................... 242 
4.2.3.  Simulation model ............................................................................................................................ 243 
4.2.4.  Parameterization............................................................................................................................. 245 
4.2.5.  Data sources ...................................................................................................................................... 255 
4.2.6.  Parameter estimation  .................................................................................................................... 265 
4.2.7.  Validation ........................................................................................................................................... 273 
4.2.8.  Comparison of alternative cigarette tax scenarios  ............................................................ 274 
4.3.  Results ............................................................................................................................................................... 276 
4.3.1.  Fit to BRFSS smoking data .......................................................................................................... 276 
4.3.2.  Validation ........................................................................................................................................... 281 
4.3.3.  Parameter estimates for predictors of smoking behavior ............................................. 285 viii 
 
4.3.4.  Causal effects of state cigarette taxes introduced over the period 1995-2013..... 286 
4.3.5.  Price elasticity of demand ........................................................................................................... 292 
4.3.6.  Sensitivity analyses ........................................................................................................................ 293 
4.4.  Discussion ........................................................................................................................................................ 295 
4.5.  Citations ............................................................................................................................................................ 303 
 
   ix 
 
List of Tables 
Table 2.1.   Selected model parameter values and ranges ........................................................................... 30 
Table 2.2.   Average programmatic outcomes and costs over 10 years following choice of 
strategy (2011 US dollars) ................................................................................................................. 39 
Table 2.3.   Cost-effectiveness results for Xpert compared to status quo in southern Africa ........ 44 
Table 2.4.    Definition of core model states and transitions ........................................................................ 71 
Table 2.5.   Base-case parameter values and ranges ...................................................................................... 81 
Table 2.6.   Univariate sensitivity analysis, Botswana (base-case ICER =$1,289) .............................. 95 
Table 2.7.   Univariate sensitivity analysis, Lesotho (base-case ICER =$1071) .................................. 99 
Table 2.8.   Univariate sensitivity analysis, Namibia (base-case ICER =$863) ................................. 103 
Table 2.9.   Univariate sensitivity analysis, South Africa (base-case ICER =$986) ......................... 107 
Table 2.10.   Univariate sensitivity analysis, Swaziland (base-case ICER =$770)  .............................. 111 
Table 3.1.   Prior distributions for model parameters ................................................................................ 158 
Table 3.2.   Incremental costs, DALYs averted, and cost-effectiveness ratios (US dollars per 
DALY averted) of competing policy options, assessed over both extended and 
truncated time horizons ................................................................................................................... 194 
Table 4.1.   Crosswalk between smoking categories used in the BRFSS and those reported in 
Thun et al., for the purposes of estimating smoking deleted mortality rates ............ 262 
Table 4.2.   Value of anti-smoking sentiment index for each state ........................................................ 265 
Table 4.3.   Prior distributions for model parameters ................................................................................ 268 
Table 4.4.   Posterior mean values for predictors of smoking behavior .............................................. 285 
Table 4.5.   Changes in lifetime smoking behavior and life expectancy for the 2013 national birth 
cohort exposed to 1996 tax levels as compared to 2013 tax levels ............................... 292 
Table 4.6.   Comparison of parameter estimates and major outcomes from different approaches 
to operationalizing the effect of cigarette taxes on smoking behavior ......................... 294 
 
 x 
 
List of Figures 
Figure 2.1.   Status quo and Xpert diagnostic algorithms ............................................................................... 23 
Figure 2.2.   Model states, subdivisions, and transitions ................................................................................ 25 
Figure 2.3.   Estimated and projected TB prevalence, TB incidence, and multidrug-resistant TB 
prevalence in southern Africa under status quo diagnostic algorithm, 1990–2032 . 37 
Figure 2.4.   Epidemiologic outcomes in Xpert and status quo scenarios, 2012–2032  ...................... 40 
Figure 2.5.   Incremental difference in epidemiologic outcomes between Xpert and status quo 
scenarios, 2012-2032 ........................................................................................................................... 41 
Figure 2.6.   Incremental costs of Xpert strategy (based on US$30 Xpert per-test cost) compared 
to status quo strategy, by cost category, 2012–2032 (2011 US dollars) ........................ 42 
Figure 2.7.   Cost-effectiveness of Xpert strategy compared to status quo strategy in five southern 
African countries (2011 US dollars)............................................................................................... 45 
Figure 2.8.   Results from univariate sensitivity analyses, showing 10 parameters with greatest 
influence on the cost-effectiveness of Xpert compared to status quo, South Africa .. 46 
Figure 2.9.   Partial rank correlation coefficients for 10 parameters with greatest influence on the 
cost-effectiveness of Xpert compared to status quo, South Africa, 10-year time 
horizon ....................................................................................................................................................... 47 
Figure 2.10.   Cost-effectiveness acceptability curves showing probability that Xpert strategy is 
cost-effective as a function of willingness to pay for health benefits ............................... 50 
Figure 2.11.   Time-varying parameter inputs for TB diagnosis and treatment  ...................................... 90 
Figure 2.12.   Calibrated outcomes for South Africa based on sampling / importance resampling 93 
Figure 2.13.   Three-way sensitivity analyses showing effects of changes in culture and DST 
coverage on major study outcomes in Botswana .................................................................. 119 
Figure 2.14.   Three-way sensitivity analyses showing effects of changes in culture and DST 
coverage on major study outcomes in Lesotho ...................................................................... 120 
Figure 2.15.   Three-way sensitivity analyses showing effects of changes in culture and DST 
coverage on major study outcomes in Namibia ..................................................................... 121 
Figure 2.16.   Three-way sensitivity analyses showing effects of changes in culture and DST 
coverage on major study outcomes in South Africa ............................................................. 122 xi 
 
Figure 2.17.   Three-way sensitivity analyses showing effects of changes in culture and DST 
coverage on major study outcomes in Swaziland ................................................................. 123 
Figure 3.1.   Schematic of model compartments, transitions, and sexual interactions ................... 145 
Figure 3.2.   Mixing matrix for casual sex (M) .................................................................................................. 150 
Figure 3.3.   Prior distributions for time-varying model parameters .................................................... 162 
Figure 3.4.   Data used for HIV prevalence likelihood ................................................................................... 165 
Figure 3.5.   Data used for CD4 cell count distribution likelihood ........................................................... 167 
Figure 3.6.   Results of calibrated model vs. calibration data .................................................................... 171 
Figure 3.7.   Epidemiological outcomes, 1985-2032, with current ART eligibility and coverage 
policy ........................................................................................................................................................ 183 
Figure 3.8.   Major epidemiological outcomes at 5 and 20 years after policy introduction .......... 186 
Figure 3.9.   Total DALYs averted, and DALYs averted by therapeutic effects alone (i.e., excluding 
prevention benefits) for each policy compared to to policy A2 ...................................... 189 
Figure 3.10.   Disaggregation of total incremental costs by year and by cost category, for four 
policy options as compared to continuation of current eligibility and coverage 
(policy A2) ............................................................................................................................................. 191 
Figure 3.11.    Summary estimates of total incremental costs over 20 years for competing policies, 
compared to continuation of current ART eligibility and coverage (policy A2)  ....... 192 
Figure 3.12.   Cost-effectiveness of competing policies, assessed over extended and truncated time 
horizons .................................................................................................................................................. 195 
Figure 3.13.   Change in costs and health benefits as one policy dimension is expanded while the 
other is held fixed, for both truncated and extended time horizons ............................. 197 
Figure 3.14.   Cost-effectiveness of competing policies with different discount rates applied to 
future costs and health benefits  .................................................................................................... 201 
Figure 3.15.   Cost-effectiveness acceptability curves for competing policies ...................................... 203 
Figure 3.16.   Value of perfect information, and probability that new information will lead to a 
different policy being chosen, as a function of willingness-to-pay and under 
truncated and extended time horizons ...................................................................................... 205 
Figure 3.17.   Expected value of partial perfect information for individual model parameters .... 207 xii 
 
Figure 3.18.   Expected value of partial perfect information on relative infectiousness by disease 
stage  .......................................................................................................................................................... 209 
Figure 3.19.   Expected value of partial perfect information, summary rankings ............................... 211 
Figure 3.20.   Cost-effectiveness results for a choice set including only policies A2, B2 and C2 ... 213 
Figure 3.21.   EVPI for a choice set including only policies A2, B2 and C2, compared to EVPI 
calculated for the original choice set .......................................................................................... 215 
Figure 3.22.   EVPPI for a choice set including only policies A2, B2 and C2, compared to EVPI 
calculated for the original choice set .......................................................................................... 216 
Figure 4.1.   Directed acyclic graph describing causal relationships assumed in this analysis ... 243 
Figure 4.2.   Schematic of simulation model, showing model compartments and transitions for a 
single cohort .......................................................................................................................................... 244 
Figure 4.3.   Average number of cigarettes smoked each day for individuals reporting smoking 
every day, as a function of age, sex, and BRFSS survey year ............................................. 256 
Figure 4.4.   Estimates for the mean and posterior intervals of major parameters and outcomes 
for successive iterations of the IMIS algorithm ...................................................................... 273 
Figure 4.5.   Comparison of modeled estimates to BRFSS data on smoking behavior, as a function 
of age and year ..................................................................................................................................... 278 
Figure 4.6.   Comparison of modeled estimates to BRFSS data on smoking behavior, as a function 
of year and state .................................................................................................................................. 279 
Figure 4.7.   Comparison of modeled estimates to BRFSS data on time since quitting in former 
smokers, as a function of age and year ...................................................................................... 280 
Figure 4.8.   Comparison of modeled estimates to independent data on smoking prevalence from 
the Tobacco Use Supplement of the Current Population Survey .................................... 282 
Figure 4.9.   All-cause mortality rate for 2010 by age group and sex, comparing modeled 
estimates to published estimates from the CDC’s National Vital Statistics System 283 
Figure 4.10.   Population size and distribution in 2010, comparing modeled estimates to data from 
the 2010 U.S. Census .......................................................................................................................... 284 
Figure 4.11.   Change in various measures of smoking behavior (national-average) due to 
increases in state cigarette taxes over the period 1996-2013 ......................................... 287 xiii 
 
Figure 4.12.   Reductions in state-level smoking prevalence due to increases in state cigarette 
taxes over the period 1996-2013 ................................................................................................. 288 
Figure 4.13.   Changes in major behavioral and health outcomes over 1996-2013 due to increase 
in state cigarette taxes, disaggregated by age group............................................................ 289 
Figure 4.14.   Projected changes in major behavioral and health outcomes over the next four 
decades due to increase in state cigarette taxes introduced between 1996 and 2013, 
by decade ................................................................................................................................................ 291 
 
 
   xiv 
 
Acknowledgements 
Firstly, I would like to thank Joshua Salomon, my dissertation chair. Josh somehow managed to be 
mentor and comrade at the same time, and I am deeply grateful for both.  I would like to thank the 
other members of my committee – Milt Weinstein, for taking my sometimes loosely developed 
arguments and helping to add structure and sense, and Tom McGuire, for providing a willing ear 
and deep thought for any number of proposals trying to build an analysis that bridged disciplines.  
I would also like to thank others who helped me develop or implement the analyses in this 
dissertation – Megan Murray, Barry Bloom, Leonid Chindelevitch, Dan Hogan, and many others.  In 
particular I would like to thank Ted Cohen, who helped teach me both the fine detail and broad 
picture of TB epidemiological modelling, and who is generally a great guy. 
I would like to thank the funding bodies that allowed me to devote my time to this work: the 
National Libraries of Medicine, the MGH Program in Cancer Outcomes Research Training, the 
Jeremy Knowles Graduate Fellowship, UNITAID, the HIV Modelling Consortium and the TB 
Modelling and Analysis Consortium. In addition to financial support, I would like to acknowledge 
the feedback and collegiality I received from the MGH Institute of Technology Assessment as well as 
the TB and HIV modeling consortia. The ability to share my work with interested experts helped to 
make it stronger. 
I would like to thank the fellow students who provided companionship on a long journey – Mike 
Botta, Rebecca Cadigan, Laura Garabedian, Keren Ladin, Jessica Perkins, Tisa Sherry, Zirui Song, Sae 
Takeda, Melissa Valentine, and Beth Wikler within my cohort, and Dorothy Romanus, Sorapop 
Kiatpongsan, Paula Chu, Craig White, Arielle Bensimon, Mark Shrime, Emily Burger, and Lina Song 
within Decision Sciences. I would also like to thank my peer mentoring group—Ankur Pandya, 
Natalie Carvalho, Brendan Saloner, Tara Lavelle and Davene Wright—for providing a lesson in how xv 
 
to get it done and letting me know that something actually happens after graduation. I would like to 
thank the Health Policy program office, Joan, Debbie, and Ayres, for being ever helpful and 
supportive, and Joe Newhouse and the rest of the Health Policy PhD program for providing an 
intellectually vigorous environment.  I would like to thank Sue Goldie, Jim Hammitt, Stephen Resch, 
Jane Kim, Jennifer Yeh, Eve Wittenberg, Uwe Siebert, Myriam Hunink, and Natasha Stout, for 
counsel and encouragement at various points over the past years, and the CHDS community—
including Christine Bell, Jeannie Millar, Steven Sweet and others—for providing a roof over my 
head and a happy place to work. 
I would also like to thank colleagues and mentors in Atlanta—Deborah MacFarland, John Blandford, 
and others—who helped me realize a PhD might be a good idea in the first place.  
I would like to thank my family – Will, Di, Oli, and Sarah, as well as Jack and Rumi. To my wife 
Michele, you make the sun come up in the morning and give food its flavor. I cannot thank you 
enough for your love and companionship, but over the years I will try. 
Finally, I would like to dedicate this dissertation to my children Simon and Hazel. You certainly did 
not make this any easier, but I feel like I won the lottery with both of you. Don’t prove me wrong. 
 
 1 
 
 
 
  Dissertation Overview   Chapter 1.
   2 
 
In order to make good public policy, decision-makers must understand the consequences of 
competing policy options. In evaluating these options, it is rare to have all the information that 
might be desired – the available information about an intervention might be derived from a setting 
very different to that anticipated for the new policy, and understanding long-term outcomes may 
require piecing together information about many intermediate steps. Each of the three chapters in 
this dissertation takes a formal approach to combining available data to estimate policy outcomes. 
Addressing very different policy questions, each chapter develops a mathematical model describing 
how quantities about which we have some understanding—such as historical time trends in disease 
epidemiology, or the individual-level effects of an intervention under defined conditions—combine 
to generate population-level outcomes. This approach brings with it both weaknesses and 
strengths. From the outset, all of these mathematical models are known to be wrong, in the sense 
that they involve simplification of complex disease processes, and ignore various sources of 
heterogeneity in how individuals will be affected by a given policy. The challenge for policy analysis 
using these models is to produce reasonable estimates about quantities of interest, despite the 
simplifications. Of course, any attempt to predict future events requires assumptions, even if these 
are not plainly stated. A strength of the approach adopted for these analyses comes from the 
opportunity to examine and test modeling assumptions. By modeling the various processes that 
generate long-term outcomes, mechanistic models allow many different intermediate outcomes to 
be estimated. Even though we may not have empirical data on long-term outcomes to validate 
policy predictions, we often have data on these intermediate outcomes, which can be used to both 
calibrate model inputs and identify modeling assumptions that are inconsistent with reality, 
providing the opportunity for iterative model refinement.    3 
 
 Chapter 2: Population health impact and cost-effectiveness of tuberculosis diagnosis  1.1.
with Xpert MTB/RIF, a dynamic simulation and economic evaluation 
In Chapter 1 I investigate the consequences of introducing new technology for diagnosis of 
tuberculosis (TB) in southern African countries. TB remains a leading cause of mortality and 
morbidity in southern Africa [1]. Although significant advances have been made, continued 
progress in TB control is threatened by the inadequacy of existing diagnosis. Diagnostic algorithms 
generally rely on sputum smear microscopy, which has limited sensitivity, especially among HIV-
infected patients [2–4]. Recently, the Xpert MTB/RIF automated DNA test has been shown to 
provide rapid and sensitive detection of TB and rifampicin (RIF) resistance [5,6], and can be 
implemented by relatively unskilled healthcare workers [5,7]. In December 2010, the WHO 
recommended that Xpert be used for TB diagnosis where MDR-TB (multidrug resistant-TB) or HIV 
infection are suspected [8], and many countries have begun to adopt this technology [9].  
In this study I estimated the potential health and economic consequences of introducing Xpert in 
southern African countries, which are characterized by a high prevalence of HIV infection and 
growing TB drug resistance. I compared two alternative strategies for diagnosing TB, the first based 
on the earlier diagnostic algorithms relying on sputum smear microscopy, and the second based on 
implementing Xpert in accordance with new WHO recommendations. Comparisons between these 
two strategies were made using a dynamic mathematical model of TB, which took account of key 
features of TB transmission dynamics and natural history, interactions with HIV infection, TB drug 
resistance patterns, and trends in TB and HIV control interventions. A Bayesian approach was used 
to calibrate model parameters to reported data on TB prevalence, incidence, and the distribution of 
drug resistance in each country [10]. Model simulations were undertaken for five southern African 
countries: Botswana, Lesotho, Namibia, South Africa, and Swaziland. The analysis assessed changes 
in epidemiological outcomes and health system costs over 10-year and 20-year time horizons, as 4 
 
well as the incremental cost-effectiveness ratio (ICER) of the Xpert strategy compared to the 
current algorithm. 
The results of this analysis indicated that the introduction of Xpert has the potential to substantially 
reduce TB morbidity and mortality in southern Africa, with TB prevalence estimated to be 28% 
lower (95% posterior interval: 14, 40) and TB mortality 21% lower (10, 32) 10 years after Xpert 
introduction, as compared to outcomes estimated for the continued use of earlier diagnostics. For 
individuals with smear-negative TB, the benefits of Xpert implementation would be immediate, 
leading to the diagnosis and early treatment of many individuals who would be missed by the 
conventional diagnostic algorithm. Over a longer time frame, the introduction of Xpert would 
reduce transmission, but these secondary effects are smaller than might have been anticipated, and 
TB incidence after 10 years was estimated to be 6% lower (2, 13) under the Xpert scenario as 
compared to the status quo. As a consequence, the analysis suggests that TB incidence would 
remain substantial after three decades of Xpert use, in the absence of other modifications to the TB 
control strategy.  
Results also suggested that Xpert adoption would significantly increase demands on healthcare 
resources. While the direct costs of the Xpert technology itself are not small, a major financial 
impact of Xpert introduction would come from increased resource requirements in HIV treatment 
programs, with prompt TB treatment extending survival among TB/HIV-coinfected individuals. At 
10 years after Xpert introduction, HIV treatment costs are estimated to comprise 58% (95% CI: 40–
72) of the total incremental costs associated with the Xpert strategy. Treatment of MDR-TB 
represents another major cost, as the number of cases of MDR-TB identified increases two- to 
three-fold with Xpert introduction. Compared to continued use of earlier diagnostics, the 
introduction of Xpert was estimated to have an ICER that ranged from $711 to $1,083 per DALY 
averted, depending on the time horizon and assumptions about the Xpert test cost. These ratios 5 
 
were generally robust to changes in analytic assumptions, though did rise substantially in scenarios 
that assumed much higher availability of TB culture (a more sensitive diagnostic test than sputum 
smear, but with long turn-around times) under the status quo. 
While the ICERs estimated in this study are higher than those estimated by an earlier analysis [11], 
they still suggest that the introduction of Xpert represents good value for money according to 
typical international benchmarks. However, these results also raise important questions of 
affordability, due to the additional demand for various treatment services. It is likely that existing 
resources will be called upon to support the introduction of Xpert and the cascade of 
complementary services this will trigger, and our findings underscore the concern raised by other 
commentators regarding the possible pitfalls of introducing Xpert into health systems that are 
already facing capacity constraints [12,13]. 
 Chapter 2: Value of new research to inform HIV control policy in South Africa  1.2.
In Chapter 2 I report analyses to estimate the relative value of various targets for new research 
related to HIV control in developing countries. Despite unprecedented funding levels, many highly-
affected countries are not yet able to provide antiretroviral therapy (ART) to all who might benefit 
[14]. While the therapeutic benefits of ART are well established [15], there is increasing evidence 
that ART may also reduce HIV transmission [16]. As a consequence, policy makers are considering 
expanded ART eligibility criteria [17]. Expanded eligibility will come at the expense of other care 
unless further funding is available [18], and must compete with efforts to increase enrollment 
among groups already eligible according to current guidelines. Recent modeled analyses suggest 
uncertainty about the optimal approach to expanding ART programs according to cost-effectiveness 
criteria [19], and this uncertainty hinders the development of long-term HIV control strategy [20]. 
Uncertainty about optimal ART policy is partially due to weaknesses in the evidence base used to 
understand the consequences of HIV treatment policy. A number of specific issues are particularly 6 
 
uncertain, including the magnitude of incidence reductions associated with ART as implemented in 
routine programs [21], the therapeutic benefits of initiating ART at high CD4 cell count [22], the 
relative importance of early HIV infection to epidemic dynamics [23], and the cost and 
implementation challenges associated with expanding different programmatic components [21,24].  
This study attempts to inform decisions about new HIV research to inform ART policy, using value 
of information (VOI) methods to identify high-priority research targets [25–27]. To implement this 
analysis I developed a mathematical model to represent an HIV epidemic in the South African adult 
population, simulating transmission of HIV infection through durable sexual partnerships and 
casual sexual contacts, the progression of HIV disease for HIV-infected individuals, and initiation 
and receipt of antiretroviral therapy. I used this model to project the costs and health outcomes 
resulting from various policy options that might be adopted by the South African national HIV 
control program, and used Monte Carlo methods to quantify how uncertainty in epidemiology, 
programmatic performance and cost translated into uncertainty in modeled outcomes. These 
results were then used to estimate VOI for individual parameters or groups of parameters. Finally, I 
compared VOI estimates for different parameters to draw conclusions about high-priority research 
targets for informing ART policy. 
This analysis suggested that scaling-up ART would substantially reduce the burden of HIV in South 
Africa. Over the next 20 years the most aggressive scale-up policy was estimated to reduce 
cumulative incidence by 58% (44, 68) and reduce HIV mortality by 34% (29, 38), as compared to 
continuation of current policy. The relative impacts of therapeutic vs. preventive effects of ART 
were sensitive to the time horizon, with the prevention effects contributing the majority of DALYs 
averted from ART expansion over an extended timeline. Expanded ART was also estimated to 
require large increases in health system costs, with higher HIV programs costs being only modestly 
offset by savings in routine health services. The cost-effectiveness findings suggested that 7 
 
expanding ART access, either through raising CD4 cell count-based eligibility criteria or through 
more aggressive testing programs, would be cost-effective under a wide range of assumptions, and 
despite uncertainties about epidemiology and intervention effects. These findings are broadly 
consistent with other analyses investigating the long-term outcomes of ART expansion in South 
Africa [19,28–30]. The relative ordering of ART scale-up approaches was sensitive to the time 
horizon, with expansions in eligibility preferred to expansions in coverage in analyses that adopted 
an extended time horizon.  
The cost-effectiveness results described above formed the basis of the value-of-information 
analysis. Issues found to have the highest potential value of information included (1) issues of cost 
and implementation, (2) relative infectiousness during late HIV and the reduction in infectiousness 
for individuals on ART, and (3) the therapeutic health benefits of ART for individuals with CD4 cell 
counts above current eligibility guidelines. These findings generally held up across truncated and 
extended time horizons. The prevention benefits of ART are the subject of an increasing volume of 
research [31,32], as are the therapeutic benefits of early ART initiation [33,34]. There has been less 
systematic investigation of issues of cost and implementation, though recent work has focused on 
HIV treatment costs [35–38]. One challenge for new research on costs and implementation issues is 
generalizability: while studies examining physiological processes may generalize broadly, the costs 
and quality of service provision are a consequence of complex social and institutional interactions, 
and outcomes might differ substantially across settings or as intervention approaches change. The 
most notable finding of the VOI results is the apparent unimportance of information about 
transmission during early HIV infection. Resolving uncertainty for this parameter (the relative risk 
of transmission during early HIV infection) accounts for approximately 1% of the value of 
information estimated for the most valuable research targets, and suggests that research funding 
might be better devoted to other subjects. 8 
 
 Chapter 3: Estimating the health impact of recent changes in state-level cigarette taxes  1.3.
Chapter 3 describes an analysis of the effects of changes in state cigarette taxes over the period 
1996-2013 on smoking behavior and health outcomes in the United States. Cigarette smoking is 
estimated to cause one out of every five deaths in the U.S. [39], and both state and federal 
governments have introduced cigarette excise taxes to limit cigarette consumption. Many states 
have raised these taxes in recent years, with the real value of the average state cigarette tax rising 
by over 200% since 1996 [40]. Studies of the effect of state cigarette taxes over earlier periods [41–
45] have identified a relationship between taxes and smoking behavior that is weaker and less 
robust than would be expected from the broader literature on taxes and smoking [46].  
For this study I developed a mechanistic model of smoking behavior and associated health 
outcomes in the 50 U.S. states and District of Columbia, and used this model to assess the impact of 
state cigarette taxes introduced over 17 years from 1996 to 2013. This analysis departs from 
previous analyses of the causal effects of cigarette taxes by allowing for separate effects on smoking 
initiation, smoking intensity, and quitting behavior, and by estimating these effects in the context of 
a demographic model that directly links smoking behavior and smoking history with mortality risks 
[47]. I estimated causal effects of cigarette taxes using the 1996-2012 rounds of the CDC’s 
Behavioral Risk Factor Surveillance System survey, which describe current and past smoking 
behavior for a large population-based sample of the adult in the United States [48]. These analyses 
made use of inter-state variation in the timing and magnitude of new cigarette taxes to identify 
causal effects, using a measure of anti-smoking sentiment [42] to control for state-level factors that 
influence both smoking behavior and the introduction of new cigarette taxes. 
The results of this analysis suggest that average national cigarette consumption by the beginning of 
2013 was 4.4% lower among men (3.7, 5.3), and 3.6% lower among women (2.6, 4.2), compared to 
a counterfactual scenario in which no new state cigarette taxes were introduced after 1996, for a 9 
 
4.0% reduction in overall consumption (3.3,4.6). These reductions differ widely by state depending 
on the timing and magnitude of tax increases. The behavioral effects of tax increases were projected 
to be larger if a longer time horizon is considered, with the average number of years spent smoking 
estimated to drop by 10 months (7, 12) for the 2013 birth cohort if exposed to 2013 versus 1996 
tax levels, for a 6.1% (4.5, 7.8) reduction in overall consumption. These behavioral effects are still 
modest, with estimates of the price elasticity of demand implied by these results varying from -0.14 
to -0.39 depending on sex and the time horizon over which effects were estimated. These 
elasticities are smaller than conventional estimates for cigarette taxes and cigarette consumption, 
but are in line with other studies based on variation in cigarette taxes across U.S. states [41–45]. 
As a consequence of the behavioral outcomes, these analyses suggest that 27 thousand (22, 34) 
deaths have been averted as a result of the state cigarette taxes introduced over the period 1996-
2013, for an extra 119 thousand life-years lived (92, 151). These mortality reductions are relatively 
trivial compared to overall U.S. mortality. However, projections of future health outcomes under 
scenarios that compared 2013 and 1996 tax levels suggest that the health benefits of recent state 
tax increases will largely accrue in future decades, with over a million extra life-years lived in the 
decade 2020-2029. The results indicate a 2.0 month (1.4, 2.7) overall gain in life expectancy for the 
2013 birth cohort due to state tax increases since 1996, with larger gains for men. While valuable, 
these effects are still modest compared to recent estimates of the overall effect of tobacco control in 
the U.S. [49], which find life expectancy gains 10-20 times larger than estimated by this analysis. 
This finding of minor gains in life expectancy is consistent with the modest behavioral effects 
estimated for the recent tax changes. 
In sum, this analysis confirms the beneficial effect of recent state-level cigarette tax increases on 
smoking behavior, providing detailed evidence about the magnitude and distribution of these 
effects on both smoking behavior and smoking-related mortality.  10 
 
In addition to addressing three substantive questions of policy interest, this dissertation also 
features a number of small methodological innovations. As part of the analyses for Chapter 2, new 
methods were developed for the application of VOI methods in the context of calibrated models. 
Common calibration approaches result in a parameter distribution that is approximated by a large 
sample of parameter sets, rather than a mathematical function. In this context, it is difficult to draw 
new samples from the conditional distribution of model parameters (i.e., the distribution of other 
parameters when one parameter is held fixed at a specific value). However, simulating from this 
conditional distribution is necessary with conventional methods for estimating VOI for a single 
parameter1, as it this is used to calculate the expected net monetary benefit for a given strategy and 
parameter value (E(NMB|i,θz) where i represents a strategy and θz is the parameter of interest). To 
resolve this problem, I developed a method that does not require simulating from this posterior 
distribution, and instead uses the information from the existing parameter sets to approximate 
E(NMB|i,θz) with a flexible function. These methods are more demanding than conventional 
approaches, yet will be of increasing relevance as a greater number of analyses adopt numerical 
methods to calibrate complex disease models. 
The analysis undertaken for the third paper is novel in its use of a mechanistic disease model as the 
vehicle for an econometric analysis, estimating the behavioral response to tax changes. This 
approach more closely integrates the task of causal inference about the effects of cigarette taxation 
with the task of estimating final health outcomes, and in so doing may provide a more nuanced 
understanding of the long-term consequences of cigarette tax policy. 
   
                                                             
1 Or, equally, for subsets of parameters. 11 
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Abstract 
Background: The Xpert MTB/RIF test enables rapid detection of tuberculosis and rifampicin 
resistance. The World Health Organization recommends Xpert for initial diagnosis in people 
suspected of having multidrug-resistant-TB or HIV-associated-TB, and many countries are moving 
quickly toward adopting Xpert. As roll-out proceeds, it is essential to understand the potential 
health impact and cost-effectiveness of diagnostic strategies based on Xpert. 
Methods and Findings: We evaluated potential health and economic consequences of 
implementing Xpert in five southern African countries—Botswana, Lesotho, Namibia, South Africa 
and Swaziland—where drug resistance and TB-HIV coinfection are prevalent. Using a calibrated, 
dynamic mathematical model, we compared the status quo diagnostic algorithm, emphasizing 
sputum smear, against an algorithm incorporating Xpert for initial diagnosis, with results projected 
over 10- and 20-year time periods starting from 2012. Compared to status quo, implementation of 
Xpert would avert 132 [95% CI: 55-284] thousand TB cases and 182 [97-302] thousand TB deaths 
in southern Africa over 10 years following introduction, and reduce prevalence by 28% [14-40%] 
by 2022, with more modest reductions in incidence. Health system costs are projected to increase 
substantially with Xpert, by US$460 [294-699] million over 10 years. Antiretroviral therapy for HIV 
represents a substantial fraction of these additional costs, due to improved survival in TB/HIV-
infected populations through better TB case-finding and treatment. Costs for treating MDR-TB are 
also expected to rise significantly with Xpert scale-up. Relative to status quo, Xpert has an estimated 
cost-effectiveness of US$959 [$633-$1,485] per DALY averted over 10 years. Across countries, cost-
effectiveness ratios ranged from $792 [$482-$1,785] in Swaziland to $1,257 [$767-$2,276] in 
Botswana. Assessing outcomes over a 10 year period focuses on the near-term consequences of 
Xpert adoption, but the cost-effectiveness results are conservative, with cost-effectiveness ratios 
assessed over a 20-year time horizon approximately 20% lower than the 10-year values. 18 
 
Conclusions: Introduction of Xpert could substantially change TB morbidity and mortality through 
improved case-finding and treatment, with more limited impact on long-term transmission 
dynamics. Despite extant uncertainty about TB natural history and intervention impact in this 
setting, it is nonetheless clear that Xpert offers reasonable value for money based on conventional 
benchmarks for cost-effectiveness. However, the additional financial burden would be substantial, 
including significant increases in costs for treating HIV and MDR-TB. Given the fundamental 
influence of HIV on TB dynamics and intervention costs, care should be taken when interpreting the 
results of this analysis outside of high HIV prevalence settings. 
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 Introduction  2.1.
Tuberculosis (TB) remains a leading cause of global mortality and morbidity, with an estimated 9 
million new TB cases and 1.5 million TB-related deaths in 2010 [1]. Although significant advances 
have been made in improving TB outcomes under the DOTS approach championed by the World 
Health Organization (WHO) and its partners in the Stop TB Partnership [2], continued progress is 
threatened by the inadequacy of existing diagnostic tools [3]. In most high-burden settings, TB 
diagnosis relies principally on sputum smear microscopy, which has limited sensitivity, especially 
among HIV-infected patients [4–6]. Traditional culture-based diagnosis and evaluation of drug 
sensitivity is relatively costly and slow [7,8], and many resource-limited settings lack the laboratory 
capacity to perform culture and sensitivity testing at high volume [9,10]. Lack of prompt diagnosis 
and appropriate treatment of TB increases the risks of transmission, drug resistance, and case 
fatality [11–13]. 
Recently, the Xpert MTB/RIF automated DNA test has been shown to provide rapid and sensitive 
detection of TB and rifampicin (RIF) resistance [14–17]. The Xpert test uses a cartridge-based 
system that integrates sample processing and real-time PCR, accommodates use by relatively 
unskilled healthcare workers, and provides results in <2 h [15,18]. In a large multicenter evaluation 
and subsequent implementation study, a single Xpert MTB/RIF test was found to identify >98% of 
patients with smear-positive TB and >70% of patients with smear-negative TB [14,15]. Sensitivity 
and specificity for RIF resistance were above 94% and 98%, respectively. More recent analyses 
have suggested that Xpert can greatly reduce the delay until treatment initiation for individuals 
with active TB [19]. 
In December 2010, WHO recommended that Xpert be used for initial diagnosis in patients 
suspected of having multidrug-resistant TB (MDR-TB) or HIV-associated TB disease [20]. By the 
end of May 2012, 66 of 145 countries eligible to purchase Xpert equipment at reduced prices had 20 
 
already done so [21]. A volume-dependent price mechanism is being used for purchase of test 
cartridges [22], such that by August 2012 the ex-works price of Xpert cartridges had dropped to 
less than US$10 for eligible countries [23]. Whereas the global TB control community has moved 
quickly to embrace the new technology, several studies and commentaries have sounded important 
notes of caution concerning the cost of the technology, the demand it will place on existing 
infrastructure, and the challenge of addressing false positive indications of RIF resistance [24–30]. 
As implementation advances, evidence on the epidemiologic impact and cost-effectiveness of Xpert 
is urgently needed, particularly as the consequences of Xpert introduction may vary across 
epidemiologic settings and may depend on the specific diagnostic algorithms that are considered 
[31,32]. 
In this study we used a calibrated, dynamic mathematical model of TB to quantify the potential 
health and economic consequences of introducing Xpert in five southern African countries 
characterized by high prevalence of HIV infection and extant multidrug resistance. Comparing a 
diagnostic strategy based on Xpert to the status quo, we predicted changes in TB incidence, 
prevalence, mortality, and drug resistance; estimated health system costs; and assessed the 
incremental cost-effectiveness of Xpert adoption. 
 
 Methods  2.2.
2.2.1.  Overview 
We evaluated the population health outcomes and health system costs associated with two 
alternative strategies for diagnosing TB, the first based on current diagnostic algorithms and the 
second based on implementing Xpert in accordance with current WHO recommendations. 
Comparisons between these two strategies were made using a calibrated mathematical model of 21 
 
TB, reflecting key features of TB transmission dynamics and natural history, interactions with HIV 
infection, and patterns and trends in TB control interventions and treatment for HIV/AIDS. Model 
simulations were undertaken for five southern African countries: Botswana, Lesotho, Namibia, 
South Africa, and Swaziland. We assessed changes in epidemiological outcomes and health system 
costs over 10-y and 20-y time horizons, as well as the incremental cost-effectiveness ratio (ICER) of 
the Xpert strategy compared to the current algorithm. 
2.2.2.  Diagnostic strategies 
A “status quo scenario” was created to represent the current diagnostic approach. Under this 
approach, all patients with suspected TB receive an initial sputum smear, and those diagnosed as 
smear-positive are directed to treatment. Sputum culture is indicated for patients with suspected 
TB who test smear-negative but who have a history of TB treatment or in whom there is a strong 
suspicion of TB. Drug sensitivity testing (DST) is indicated for treatment-experienced patients 
diagnosed with TB. Those who receive DST are initiated on a treatment regimen appropriate to 
their drug resistance profile, while those who do not receive DST are initiated on the standard first-
line regimen. In the main analysis we assumed that the coverage of culture testing would be 20% 
(range 10%–30%) among smear-negative, treatment-naïve patients, and 80% (range 70%–90%) 
among smear-negative, treatment-experienced patients. We assumed further that 80% (range 
70%–90%) of treatment-experienced patients diagnosed with TB would go on to receive DST. 
Given limited empirical data on country-specific coverage of culture and DST, these values were all 
varied across wide ranges in sensitivity analyses.  
An “Xpert scenario” was constructed based on the diagnostic algorithms suggested for high HIV 
prevalence settings in the May 2011 WHO recommendations for Xpert implementation [33]. These 
recommendations suggest the use of Xpert as an initial diagnostic for all individuals of HIV-positive 
or unknown status. Given the high prevalence of HIV among patients with suspected TB in southern 22 
 
Africa and the low number of individuals with a recent HIV test result [34], we modeled an 
algorithm in which Xpert was used as the initial diagnostic for all patients with suspected TB. 
According to this algorithm, such patients are first tested with a single Xpert assay, and no sputum 
smear is performed. Those testing TB-positive but negative for RIF resistance are initiated on a 
standard first-line regimen. Those testing positive for RIF resistance go on to receive DST. If the 
DST result indicates drug resistance, the individual is treated with a drug regimen tailored to the 
observed resistance profile. Under this scenario we assumed that scale-up to full coverage of Xpert 
within the national TB program would occur over the 3-y period starting in 2012. A diagram of the 
two alternative diagnostic algorithms is shown in Figure 2.1. 23 
 
 
Figure 2.1. Status quo and Xpert diagnostic algorithms 
 
2.2.3.  Modeling approach 
We developed a dynamic compartmental model of TB following the conventions of earlier models 
[35–41], with additional detail to accommodate evaluation of alternative diagnostic strategies. The 
model structure (Figure 2.2) is defined by a set of core TB states, and these states are further 
subdivided to account for (1) aspects of HIV infection, progression, and treatment relevant to TB 24 
 
epidemiology; (2) multiple circulating TB strains, with different drug resistance profiles; and (3) 
tracking of TB treatment history.  
2.2.3.1.  Core TB states 
The core TB model simulates the movements of individuals between states that capture important 
features of TB transmission, natural history, and treatment. Individuals enter the model in the 
susceptible state, where they face a risk of TB infection. The risk of infection is modeled as a time-
dependent variable that reflects contact rates between infected and uninfected individuals, and 
transmission probabilities that allow for varying infectivity across different categories of active 
disease. Upon infection, individuals progress either directly to active disease or to latent infection. 
Individuals with latent infection may subsequently progress to active TB or be superinfected by a 
different TB strain. Active disease is categorized as smear-positive or smear-negative. Smear-
negative cases may progress to smear-positive, and all individuals with active disease may 
spontaneously self-cure, which returns them to the latent/recovered state. An individual with 
active disease can be diagnosed as a TB case, according to the characteristics of the diagnostic 
algorithm, and initiated on treatment (as described in detail below). All individuals in the model are 
subject to a background mortality rate and to TB-related mortality specific to each active disease 
state. 
 25 
 
 
Figure 2.2. Model states, subdivisions, and transitions 
 
2.2.3.2.  HIV subdivisions 
HIV coinfection can alter the natural history of TB, with HIV-infected individuals having a higher 
probability of primary progressive TB upon initial infection [42,43], a higher rate of breakdown 
from latent infection to active TB [44], a lower probability of smear-positivity amongst those with 
active disease [4–6], and higher mortality rates [4,45,46]. The HIV sub-model draws on model 
structure and key parameters from an array of published HIV models [47–50]. Seven HIV 
subdivisions were created, defined by CD4 cell count (>350 cells/µl, 200–350 cells/µl, and <200 
cells/µl) and by whether or not an individual is receiving antiretroviral therapy (ART). HIV 
incidence is modeled as a transition from the HIV-negative category to the HIV-positive, CD4 count 
>350 cells/µl category, with time-varying incidence rates defined as exogenous model parameters. 26 
 
HIV-positive individuals not on ART progress over time to subdivisions with lower CD4 counts. 
Untreated individuals transition onto ART at rates specific to their CD4 category. These rates are 
allowed to vary over time to capture changing eligibility criteria and coverage of testing and 
referral. HIV-related mortality occurs at rates specific to each subdivision. 
2.2.3.3.  Drug resistance subdivisions 
Model states are further subdivided to account for differences in drug resistance among circulating 
TB strains, including (1) pan-sensitive TB, (2) isoniazid (INH) mono-resistant TB, (3) RIF mono-
resistant TB, (4) TB resistant to both INH and RIF (MDR-TB), and (5) TB resistant to INH and RIF 
plus one or more second-line drugs (MDR+/XDR-TB). An individual in the susceptible state who is 
newly infected with TB transitions to the subdivision of the infecting strain. An individual with 
latent TB who is superinfected by a different strain transitions to the subdivision of the 
superinfecting strain. Individuals may also develop acquired drug resistance as a result of TB 
treatment, transitioning to subdivisions with broader resistance profiles.  
2.2.3.4.  Treatment history subdivisions 
A final subdivision of model states distinguishes treatment-naïve from treatment-experienced 
individuals, as diagnostic algorithms may dictate different confirmatory tests depending on an 
individual’s history of prior treatment. Individuals enter the model in the treatment-naïve 
subdivision, and all individuals exiting their first course of TB treatment (through default, failure, or 
cure) transition to the treatment-experienced subdivision.  
The model is implemented as a series of difference equations with a monthly time step. A full 
description of model structure and equations is given in Section 2.6. 
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2.2.4.  TB diagnosis and treatment 
The model allows for TB diagnosis and treatment through the national TB DOTS program, or 
through non-DOTS providers functioning outside the national program. Uptake into treatment 
programs requires that individuals (1) present to a health facility and are identified as patients with 
suspected TB, (2) are diagnosed as active cases, and (3) are initiated on regimens determined by 
their background characteristics and information on drug sensitivity, if available. The model 
accounts for differences in test performance and information provided by each diagnostic 
algorithm, and for attrition between diagnosis and treatment, which varies depending on the delay 
to test results [51]. Individuals with false negative diagnoses for active TB will remain in the pool of 
undiagnosed active TB cases, with the possibility of presenting for diagnosis again. Individuals 
without active TB who attend with TB symptoms and are incorrectly diagnosed with active TB are 
assumed to undergo TB treatment, incurring costs but no positive or negative health effects. 
Algorithms for diagnosis and treatment in non-DOTS programs are assumed to be the same in both 
the status quo and Xpert scenarios, i.e., independent of the choice of diagnostic algorithm in the 
national DOTS program. 
Individuals on TB treatment may successfully complete treatment, fail, default (become lost to 
follow-up), or die. Those who successfully complete treatment return to the latent/recovered state. 
A percentage of individuals failing therapy are identified as failures by the treatment program and 
reinitiate treatment, while all others return to active disease. Individuals who fail or default from 
treatment may acquire resistance to the drugs they have received. The model allows individuals 
with pan-sensitive TB to develop mono-INH-resistant TB, mono-RIF-resistant TB, or MDR-TB 
directly. Individuals with mono-INH- or mono-RIF-resistant TB can develop MDR-TB, and 
individuals with MDR-TB can develop MDR+/XDR-TB, with the rates of acquiring drug resistance 
dependent on a patient’s TB drug regimen and current drug resistance profile (see Section 2.6).  28 
 
2.2.5.  Impact of diagnostic algorithms on TB epidemiology 
Any change in diagnostic algorithm is assumed to impact TB epidemiology through two channels. 
The first major effect is via changes in the overall sensitivity and specificity of TB diagnosis. For the 
population with undiagnosed active TB, an improvement in diagnostic sensitivity results in 
improved case detection and reduced delay to treatment initiation and, consequently, increases 
survival and decreases the duration of infectiousness. The second major effect is via changes in the 
distribution of regimens received by newly diagnosed TB cases. Drug-resistant TB cases identified 
by an algorithm with better sensitivity for diagnosing resistance have a higher probability of being 
initiated on a more effective treatment regimen, which in turn improves cure rates, increases 
survival, and reduces the probability that a patient will return to an infectious state.  
2.2.6.  Estimation approach 
We used a Bayesian estimation approach developed by Raftery and colleagues [52,53] and recently 
adopted by the Joint United Nations Programme on HIV/AIDS for HIV epidemic projections [54–
56]. This approach provides a method for calibrating complex nonlinear models to reported data on 
disease burden, and for characterizing uncertainty in analysis results using Bayesian posterior 
intervals and similar metrics. These features are particularly important for our analysis, given the 
substantial uncertainty around many of the parameters describing TB epidemiology. We used this 
approach to calibrate the model to independent WHO estimates of TB incidence and prevalence in 
each of the five countries [57], and to data from drug resistance surveys available for all countries 
except Namibia [58]. The analysis was implemented using a sampling/importance resampling 
algorithm [52,55,59]. First, a large number of parameter sets were drawn from the joint prior 
distribution of the input parameters. For each of these parameter sets the model was run and a 
likelihood statistic calculated by comparing model outcomes to the corresponding calibration data. 
The likelihood for each parameter set was then used as the probability weight in a second-stage 29 
 
resample of the parameter sets, which yielded draws representing the posterior parameter 
distribution, reflecting the information available on both model inputs and calibration data. The 
results of this simulation are similar to those produced by traditional Monte Carlo simulation and 
probabilistic sensitivity analyses, with the additional benefit of being constrained to be consistent 
with independent estimates on TB outcomes for each country. For each modeled outcome, 
uncertainty intervals were calculated by taking the 2.5th and 97.5th percentiles of the distribution 
for this outcome generated by the the resampled parameter sets, and the point estimate calculated 
by taking the arithmetic mean of this distribution (see Section 2.6 for further detail). 
2.2.7.  Model parameter values 
We parameterized the model using historical demographic and epidemiologic data available for 
each country. Parameter values relating to population demographics were derived from United 
Nations Population Division estimates and projections. Parameter values relating to TB 
transmission dynamics were chosen to be consistent with data and assumptions used in earlier TB 
models [35–41]. Parameter values relating to TB program coverage and treatment outcomes were 
derived from published reporting data [57]. Key parameter values relating to TB diagnosis and 
treatment are summarized in Table 2.1. Estimates for HIV incidence and ART access between 1983 
and 2010 were derived from unpublished data provided by the Joint United Nations Programme on 
HIV/AIDS. Future ART access was assumed to increase from current levels to the WHO universal 
access target of 80% coverage [60] over the course of 10 y. For Botswana, which was providing ART 
to an estimated 83% of those in need by 2009, coverage was maintained at current levels. ART 
eligibility was initially limited to individuals with CD4 count <200 cells/µl and then extended to 
include those with a CD4 count in the range 200–350 cells/µl from 2010 onward, consistent with 
the expansion of ART eligibility in WHO HIV treatment guidelines [61,62]. A full description of all 
parameters in the model is provided in Section 2.6.    30 
 
Table 2.1. Selected model parameter values and ranges 
Description 
Base-Case 
Value  Range  Source 
Sensitivity of sputum smear microscopy       
Smear-negative TB   0.0  —   
Smear-positive TB   1.0  —  Assumeda 
Specificity of sputum smear microscopy  0.974  (0.965–0.982)  [82] 
Sensitivity of sputum culture  1.0  —  Assumedb 
Specificity of sputum culture  0.984  (0.978–0.989)  [83] 
Sensitivity of Xpert for TB       
Smear-negative TB   0.725  (0.655–0.788)   
Smear-positive TB   0.982  (0.969–0.991)  [14] 
Specificity of Xpert for TB  0.992  (0.982–0.997)  [14] 
Sensitivity of Xpert for RIF resistance  0.976  (0.946–0.992)  [14] 
Specificity of Xpert for RIF resistance  0.981  (0.966–0.990)  [14] 
Probability of sputum culture following a 
negative sputum smear (status quo) 
   
 
Treatment-naïve patients   0.20  (0.11–0.31)   
Treatment-experienced patients   0.80  (0.69–0.89)  [84] 
Probability of DST following a positive TB 
diagnosis (status quo algorithm) 
   
 
Treatment-naïve patients   0.00  —   
Treatment-experienced patients   0.80  (0.69–0.89)  [84] 
Probability of loss to follow-up between 
presentation and treatment initiation 
   
 
With prompt diagnosis (smear, Xpert)  0.15  (0.09–0.24)   
With delayed diagnosis (culture, DST)  0.25  (0.14–0.39)  [51] 
Background mortality rate (ages 15+ y)  Time-varying  —  WHO 
unpublished data 
Excess mortality rate, active TB       
Smear-negative  0.21  (0.18–0.25)   
Smear-positive  0.30  (0.21–0.41)  [38] 
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Table 2.1. Selected model parameter values and ranges (continued) 
Description 
Base-Case 
Value  Range  Source 
Excess mortality rate, HIV       
CD4 >350, no ART  0. 008  (0.005–0.012)   
CD4 200–350, no ART  0.030  (0.018–0.048)   
CD4 <200, no ART  0.230  (0.136–0.366)   
On ART initiated at CD4 >350   0.008  (0.005–0.012)   
On ART initiated at CD4 200–350   0.023  (0.014–0.037)   
On ART initiated at CD4 <200   0.050  (0.031–0.076)  [85–90] 
Excess mortality rate, CD4<200, active TB  0.80  (0.472–1.272)  [45,46] 
Per-test cost of Xpert  $20, $30, $40  Fixedc  [33,64,65] 
Per-test cost of smear diagnosis       
Botswana  $6.13  (4.18–8.68)   
Lesotho  $3.31  (2.26–4.68)   
Namibia  $5.31  (3.63–7.51)   
South Africa  $5.94  (4.06–8.39)   
Swaziland  $4.24  (2.90–5.99)  [51,91–97] 
Per-test cost of culture       
Botswana  $15.83  (13.07–18.99)   
Lesotho  $8.56  (7.07–10.27)   
Namibia  $13.72  (11.33–16.46)   
South Africa  $15.33  (12.66–18.39)   
Swaziland  $10.94  (9.04 -13.13)  [51,91,93,94,97] 
Per-test cost of chest X-ray       
Botswana  $16.69  (11.35–23.70)   
Lesotho  $9.03  (6.14–12.81)   
Namibia  $14.46  (9.83–20.52)   
South Africa  $16.16  (10.99–22.94)   
Swaziland  $11.54  (7.85–16.38)  [91,96,98] 
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Table 2.1. Selected model parameter values and ranges (continued) 
Description 
Base-Case 
Value  Range  Source 
Per-test cost of DST       
Botswana  $81.97  (61.44–107.17)   
Lesotho  $44.32  (33.22–57.94)   
Namibia  $71.02  (53.24–92.85)   
South Africa  $79.37  (59.50–103.77)   
Swaziland  $56.65  (42.47–74.07)  [7,99] 
Cost of outpatient diagnostic visit        
Botswana  $10.32  (6.09–16.40)   
Lesotho  $2.94  (1.73–4.67)   
Namibia  $7.99  (4.71–12.70)   
South Africa  $10.30  (6.08–16.39)   
Swaziland  $6.21  (3.66–9.87)  [100] 
Cost of outpatient treatment visit        
Botswana  $6.85  (4.04–10.89)   
Lesotho  $1.95  (1.15–3.10)   
Namibia  $5.31  (3.13–8.44)   
South Africa  $6.85  (4.04–10.89)   
Swaziland  $4.13  (2.44–6.57)  [100] 
Cost of inpatient care, per day        
Botswana  $38.99  (23.00–61.99)   
Lesotho  $8.78  (5.18–13.96)   
Namibia  $28.76  (16.97–45.73)   
South Africa  $39.38  (23.23–62.61)   
Swaziland  $21.91  (12.93–34.84)  [100] 
Monthly TB regimen cost       
First-line  $5.86  (3.46–9.32)   
Mono-INH resistant  $18.02  (10.63–28.65)   
Mono-RIF resistant  $33.91  (20.01–53.92)   
MDR-TB  $119.37  (70.43–189.79)   
MDR+/XDR-TB  $179.06  (105.64–284.70)  [63] 
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Table 2.1. Selected model parameter values and ranges (continued) 
Description 
Base-Case 
Value  Range  Source 
Monthly cost of ART       
Botswana  $104.97  (84–80–128.48)   
Lesotho  $69.63  (57.22–83.92)   
Namibia  $94.68  (76.78–115.52)   
South Africa  $102.53  (82.90–125.40)   
Swaziland  $81.20  (66.25–98.52)  [63,101–105] 
Disability weights       
Active TB  0.271  (0.151–0.422)   
HIV-positive, CD4 >350, no ART  0.135  (0.078–0.213)   
HIV-positive, CD4 200–350, no ART  0.320  (0.176–0.496)   
HIV-positive, CD4 <200, no ART  0.505  (0.252–0.757)   
HIV-positive, ART initiated at CD4 
>350  
0.135  (0.078–0.213) 
 
HIV-positive, ART initiated at CD4 
200–350  
0.151  (0.087–0.238) 
 
HIV-positive, ART initiated at CD4 
<200  
0.167  (0.096–0.262) 
[66,67] 
All costs are given in 2011 US dollars. 
a As smear status is tracked in the model, the sensitivity of sputum smear for individuals classed as 
smear-negative and smear-positive is 0% and 100% (respectively) by construction. 
b As sputum culture is the gold standard for TB detection, the sensitivity is assumed to be 100%. 
c As the per-test cost of Xpert is of key interest to policy-makers (and potentially subject to price 
negotiation), the results of the analyses are presented for three separate values for the Xpert cost. 
 
2.2.8.  Measurement of resource use and costs 
Costs were assessed from a health system perspective and expressed in 2011 US dollars. Costs 
reflected resources used to deliver TB diagnosis and treatment, as provided by both public and 
private providers, and resources used in providing ART to HIV-infected individuals. An ingredients 
approach to costing was used, by which the total cost to provide a particular diagnostic procedure 34 
 
or a course of treatment was calculated by estimating the number of units of each specific type of 
resource input needed to deliver the service, multiplying each quantity by the corresponding unit 
cost of that resource input, and summing across all inputs.  
Average costs for each type of service are shown in Table 2.1. Cost estimates extrapolated from the 
literature were adjusted for inflation, currency conversions, and price levels, where relevant. 
Treatment costs for TB and HIV included drugs, clinic visits, and monitoring tests, including regular 
smear examinations during TB treatment. Drug costs were derived from the WHO price reporting 
mechanism [63]. Costs for laboratory tests (excluding Xpert) were derived from the literature. 
Numbers of treatment monitoring visits and laboratory tests followed a previous global analysis 
[35]. For Xpert, estimates in WHO implementation guidelines [33] suggest an economic cost of 
US$25–US$35 per test in southern Africa (including consumables, equipment, personnel, transport, 
facilities, and managerial overheads). This range of estimates is consistent with the results from a 
cost analysis conducted for the South African national program, which found a cost range of US$25–
US$33 [64], as well as an analysis of potential implementation strategies that reported costs of 
US$27 per patient with suspected TB for placement of equipment at central laboratories and US$39 
for placement of equipment at point of care [65]. Costs of Xpert may continue to change as volume 
increases, through reductions in the prices of equipment and consumables [22,23], economies of 
scale, and accumulated implementation experience; we therefore conducted analyses using Xpert 
per-test costs of US$20, US$30, and US$40.  
2.2.9.  Outcomes 
We estimated trends in population-level epidemiological outcomes including TB prevalence, 
incidence, mortality, and resistance to anti-TB drugs, prior to Xpert introduction in 2012, and over 
the subsequent 20-y period. Summary outcome measures computed based on population 
survivorship in the model included life-years and disability-adjusted life-years (DALYs), the latter 35 
 
incorporating disability weights from the Global Burden of Disease study [66,67]. We evaluated the 
cost-effectiveness of introducing Xpert in terms of the ICER, expressed as the difference in total 
costs between the Xpert and status quo scenarios, divided by the difference in life-years or DALYs 
between the two scenarios. Cost-effectiveness ratios were computed over both 10-y and 20-y time 
horizons following Xpert introduction, in each case based only on the costs and health outcomes 
accrued during that period. Costs and health benefits were discounted at an annual rate of 3% 
[68,69]. Following standard benchmarks proposed in international work on cost-effectiveness, we 
compared the ICER to thresholds for cost-effectiveness defined in reference to the annual gross 
domestic product (GDP) per capita in each country. Interventions are considered to be highly cost-
effective when they have ICERs that fall below the annual per-capita GDP, and are regarded as being 
potentially cost-effective if they have ICERs between one and three times annual per-capita GDP 
[70].  
2.2.10. Sensitivity analysis 
The sensitivity of the model to changes in individual parameters was investigated through 
traditional one-way sensitivity analyses as well as by computing partial rank correlation 
coefficients across the set of simulation results produced by the Bayesian uncertainty analysis 
[38,71,72]. For the one-way sensitivity analyses, we computed the change in the ICER (calculated 
over a 10-y time horizon) that would occur when we changed one parameter value by ±1 standard 
deviation from its posterior mean value while holding all other parameter values at their posterior 
means. We also conducted an array of additional sensitivity analyses that varied assumptions 
regarding the diagnostic algorithms being compared, the use of inpatient care as part of MDR-TB 
treatment, future ART coverage decisions, and trends in antiretroviral drug prices. 
Finally, we conducted a probabilistic sensitivity analysis to assess the uncertainty around the 
optimal choice of diagnostic strategy resulting from the joint effects of uncertainty around all input 36 
 
parameters simultaneously, and these results are presented as posterior intervals around key 
model outcomes and as cost-effectiveness acceptability curves.  
 
 Results  2.3.
2.3.1.  Epidemiological projections under the current diagnostic algorithm 
Figure 2.3 shows estimates and projections for TB prevalence and incidence in the southern Africa 
region from 1990 through the end of 2032, under the assumption that the current (status quo) 
diagnostic algorithm is used over the whole period. The results for individual countries followed 
the general trend seen in the regional results, with historical declines in TB prevalence and 
incidence reversed over the period 1995–2010 as a consequence of concurrent HIV epidemics. The 
magnitude of the TB epidemic differed across individual countries, with Lesotho having the lowest 
prevalence and incidence and Swaziland the highest.  
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Figure 2.3. Estimated and projected TB prevalence, TB incidence, and multidrug-resistant TB 
prevalence in southern Africa under status quo diagnostic algorithm, 1990–2032 
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2.3.2.  Performance of diagnostic algorithms 
Based on our model simulations, the positive predictive value for Xpert diagnosis of active TB, at 
full coverage by 2014, would be 96.9% (95% CI: 93.4–98.7), compared to 88.4% (81.5–93.1) for the 
status quo algorithm. The negative predictive values for Xpert and the status quo would be 93.9% 
(88.8–97.2) and 79.3% (67.6–87.9), respectively. We estimate the positive predictive value for the 
diagnosis of RIF resistance by Xpert to be 67.3% (51.3–82.0) and the negative predictive value 
99.9% (99.8–100.0). The relatively low positive predictive value indicates that Xpert is expected to 
produce a number of false positive diagnoses of RIF resistance, with relatively modest implications 
for treatment outcomes, as we assume that a subsequent DST is required before individuals receive 
an MDR-TB diagnosis. Under the Xpert algorithm, 5.8 (95% CI: 3.8–9.2) patients are tested for TB 
for each active case starting treatment, compared to 7.5 (4.9–12.1) under the status quo, a 
consequence of improved sensitivity in the Xpert algorithm. The average duration of infectiousness 
is 9.9 mo (95% CI: 6.7–14.0) under the Xpert algorithm compared to 12.8 mo (9.6–14.0) under the 
status quo. The benefit of the reduced duration of infectiousness is primarily accrued among 
individuals with smear-negative TB, for whom the duration of infectiousness is reduced from 19.3 
mo (13.8–24.6) under the status quo to 12.1 mo (7.8–18.0) under the Xpert scenario. Results for 
those with smear-positive disease are comparable under both scenarios. Treatment effectiveness 
(the probability of cure for individuals starting treatment) rises only marginally under the Xpert 
scenario, with the probability of cure 2.7 (95% CI: 1.6–4.4) percentage points higher than in the 
status quo scenario. Table 2.2 presents estimates for the average cost per programmatic outcome 
for the status quo and Xpert strategies, summed over the first 10 y of Xpert implementation (2012–
2022). These results show that adopting the Xpert algorithm increases the cost of achieving various 
diagnostic and treatment outcomes. 
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Table 2.2. Average programmatic outcomes and costs over 10 years following choice of 
strategy (2011 US dollars)*  
 
Status quo 
strategy 
Xpert 
strategy 
Programmatic measures for DOTS diagnosis 
Average annual DOTS diagnosis costs (US $, millions)  27 [15 –46]  37 [21 –61] 
Average annual TB suspects (000s)  892 [519– 1,508]  829 [487 – 1,400] 
Average annual true positive diagnoses (000s)  151 [100– 215]  175 [120 – 245] 
Average diagnosis cost per suspect (US $)  31 [25 – 38]  45 [40 – 50] 
Average diagnosis cost per true positive diagnosis (US 
$)  181 [117 – 287]  211 [136 – 334] 
Programmatic measures for DOTS treatment 
Average annual DOTS treatment costs (US $, 
millions)  57 [30 – 102]  81 [42 – 137] 
Average treatment volume (000s)  57 [38– 85]  69 [48– 100] 
Average annual true positive treatment initiations 
(000s)  122 [81 – 175]  147 [103– 206] 
Average annual cures (000s)  100 [66– 146]  121 [84– 172] 
Average treatment cost per month (US $)  84 [59 – 135]  98 [67 – 147] 
Average treatment cost per TB case initiated (US $)  469 [321 – 761]  556 [371 –861] 
Average treatment cost per TB case cured (US $)  575 [396 – 914]  675 [461 – 1,008] 
* Results are based on $30 Xpert per-test cost. Range in brackets represents the 95% posterior interval 
for each estimate. 
 
2.3.3.  Population health impact of introducing Xpert 
Introduction of Xpert is projected to produce immediate and sustained changes in TB epidemiology 
(Figure 2.4). Within 10 y after the introduction of Xpert, prevalence would be lower by 186 (95% 
CI: 86–350) per 100,000 (28% [95% CI: 14–40]), incidence by 35 (13–79) per 100,000 (6% [2–
13]), and annual TB mortality by 50 (23–89) per 100,000 (21% [10–32]), compared to status quo 
projections. The absolute number of MDR-TB cases after 10 y would be lower by 25% (6–44) in the 
Xpert scenario compared to the status quo scenario. The decline in MDR-TB cases parallels the 40 
 
overall decline in TB prevalence in these projections. There is no significant change expected in 
MDR-TB as a percentage of all TB under the Xpert scenario (4.3% [−17.5 to 34.6] greater after 10 
y). Figure 2.5 shows the incremental differences between Xpert and the status quo for these health 
outcomes, including uncertainty intervals around these differences. 
 
  
Figure 2.4. Epidemiologic outcomes in Xpert and status quo scenarios, 2012–2032 41 
 
 
Figure 2.5. Incremental difference in epidemiologic outcomes between Xpert and status quo 
scenarios, 2012-2032 
 
Summing the health effects of Xpert introduction over the first 10 y of implementation, this strategy 
is estimated to prevent 132,000 (95% CI: 55,000–284,000) of the estimated 2.6 million (1.7–4.3 
million) new TB cases and 182,000 (97,000–302,000) of the estimated 1.2 million (0.6–2.0 million) 
TB deaths projected for southern Africa under the status quo. 
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2.3.4.  Health system costs of introducing Xpert 
Figure 2.6 shows the additional annual costs associated with the Xpert scenario compared to the 
status quo, subdivided by type of cost.  
 
 
Figure 2.6. Incremental costs of Xpert strategy (based on US$30 Xpert per-test cost) 
compared to status quo strategy, by cost category, 2012–2032 (2011 US dollars) 
 
TB program costs rise rapidly as Xpert scales up to full coverage over 2012–2015. While 
implementation of Xpert requires increased spending on TB diagnosis and treatment, the major 
financial impact of Xpert introduction in this region is on HIV treatment programs. This is because 
prompt TB treatment extends survival among TB/HIV-coinfected individuals, leading to increases 
in HIV treatment demand. The model predicts that at 10 y after Xpert introduction, HIV treatment 
costs will comprise 58% (95% CI: 40–72) of the total incremental costs associated with the Xpert 
strategy (assuming an Xpert per-test cost of US$30). Considering only the additional costs incurred 
by national DOTS programs, almost three-quarters (71% [47–87]) of these will be due to growth in 43 
 
TB treatment costs, with almost all of this increase coming from a higher volume of MDR-TB 
treatment. 
2.3.5.  Cost-effectiveness of Xpert strategy versus the status quo 
Table 2.3 shows ICERs for the Xpert strategy versus the status quo strategy under 10-y and 20-y 
analytic horizons and a range of Xpert costs. Assuming an Xpert cost of US$30 per test, the Xpert 
scenario is expected to avert approximately half a million DALYs during the first 10 y following 
introduction, at a cost of US$959 (95% CI: 633–1,485) per DALY averted.  
Figure 2.7 presents the costs per DALY averted through implementation of Xpert in each of the five 
southern African countries. In almost all cases, the cost-effectiveness ratios fall below the standard 
benchmarks for cost-effectiveness suggested by WHO, whereby interventions with cost-
effectiveness ratios less than three-times annual per-capita GDP are regarded as potentially cost-
effective, and interventions with cost-effectiveness ratios less than annual per-capita GDP are 
deemed very cost-effective. Among these five countries, per-capita GDP in 2010 ranged from above 
US$7,000 in South Africa and Botswana down to US$982 in Lesotho [73]. 
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Table 2.3. Cost-effectiveness results for Xpert compared to status quo in southern Africa* 
Outcome 
Xpert cost = 
US$20 
Xpert cost 
= US$30 
Xpert cost 
= US$40 
10-year analytic horizon (costs and benefits summed over 2012-2022) 
Incremental costs, health 
System (US $, millions)  401  [248 – 623]  460  [294 – 699]  520  [333 – 772] 
Incremental costs, DOTS 
program only (US $, 
millions) 
225  [119 – 378]  284  [166 – 448]  344  [209 – 522] 
Incremental life-years 
Saved (000s)  421  [234 –679]  421  [234 –679]  421  [234 –679] 
Incremental DALYs averted 
(000s)  480  [261 – 809]  480  [261 – 809]  480  [261 – 809] 
Incremental cost per life-
year saved*  952  [606 – 1,326]  1,093 [746 – 1,592]  1,234  [836 – 1,872] 
Incremental cost per DALY 
averted*  836  [531 – 1,223]  959  [633 – 1,485]  1,083  [716 – 1,760] 
20-year analytic horizon (costs and benefits summed over 2012-2032) 
Incremental costs, health 
System (US $, millions)  1,103  [594 – 1,979]  1,217  [691 – 2,093]  1,330  [784 – 2,205] 
Incremental costs, DOTS 
program only (US $, 
millions) 
481  [205 – 993]  594  [295 – 1,125]  707  [379 – 1,262] 
Incremental life-years 
Saved (000s)  1,500  [800 – 2,570]  1,500  [800 – 2,570]  1,500  [800 – 2,570] 
Incremental DALYs averted 
(000s)  1,550  [800 – 2,770]  1,550  [800 – 2,770]  1,550  [800 – 2,770] 
Incremental cost per life-
year saved*  734  [459 – 1,173]  810  [504 – 1,311]  885  [557 – 1,467] 
Incremental cost per DALY 
averted*  711  [422 – 1,187]  784  [476 – 1,345]  857  [523 – 1,534] 
* Incremental cost-effectiveness ratios calculated using health system costs (includes DOTS costs). Both 
costs and health outcomes discounted at 3%. Range in brackets represents the 95% posterior interval 
for each estimate. 
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Figure 2.7. Cost-effectiveness of Xpert strategy compared to status quo strategy in five 
southern African countries (2011 US dollars)* 
*For each ratio, the diamond indicates the point estimate (mean incremental costs divided by mean 
incremental DALYs averted), and the bar indicates the width of the 95% posterior interval. Results 
based on US$30 Xpert per-test cost. 
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2.3.6.  Sensitivity analyses 
We conducted one-way sensitivity analyses for all model inputs. Figure 2.8 shows the results for 
South Africa for the ten parameters producing the greatest variation in the cost-effectiveness ratio 
when varied by ±1 standard deviation from their posterior means. A complete listing of these one-
way sensitivity analyses for each country is given in Tables 2.6-2.10. 
 
 
Figure 2.8. Results from univariate sensitivity analyses, showing 10 parameters with 
greatest influence on the cost-effectiveness of Xpert compared to status quo, South Africa* 
* Sensitivity analyses on the incremental cost per DALY averted (2011 US dollars [US $]) over a 10-y 
analytic horizon, assuming a US$30 Xpert per-test cost. In each one-way analysis, one parameter was 
varied ±1 standard deviation from its posterior mean, with all other variables fixed at their posterior 
means. 
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While the overall uncertainty in model results—as expressed in the posterior intervals and in the 
cost-effectiveness acceptability curves described below—is not small, the uncertainty generated by 
any individual parameter is relatively small, and does not change the general conclusions of the 
study. Complete results, by country, for the one-way sensitivity analyses on all parameters are 
reported in Section 2.6. Partial rank correlation coefficients, which reflect a probabilistic approach 
to identifying influential parameters, were calculated for all model inputs based on the simulation 
results, and yielded conclusions that were largely consistent with those based on the one-way 
sensitivity analyses (results for South Africa presented in Figure 2.9).  
 
Figure 2.9. Partial rank correlation coefficients for 10 parameters with greatest influence on 
the cost-effectiveness of Xpert compared to status quo, South Africa, 10-year time horizon 48 
 
The cost-effectiveness ratios presented in Table 2.3 and Figure 2.7 attempt to capture the major 
changes in health system resource use and health outcomes resulting from the adoption of the 
Xpert algorithm, including increases in TB treatment and HIV treatment volume. The increase in TB 
treatment volume is a direct consequence of better case-finding under the Xpert algorithm. The 
increase in ART volume is an indirect consequence of Xpert introduction, resulting from improved 
survival of TB/HIV-coinfected individuals who are currently receiving ART or who will go on to 
receive ART in the future. As shown in Figure 2.6, the increase in health system costs due to 
increased ART volume is substantial. In order to disentangle the direct effect of Xpert from this 
secondary effect through HIV survival, we constructed a scenario in which access to ART under a 
scaled-up Xpert approach was constrained to be the same as in the status quo scenario (as might be 
the case if the future HIV treatment budget were fixed and did not increase as a function of HIV 
treatment need). While artificial, this scenario allowed us to estimate the cost-effectiveness of Xpert 
adoption separate from the effects on HIV treatment. In this scenario, incremental costs and DALYs 
averted dropped by 35%–40% and 10%–15%, respectively, compared to the main analysis, and the 
cost per DALY averted (assuming a US$30 per-test cost for Xpert) dropped to US$656 (95% CI: 
386–1,115) over a 10-y analytic horizon. 
Further sensitivity analyses (described in Section 2.6) tested the robustness of the cost-
effectiveness results to the use of clinical diagnosis as part of the status quo algorithm, to the 
removal of inpatient care from MDR-TB treatment, to the provision of empiric MDR-TB treatment 
while awaiting the results from DST for all patients diagnosed with RIF resistance by Xpert, and to a 
revised assumption about ART cost trends, in which ART prices drop 50% over 10 y. Each of these 
changes produced a change in the 10-y ICER of <20% and did not change the qualitative 
conclusions about Xpert cost-effectiveness. Detailed three-way sensitivity analyses were conducted 
to understand how current coverage of culture (among treatment-naïve and treatment-experienced 
patients) and DST affected the incremental costs, health benefits, and cost-effectiveness of Xpert in 49 
 
each country. These analyses (Figures 2.13-2.17) show that if use of culture under the status quo 
algorithm is higher than the value used in the main analysis, this reduces the incremental costs and 
health benefits produced by adopting Xpert and results in a less favorable cost-effectiveness ratio. 
In some countries, very high values of culture use would result in the status quo strategy 
dominating the Xpert strategy, i.e., having lower costs and greater health benefits. The coverage 
levels that produce such a result (80% of all treatment- naïve and treatment-experienced TB 
patients diagnosed via culture), however, are unlikely to be in place at present, given current 
infrastructure and program constraints. Higher than expected DST access under the status quo 
would produce modest reductions in incremental costs and minimal changes in cost-effectiveness 
ratios. 
We also considered an alternative Xpert algorithm that requires more aggressive investigation (via 
culture, chest X-ray, and antibiotic trial) of Xpert-determined TB-negative individuals with HIV-
positive or unknown status, as described in recent South African Xpert guidelines [74]. The ICER for 
this aggressive Xpert algorithm, compared to the base-case Xpert algorithm evaluated in the main 
analysis, was US$2,128 (95% CI: 1,215–3,954) per DALY averted, suggesting that while this more 
aggressive algorithm may be cost-effective in some settings, limited programmatic resources might 
yield higher benefits by expanding access to a simplified Xpert algorithm. 
Finally, we constructed cost-effectiveness acceptability curves to consider the likelihood that Xpert 
would be cost-effective under different thresholds for societal willingness to pay for additional 
years of healthy life (Figure 2.10). If society were willing to pay up to the average per-capita GDP 
(US$6,850 for the region) per averted DALY, our results suggest essentially no uncertainty in the 
conclusion that Xpert would be cost-effective. At a threshold of US$1,000 (representing <15% of 
per-capita GDP in the region), the probability that Xpert would be cost-effective was 85%, when we 
considered the benefits that would accumulate over 20 y, or 55%, over a 10-y horizon. 50 
 
 
 
Figure 2.10. Cost-effectiveness acceptability curves showing probability that Xpert strategy 
is cost-effective as a function of willingness to pay for health benefits 
  
 Discussion  2.4.
In this study, we used a dynamic, calibrated mathematical model of TB to evaluate the potential 
health and economic consequences associated with scaling up the new Xpert MTB/RIF test in 
settings with high TB burden, prevalent MDR-TB, and high concurrent prevalence of HIV. Our 
modeling approach enables quantification of the population-level health effects of alternative 
diagnostic strategies, projections of impact over the short term and longer time horizons, and 
assessment of the economic impact and cost-effectiveness of scaling up Xpert compared to 
continuation of the status quo diagnostic approach.  
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Our results indicate that the introduction of the Xpert MTB/RIF diagnostic has the potential to 
produce a substantial reduction in TB morbidity and mortality in southern Africa. For individuals 
with smear-negative TB, the benefits of Xpert implementation would be immediate, leading to the 
diagnosis and early treatment of many individuals who would be missed by the conventional 
diagnostic algorithm. Over a longer time frame, the introduction of Xpert would reduce 
transmission and reduce the reservoir of latent TB infection in the population, but these secondary 
effects are smaller than might have been anticipated. Even accounting for indirect transmission 
benefits, we project that TB incidence will remain substantial after three decades of Xpert use, in 
the absence of other modifications to the status quo TB control strategy. This is due to the large 
existing pool of latently infected individuals whose progression to active disease would be 
unmitigated by improved diagnostics, and to the fact that a substantial fraction of the additional 
cases diagnosed using Xpert will be smear-negative cases, who are less likely to transmit infection 
than smear-positive cases. 
Along with the projected health benefits of scaling up Xpert will come significantly increased 
demands on healthcare resources. The large increase in funding required under the Xpert scenario 
raises the question of affordability. Although our cost-effectiveness results suggest that the 
introduction of Xpert represents good value for money according to typical international 
benchmarks, it does not automatically follow that TB program budgets will be able to absorb these 
changes. Whereas current debate about the costs of Xpert roll-out focuses largely on equipment and 
consumables connected directly to the assay, our results show that the indirect cost consequences 
associated with improved case-finding overshadow the direct costs of diagnosis. If current 
guidelines are followed, the adoption of Xpert places three key demands on a health system that are 
additional to the direct costs of diagnosis: providing first-line TB treatment to the large number of 
additional pan-sensitive TB cases that will be identified, providing additional HIV treatment to 
coinfected individuals who will live longer as a result of better TB care, and providing second-line 52 
 
TB treatment to the limited number of individuals diagnosed with drug-resistant TB. While our 
analysis accounts for all three demands, we recognize that response to each of these demands could 
be evaluated as a separate policy question. Such analyses are beyond the scope of our present 
study, but it is nevertheless important to note how the economics of Xpert are dependent on the 
additional interventions triggered by Xpert introduction—which are sensitive to both 
epidemiologic context and policy decisions. It is likely that existing resources and infrastructure 
will be called upon to support the introduction of Xpert and the cascade of complementary services 
this will trigger, and our findings underscore the concern raised by other commentators regarding 
the possible pitfalls of introducing Xpert into health systems that are already facing capacity 
constraints [26,29]. 
An important observation in this study is that substantial increases in HIV treatment costs are 
expected following introduction of Xpert. This critical insight has a large influence on the cost-
effectiveness of Xpert that would be missed in simpler models that do not capture the concurrent 
dynamics of TB and HIV, and is consistent with other analyses pointing to the importance of HIV 
and ART access for TB outcomes in this setting [27,75]. Sensitivity analyses show that if future HIV 
treatment access were limited by a hard budget constraint, this would actually result in a more 
attractive cost-effectiveness ratio for Xpert adoption (reducing the ICER to less than US$700 per 
DALY over a 10-y analytic horizon), with the subtraction of ART costs from the numerator of the 
ICER outweighing the reduction in health benefits in the denominator. Note that this finding 
provides no evidence about the appropriate level of ART access in the future, but does provide a 
clear illustration of the interlinked nature of TB and HIV policy in settings with dual epidemics. 
Although the absolute increase in HIV treatment spending would eventually be larger than the 
increase in TB program costs, the relative effects on total budgets for HIV and TB control are 
reversed; we estimate that introduction of Xpert would result in a 2% increase in HIV treatment 
costs after 10 y, but a 40% increase in the costs of TB control.  53 
 
Providing treatment to additional cases diagnosed with MDR-TB represents another major 
component of the incremental costs of Xpert adoption. In our base-case analysis, we assumed that 
second-line TB treatment would be available for diagnosed MDR-TB cases, which resulted in an 
estimated 2- to 3-fold increase in the volume of MDR-TB treatment under an Xpert scale-up 
scenario. If second-line therapy were less available than we assumed, the cost-effectiveness of 
Xpert would actually improve in the short term (at the cost of faster growth in drug resistance), as 
the reduction in treatment costs would outweigh the reduction in survival among MDR-TB patients 
receiving ineffective first-line regimens. Recent empirical cost analyses suggest that MDR-TB care 
costs may be even higher than estimated in our analysis, with a South African study estimating per-
patient costs of over US$17,000 during the inpatient phase of therapy alone, more than 40 times the 
cost of treating drug-sensitive TB [76]. While this might motivate the development of more efficient 
approaches to MDR-TB treatment, it also highlights the trade-offs involved in Xpert introduction.  
Although the scenarios considered in this analysis assumed that DST would be used prior to the 
initiation of patients on second-line regimens, the availability of DST remains limited in some 
settings. Of note, the 67% positive predictive value of the Xpert test for RIF resistance in this setting 
suggests that a positive result on the Xpert RIF test would be insufficient evidence to initiate 
individuals on second-line regimens, and further screening would be necessary. Further, the 
benefits achieved through better detection and treatment of drug-resistant TB would be offset by 
increases in the number of cases developing resistance, resulting from Xpert’s better case detection 
and the resulting increase in treatment volume. Consequently, the percentage of all TB cases with 
MDR-TB after 10 and 20 y is projected to be higher under the Xpert scenario, although this result is 
not statistically significant, and—given the overall reduction in TB prevalence produced by Xpert—
the absolute number of MDR-TB cases would be lower than under the status quo. 54 
 
A recent modeling study on Xpert introduction in three countries [77] reported an ICER of US$138 
per DALY in South Africa for Xpert versus the status quo, which is around 5–8 times lower than the 
estimated ratios in our study. Because the prior study used a cohort model of patients with 
suspected TB, its results pertained only to the direct effects of diagnosis and treatment in a defined 
cohort, rather than reflecting the population-level health and economic consequences. The higher 
ratios in our study relate in part to our inclusion of HIV treatment costs, which are relevant to a 
health system or societal perspective. Exclusion of these costs from the prior analysis resulted in a 
more favorable assessment of Xpert, since the survival benefits of antiretroviral treatment were 
credited to Xpert when estimating DALYs averted, but at an implicit zero cost. An additional point of 
difference is that this prior study assumed no access to culture as part of the status quo algorithm, 
which also contributed to a lower cost-effectiveness ratio for Xpert when compared to the base-
case assumptions about culture access used in our analysis. Another recent analysis looked at the 
use of Xpert for TB screening prior to ART initiation in South Africa. This analysis included ART 
costs in the cost-effectiveness ratio, and reported a cost-effectiveness ratio of US$5,100 per life-
year saved for the Xpert algorithm compared to current diagnostics [78]. This analysis considered 
only the health benefits for the individual being screened, rather than counting the cases averted by 
reducing transmission, and focused on a population in which ART costs would dominate the cost-
effectiveness ratio, and so it is understandable that the cost-effectiveness ratio was considerably 
higher than the cost per life-year saved estimated in our study. 
Our analysis has several limitations. The application of any mathematical model of TB is inevitably 
limited by uncertainty regarding the true values of epidemiologic and programmatic parameters. 
Our approach aims to reduce this parameter uncertainty through calibration, and to provide a valid 
quantitative expression of what parameter uncertainty remains based on Bayesian statistical 
inference; however, the uncertainty associated with model structure is impossible to quantify 
without building and assessing the whole range of possible model structures that might be adopted. 55 
 
For example, the results of this analysis would be different if the interdependency of TB and HIV 
epidemics were not considered, or if the indirect effect of Xpert on TB transmission were not 
captured. It will therefore be important to undertake continued empirical research evaluating the 
impact of Xpert as it is rolled out in practice, with the information generated by these evaluation 
efforts used to progressively refine the mathematical models used to estimate long-term 
intervention effects.  
In the results reported here, we constrained estimates on costs and health outcomes to account 
only for those that would accrue during either the first 10 y or the first 20 y following introduction 
of Xpert. While the choice of a limited time horizon acknowledges our increasing uncertainty about 
the distant future and reflects the immediacy of policy decisions, it also makes our results 
somewhat conservative. This is particularly true for the 10-y results, which truncate the full 
streams of future benefits that will be enjoyed by those patients who avert TB mortality or infection 
during the 10-y analysis period. Likewise, we observe that cost-effectiveness ratios are more 
attractive over the 20-y horizon than the 10-y horizon, reflecting the compounding benefits of 
interrupting transmission dynamics through better diagnosis and treatment. Moreover, the 
restriction of our study to adult populations will underestimate the total burden of disease that 
might be averted, with Xpert adoption likely to reduce pediatric TB through reduced exposure to 
actively infected adults as well as the direct application of the test for pediatric diagnosis [79,80]. 
Finally, we note that the results of the present analysis emphasize the importance of interactions 
between TB and HIV epidemiology in settings where both are highly prevalent, but we caution 
against generalizing these results to regions where HIV rates are meaningfully different from those 
in southern Africa. Additional analyses are urgently needed to assess the consequences of 
introducing Xpert elsewhere, particularly regions of low HIV prevalence or with different TB drug 
resistance patterns. Similarly, this study focused on the relative benefits of the status quo algorithm 56 
 
and the Xpert algorithm suggested by WHO for diagnosis of patients with suspected TB in settings 
with high HIV burden. While this is an important comparison to make, there is abundant scope for 
considering a wide array of alternatives, for example, considering different potential roles for 
sputum smear microscopy or chest X-ray within diagnostic algorithms designed around Xpert, or 
use of Xpert for different purposes, such as prior to provision of INH preventive therapy for 
individuals with HIV, or as part of active case-finding efforts [81]. Because the model developed for 
this analysis reflects detailed structure relating both to HIV and to patterns of resistance to major 
anti-TB drugs, it offers substantial flexibility to accommodate adaptation to other settings. In view 
of these features, and our statistical approach to calibrate this model to available epidemiologic 
data, we envision that the model can provide a durable platform for evaluating an array of different 
diagnostic strategies in diverse settings in the future. 
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 Additional information   2.6.
2.6.1.  Model overview and structure 
Analyses were conducted using a dynamic compartmental model of tuberculosis (TB) in adult 
populations. The model simulates transitions between health states deterministically, recalculating 
the population distribution across states in discrete monthly time steps. The model was 
constructed and run using R statistical computing software. 
The model follows the conventions of earlier TB models [1-7], with additional detail to 
accommodate evaluation of alternative diagnostic strategies. The model structure is defined by a 
set of core TB states, and these states are further subdivided to account for: (1) aspects of HIV 
infection, progression and treatment relevant to TB epidemiology; (2) multiple circulating TB 
strains, with different drug resistance profiles; and (3) tracking of TB treatment history.  
2.6.1.1.  Core TB states 
The core TB states capture important features of TB transmission, natural history, and treatment. 
Eight states are included. Individuals who have never been infected reside in the susceptible state. 
Those who are infected but do not have active disease are in the latent infection/recovered state. 
Active disease is categorized as smear-negative or smear-positive. Smear-negative or smear-
positive active cases may be treated either through the national TB control program (DOTS), or 
through providers outside of the national program (non-DOTS).  
2.6.1.2.  HIV subdivisions 
HIV co-infection can alter the rate of progression of TB disease, with HIV-infected individuals 
having a higher probability of primary progressive TB upon initial infection [8,9], a higher rate of 
breakdown from latent infection to active TB [10], a lower probability of smear-positivity amongst 
those with active disease [11-13] and higher mortality rates [11,14,15]. The HIV sub-model draws 69 
 
on structure and assumptions from an array of published HIV models [16-19]. There are seven HIV 
subdivisions. Individuals may be HIV-negative, they may be in one of three categories reflecting 
untreated HIV infection with a specified CD4 cell count (>350 cells/µL, 200-350 cells/µL, and <200 
cells/µL), or they may be receiving antiretroviral therapy (ART) in one of three categories 
distinguished by the CD4 count at treatment initiation.  
2.6.1.3.  Drug resistance subdivisions 
Five subdivisions were created to account for differences in drug resistance among circulating TB 
strains, including: (1) pan-sensitive TB, (2) isoniazid (INH) mono-resistant TB, (3) rifampicin (RIF) 
mono-resistant TB, (4) resistance to both INH and RIF (MDR-TB), and (5) resistance to INH and RIF 
plus one or more second-line drugs (MDR+/XDR-TB).  
2.6.1.4.  Treatment history subdivisions 
A final subdivision of model states distinguishes treatment-naïve from treatment-experienced 
individuals, as diagnostic algorithms may dictate different confirmatory tests depending on an 
individual’s history of prior treatment. 
2.6.1.5.  Summary of model structure 
At any point in time, all individuals in the model are categorized by the combination of their TB 
status and their status with respect to each of the three subdivisions. Thus, each of the 8 core states 
is ‘exploded’ into 70 unique sub-states (resulting from 7 HIV categories × 5 drug resistance 
categories × 2 treatment history categories), which yields a total of 8 × 70 = 560 unique 
compartments in the model. We note that some of these 560 compartments are null, in instances 
where the crossing of specific categories is meaningless; for example, susceptible individuals are 
defined by having never been infected, which means that they cannot be characterized in terms of a 
TB strain with a specific drug resistance profile. 70 
 
2.6.2.  Transitions between model states and subdivisions 
The model transitions may be represented by a set of difference equations. Table 2.4 defines the 
general notation used in the formal description of the model that follows.  
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Table 2.4. Definition of core model states and transitions 
Symbol  Description 
Core model states  
    Number of individuals in the susceptible state at time t 
    Number of individuals in the latent/recovered state at time t 
    Number of individuals in the smear-negative active TB state at time t 
    Number of individuals in the smear-positive active TB state at time t 
    Number of individuals in smear-negative DOTS treatment state, at time t 
    Number of individuals in smear-negative non-DOTS treatment state, at time t  
    Number of individuals in smear-positive DOTS treatment state, at time t 
    Number of individuals in smear-positive non-DOTS treatment state, at time t 
Time-varying model transitions 
    New entrants at time t 
    Force of infection at time t 
         Rate of attending TB testing site, in DOTS (D) or non-DOTS (N) program, for 
individuals with active TB, at time t 
           Probability of positive diagnosis for individuals attending testing site in DOTS or 
non-DOTS program, for state     {   }, at time t 
          
Probability of loss to follow-up between initial presentation and treatment 
initiation, for individuals attending testing site in DOTS or non-DOTS program, 
for state     {   }, at time t 
     Default rate for treatment state     {       }, at time t 
     Probability of treatment success, for individuals completing treatment in state 
    {       }, at time t 
    
All-cause mortality rate for model state i at time t, calculated as the sum of 
background mortality at time t (   ), and disease-specific excess mortality 
(   ,     ,        ) 
Time-invariant model transitions 
   Partial immunity afforded by prior infection 
   Probability of fast breakdown to active TB, for new infections  
   Probability of smear positivity, for incident TB cases 
   Rate of breakdown from latent / recovered to active TB  
   Rate of conversion from smear-negative to smear-positive active TB 
   Rate of self-cure for active TB 
    Rate of treatment completion for treatment state   
   Probability that failed treatment cases are identified and returned to treatment 72 
 
2.6.2.1.  Transitions between core TB states 
We begin with a set of model equations that describe changes in the population distribution across 
the eight core TB states between one time step and the next. In the following equations    indicates 
the number of residents in state   at time  , and  ̇ 
 
(with a dot above the X) indicates the number of 
residents in state   at time      .  
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The total population is given by 73 
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Individuals enter the model in the susceptible state (  ), where they face a time-varying risk of TB 
infection. Formally, the force of infection,   , describes the hazard rate (at time  ) by which a 
susceptible individual acquires TB. The population is assumed to mix randomly with density-
independent contact rates, so transmission is modeled as frequency-dependent. The force of 
infection allows for varying infectivity across different categories of disease, and for temporal 
trends in contact rates, which yields the following formulation in the simple case of a single 
circulating TB strain: 
     ∑
  
 
 
     
where    is the transmission parameter for those with untreated, smear-positive, active disease at 
time  , and    is the infectivity of individuals in core state   relative to those with untreated, smear-
positive active disease.  
Upon infection, individuals progress either directly to active disease or to latent infection. 
Individuals with latent infection may subsequently progress to active TB, or they may be re-infected 
at a rate that is subject to the partial immunity conferred by an existing infection. Active disease is 
categorized as smear-positive or smear-negative. Smear-negative cases may progress to smear-
positive, and all individuals with active disease may spontaneously self-cure, which returns them to 
the latent/recovered state. An individual with active disease can be diagnosed as a TB case, 
according to the characteristics of the diagnostic algorithm, and initiated on treatment. Treatment 
may be provided either through the national TB control program (DOTS), or through providers 
outside of the national program (non-DOTS). Treated individuals may complete treatment, default 
(returning to active disease) or die. Those who complete treatment are categorized as failures 74 
 
(returning to active disease) or cures (returning to the latent/recovered state). In addition to these 
transitions, all individuals in the core model are subject to a background mortality rate that is 
updated in each time step based on demographic data for each country, and to TB-related mortality 
specific to each active disease state. 
2.6.2.2.  Transitions between HIV subdivisions 
Rates of transition from one HIV subdivision to another are based on estimates of HIV incidence, 
disease progression and treatment initiation (see Section 2.6.3.4 and Table 2.5). These rates are 
assumed independent of core TB states and other subdivisions. HIV incidence is modeled as a 
transition from the HIV-negative category to the HIV-positive, CD4 count >350 cells/µL category, 
with time-varying incidence rates defined as exogenous model parameters. HIV-positive individuals 
not on ART may progress over time to lower CD4 counts. Untreated HIV-positive individuals 
transition onto ART at rates specific to CD4 count category, which are allowed to vary over time to 
capture changing eligibility criteria and coverage of testing and referral. HIV-related mortality 
occurs at rates specific to each subdivision. Certain parameters governing the natural history of TB 
vary with respect to HIV status, as indicated in Table 2.5. 
2.6.2.3.  Transitions between drug resistance subdivisions 
Transitions between TB strain subdivisions occur through infection, superinfection and acquired 
resistance. First, we elaborate the specification for the force of infection to allow for multiple 
circulating strains distinguished by their drug resistance profiles. Individuals may be infected by 
any of the five types of strains. When calculating the force of infection for a particular strain (   for 
strain s) we allow for differential fitness across strains, for example indicating lower 
transmissibility among drug resistant vs. drug sensitive strains. The total force of infection (λ) 
equals the sum across the five strain-specific forces of infection (  ). The general formulation for 
the force of infection is thus given by: 75 
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where     is the relative reduction in fitness for strain s compared to the corresponding pan-
sensitive strain. An individual in the susceptible state who is newly infected with TB transitions to 
the subdivision of the infecting strain. An individual with latent TB who is superinfected by a 
different strain transitions to the subdivision of the superinfecting strain. Following Lipsitch et al. 
[20], we allow for superinfection by the same strain in order to preserve model neutrality with 
respect to strain distribution. 
Individuals may also develop acquired drug resistance during TB treatment, such that individuals 
with pan-sensitive TB can develop mono-INH resistance, mono-RIF resistance, or MDR-TB directly. 
Individuals with mono-INH or mono-RIF can develop MDR-TB, and individuals with MDR-TB can 
develop MDR+/XDR-TB. Cases of acquired resistance arise as individuals default from or fail 
treatment, with rates of acquiring resistance specified for each combination of current strain and 
specific treatment regimen (Table 2.5).  
2.6.2.4.  Transitions between treatment history subdivisions 
Individuals enter the model in the treatment-naïve category. Treatment-naïve individuals move 
into the treatment-experienced category upon the first transition out of any of the TB treatment 
states (  ,   ,    or   ) in the core model. 
2.6.3.  Model parameterization 
2.6.3.1.  Initialization 
The model was used to estimate TB prevalence and incidence starting in 1950 onwards, with this 
long historical projection allowing the simulation of a realistic TB epidemic as well as providing 
prevalence and incidence estimates for the recent past to compare to independent data in the 76 
 
calibration procedure. First, we simulated a virgin epidemic, in which one infectious source case is 
introduced into a population of susceptibles. This epidemic was run to equilibrium, which was 
assumed to represent the starting conditions in 1950. The model was then run from 1950 through 
the end of 2011 to produce a historical time trend in TB epidemiology, with time-varying parameter 
values capturing changes in birth rates, background mortality rates, TB contact rates, access to TB 
and HIV treatment interventions, and treatment success and default rates.  
Table 2.5 summarizes estimates and ranges for all model parameters. Following is a description of 
key data sources used to derive these values and ranges. 
2.6.3.2.  Demographics 
Demographic inputs were estimated separately for each country. Historical estimates for mortality 
excluding HIV were obtained from the World Health Organization (unpublished data), and future 
background mortality was held constant at current values. Historical estimates and future 
projections for population growth were obtained from the United Nations Population Division [21]. 
2.6.3.3.  TB epidemiology, diagnosis and treatment 
Estimates for transition rates between TB-related health states were drawn from the literature and 
chosen to be consistent with prior TB modeling work [3-5,22-24]. ART delays the 
immunosuppression associated with HIV thereby reducing the effect of HIV on TB disease 
progression. We operationalized this as an ART effectiveness parameter (z); the values of TB 
natural history parameters for individuals on ART were calculated as weighted sums of parameter 
values for HIV-negative and untreated HIV-positives, with weights z and (     ) respectively.  
Individuals receiving TB treatment were assumed to have reduced infectiousness compared to 
untreated individuals, with the reduction in infectiousness approximated as 1 minus the failure 
probability for each regimen/strain pair. Diagnostic algorithms were based on current practice and 77 
 
on WHO guidelines for Xpert implementation [25]. Values for the sensitivity and specificity for each 
diagnostic test were derived from the published literature [26-28]. As the model distinguishes 
between smear-negative and smear-positive TB the sensitivity of smear was defined as 0% and 
100%, respectively, for these two groups. As sputum culture is considered the gold standard for 
diagnosis the sensitivity of this test was assumed to be 100%. Few data are available on the 
percentage of individuals testing negative on smear microscopy who subsequently have this 
diagnosis confirmed by sputum culture. Dowdy et al. [23] estimated this percentage as 5% and 37% 
for treatment-naïve and treatment-experienced individuals, respectively, based on 2004 South 
African data. It is likely that access to sputum coverage will have risen since then, and we assumed 
starting values for these parameters of 20% and 80% respectively. In addition, 80% of individuals 
who are diagnosed positive with a history of prior treatment were assumed to receive DST. 
Parameters relating to treatment program coverage and performance were based on routine 
monitoring data aggregated by the WHO Stop TB Department [29]. Access to DOTS TB programs 
(parameterized as the rate at which those with active TB attend a health center providing TB 
diagnosis and treatment) was estimated from reported trends in the case detection rate (CDR). 
First, a simple time trend was fit to national CDR data using a logistic regression model (see Figure 
2.11). As the CDR more closely approximates a probability rather than a rate, we transformed the 
predicted CDR (CD   R) to calculate the attendance rate (whereby rate = 1 – e –CD   R). For the pre-1990 
period, the rate of attendance for DOTS diagnosis was assumed to increase from zero to the 1990 
value over a 4-year period. For future years the attendance rate was held constant at the most 
recent value for which data were available. The imperfections of the CDR as a measure of the 
probability of detection are well understood [30], and this uncertainty was reflected in the analysis 
by assuming a wide prior distribution for the attendance rate, with a range spanning from zero to 
two times the point estimate. There is little information on non-DOTS diagnosis, but this was 
assumed to start earlier (1970) and to continue at a low level in the future (rate of 0.2 per year, also 78 
 
varying within a range spanning zero to two times the point estimate). The volume of non-DOTS 
care was calibrated to produce observed drug resistance levels.  
Rates of treatment default were based on reported program outcomes [29] for each country and 
calculated in a similar fashion to the attendance rate, by fitting a simple time trend to the national 
program data using a logistic regression model (Figure 2.11), and transforming the estimated 
probability of default to obtain the annualized default rate. TB-specific excess mortality rates were 
assumed to persist for the first two months of treatment before dropping to zero, and the treatment 
mortality rates produced by this assumption were consistent with reported program outcomes.  
The probability of treatment success (probability of cure or completion among all individuals 
finishing a treatment regimen) will be determined by the appropriateness of the drug regimen as 
well as other characteristics of the treatment program—such as quality of adherence support—
which might change over time. To capture the influence of these other program characteristics we 
assumed that the effectiveness of the first-line regimen in pan-sensitive TB was equivalent to the 
fraction of all individuals cured or completing treatment estimated from national program data. 
This was operationalized as a time trend fit to the observed data in a logistic regression model 
(Figure 2.11). The probabilities of treatment success for other strain-regimen combinations were 
assumed to be fixed proportions of this value, shown in Table 2.5.  
It is assumed that diagnosis and treatment was more rudimentary in the early years of TB control 
programs. This assumption was operationalized in the model as a linear increase in the availability 
of culture, DST, and second-line regimens over the last 20 years, from an initial scenario in which 
there was no access to advanced tests or second line regimens. 
Little information is available to estimate rates of acquired resistance by regimen and initial strain. 
We based our estimates on data reported in Lew et al. [31], adjusted for the prevalence of 79 
 
resistance to other first-line drugs (streptomycin, ethambutol) not tracked in the model (values 
shown in Table 2.5). 
2.6.3.4.  HIV epidemiology and treatment 
Estimates for HIV incidence and ART coverage were obtained from UNAIDS (unpublished data). For 
future years, HIV incidence was assumed to decline at an exponential rate estimated from the last 7 
years of incidence data. Untreated HIV-positive individuals in the model transition onto ART at 
rates calculated to match national reporting data on ART program scale-up. ART coverage (the 
fraction of eligible individuals receiving ART) was assumed to increase from current levels to the 
WHO universal access target of 80% coverage [32] over the course of 10 years. For Botswana, 
which was providing ART to over 83% of those in need by 2009, coverage was maintained at 
current levels. Early HIV treatment guidelines suggested a CD4 count criterion of <200 cells/µL for 
initiating ART [33], while recent revisions to the guidelines have raised this CD4 count criterion to 
<350 cells/µL [34]. For this reason all ART initiations prior to 2010 were assumed to come from the 
CD4 count <200 cells/µL group, and for 2010 onwards the fraction of HIV initiations coming from 
the CD4 count 200–350 cells/µL group was assumed to rise such that by 2015 individuals in the 
CD4 count 200–350 and <200 cells/µL groups would have equal probability of initiation on ART. 
Estimates for HIV-specific mortality rates (with and without ART) were drawn from the literature 
[35-40]. 
2.6.3.5.  Resource use and costs 
Costs were assessed from a health system perspective and expressed in 2011 US dollars. Costs 
reflected resources used to deliver TB diagnosis and treatment, as provided by both public and 
private providers, and those used in providing ART to HIV-infected individuals. An ingredients 
approach to costing was used, by which the total cost to provide a particular diagnostic procedure 80 
 
or a course of treatment was calculated as the number of units of each specific type of resource 
input needed to deliver the service, multiplied by the unit cost of each resource input.  
Average costs for each type of service are shown in Table 2.5. Unit costs for service delivery 
(excluding Xpert) were calculated as the average of values reported in the literature, after 
adjustment for inflation and differences in price levels. These adjustments were undertaken by (i) 
inflating values to 2011 prices using the GDP deflator in the country in which the data were derived, 
then (ii) adjusting for price levels between countries using per-capita GDP as a price index and (iii) 
converting to US dollars based on market exchange rates. Treatment costs for TB and HIV included 
drugs, clinic visits and monitoring tests, as well as inpatient care for individuals receiving treatment 
for MDR-TB. Drug costs were derived from average prices reported to the WHO price reporting 
mechanism [41]. Quantities of treatment monitoring visits and laboratory tests (including 
monitoring smears and cultures) followed a previous global analysis [1]. The cost of clinic visits 
associated with TB diagnosis was based on the cost of a 10-minute outpatient clinic visit as 
reported for each country by the WHO-CHOICE project, and the cost of a clinic visit during TB 
treatment based on the cost of a short (<5 minute) outpatient clinic visit from the same source. 
Inpatient care for MDR-TB treatment was assumed to last for 4 months, with the cost per inpatient 
day estimated from the WHO-CHOICE data. For Xpert, limited data are available on the per-test cost 
of providing the test in routine programmatic settings, although information reported in WHO 
implementation guidance suggests an economic cost of US$25-35 in southern Africa (including 
consumables, equipment, personnel, transport, facilities and managerial overheads), and a recent 
costing study in South Africa suggested a per-test cost of US$26-US$36 in the national program 
[42]. As the per-test cost of Xpert is of interest to decision-makers and may be sensitive to 
negotiation, results were calculated and reported separately for three values for the Xpert per-test 
cost: US$20, US$30 and US$40. 81 
 
2.6.3.6.  Other parameters 
Disability weights were derived from estimates published by the Global Burden of Disease study 
[43,44]. Published disability weights generally only cover individual conditions, and so to calculate 
disability weights for comorbid TB-HIV states we assumed a multiplicative functional form, 
whereby the combined weight was equal to one minus the product of one minus the disability 
weight for each of the individual conditions [45,46]. An annual discount rate of 3% was applied to 
all future costs and benefits included in the cost-effectiveness analysis. This value was varied 
between 0 and 10% in univariate sensitivity analyses. 
Table 2.5. Base-case parameter values and ranges 
Description  Base-case value  Range*  Source 
Parameters related to    
New entrants at time t  Time-varying  —  [21] 
Parameters related to    
Transmission parameter for individuals 
with (pan-sensitive) smear-positive TB in 
1950 (     ) 
11.0  [8.3-14.3]  Values chosen to 
produce plausible 
value on burn-in 
Annual percentage decline in transmission 
parameter 
0.7%  [0.2%-1.6%] 
[4] 
Infectivity of smear-negative TB, relative to 
smear-positive TB (  ) 
0.22  [0.12-0.37] 
[3] 
Fitness cost,drug-resistant TB strains (   ):  
Mono-INH resistant 
Mono-RIF resistant 
MDR-TB 
MDR+ / XDR-TB 
 
0.05 
0.15 
0.27 
0.27 
 
[0.03-0.08] 
[0.08-0.23] 
[0.15-0.42] 
[0.15-0.42]  [5,22,47,48] 
Parameters related to     and     
Rate of attending TB testing site, for 
individuals with active TB 
Time-varying  0-200% of 
base-case 
value 
Trend estimated 
from country 
program data 
1990-2011 [29] 
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Table 2.5. Base-case parameter values and ranges (continued) 
Description  Base-case value  Range*  Source 
Parameters related to    
New entrants at time t  Time-varying  —  [21] 
Parameters related to    
Transmission parameter for individuals 
with (pan-sensitive) smear-positive TB in 
1950 (     ) 
11.0  [8.3-14.3]  Values chosen to 
produce plausible 
value on burn-in 
Annual percentage decline in transmission 
parameter 
0.7%  [0.2%-1.6%] 
[4] 
Infectivity of smear-negative TB, relative to 
smear-positive TB (  ) 
0.22  [0.12-0.37] 
[3] 
Fitness cost,drug-resistant TB strains (   ):  
Mono-INH resistant 
Mono-RIF resistant 
MDR-TB 
MDR+ / XDR-TB 
 
0.05 
0.15 
0.27 
0.27 
 
[0.03-0.08] 
[0.08-0.23] 
[0.15-0.42] 
[0.15-0.42]  [5,22,47,48] 
Parameters related to     and     
Rate of attending TB testing site, for 
individuals with active TB 
Time-varying  0-200% of 
base-case 
value 
Trend estimated 
from country 
program data 
1990-2011 [29] 
Rate ratio of attending TB testing, for 
individuals without active TB compared to 
those with active TB 
0.015  [0.009-0.023]  Calibrated to 
observed ratio of 
TB testing to TB 
notifications [29] 
Parameters related to yDit and yNit 
Sensitivity of sputum smear microscopy: 
Smear-negative TB  
Smear-positive TB  
 
0.0 
1.0 
 
— 
—  Assumed 
Specificity of sputum smear microscopy  0.974  [0.965-0.982]  [27] 
Sensitivity of sputum culture  1.0  —  Assumed 
Specificity of sputum culture  0.984  [0.978-0.989]  [28] 
Sensitivity of Xpert for TB: 
Smear-negative TB  
Smear-positive TB  
 
0.725 
0.982 
 
[0.655-0.788] 
[0.969-0.991]  [26] 
Specificity of Xpert for TB  0.992  [0.982-0.997]  [26] 
Sensitivity of Xpert for RIF resistance  0.976  [0.946-0.992]  [26] 
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Table 2.5. Base-case parameter values and ranges (continued) 
Description  Base-case value  Range*  Source 
Specificity of Xpert for RIF resistance  0.981  [0.966-0.990]  [26] 
Probability of sputum culture following a 
negative sputum smear (status quo): 
Treatment-naïve patients 
Treatment-experienced patients 
 
 
0.20 
0.80 
 
 
[0.11-0.31] 
[0.69-0.89]  [23] 
Probability of DST following a positive TB 
diagnosis (status quo): 
Treatment-naïve patients 
Treatment-experienced patients 
 
 
0.00 
0.80 
 
 
— 
[0.69-0.89]  [23] 
Sensitivity of clinical diagnosis  0.209  [0.12-0.33]  [49] 
Specificity of clinical diagnosis  0.953  [0.92-0.97]  [49] 
Parameters related to      and      
Probability of loss to follow-up between 
presentation and treatment initiation: 
With prompt diagnosis (smear, Xpert) 
With delayed diagnosis (culture, DST) 
 
 
0.15 
0.25 
 
 
[0.09 – 0.24] 
[0.14 – 0.39]  [24] 
Parameters related to     
Treatment default rate, DOTS  Time-varying  50-150% of 
point 
estimate 
Trend estimated 
from country 
program data 
1990-2011 [29] 
Treatment default rate, non-DOTS   0.58  [0.27-0.85]  [27] 
Parameters related to     
Probability of treatment success, for 
individuals with pan-sensitive TB 
completing first-line regimen  
Time-varying  50-150% of 
point 
estimate 
Trend estimated 
from country 
program data 
1990-2011 [29] 
Risk ratio of treatment success, relative to 
pan-sensitive TB with first-line regimen: 
First-line regimen, partially-sens strain 
First-line regimen, non-sens strain 
Second-line regimen, sens strain 
Second-line regimen, non-sens strain 
Non-DOTS regimen, non-MDR strain 
Non-DOTS regimen, MDR strain 
 
 
0.83 
0.44 
0.93 
0.44 
0.73 
0.44 
 
 
[0.73-0.90] 
[0.23-0.67] 
[0.89-0.96] 
[0.23-0.67] 
[0.58-0.85] 
[0.23-0.67]  [50-54] 
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Table 2.5. Base-case parameter values and ranges (continued) 
Description  Base-case value  Range*  Source 
Parameters related to     
Background mortality rate, (ages 15+)  Time-varying  —  WHO unpublished 
data 
Excess mortality rate, active TB (μTB): 
Smear-negative 
Smear-positive 
 
0.21 
0.30 
 
[0.18 – 0.25] 
[0.21 – 0.41]  [4] 
Excess mortality rate, HIV (μHIV): 
CD4 >350 cells/µl, no ART 
CD4 200–350 cells/µl, no ART 
CD4 <200 cells/µl, no ART 
On ART initiated at CD4 >350 cells/µl 
On ART initiated at CD4 200-350 cells/µl 
On ART initiated at CD4 <200 cells/µl 
 
0. 008 
0.030 
0.230 
0.008 
0.023 
0.050 
 
[0.005-0.012] 
[0.018-0.048] 
[0.136-0.366] 
[0.005-0.012] 
[0.014-0.037] 
[0.031-0.076]  [35-40] 
Excess mortality rate, CD4<200, active TB 
(μTB-HIV) 
0.80  [0.472-1.272] 
[14,15] 
Parameters related to m 
Partial immunity from prior infection:  
HIV-neg 
HIV-pos, CD4 >350 cells/µl, no ART 
HIV-pos, CD4 200–350 cells/µl, no ART 
HIV-pos, CD4 <200 cells/µl, no ART 
 
0.65 
0.45 
0.25 
0.25 
 
[0.37-0.87] 
[0.23-0.68] 
[0.14-0.39] 
[0.14-0.39]  [2,3,5,47] 
Parameters related to p 
Probability of fast breakdown to active TB, 
for new infections:   
HIV-neg 
HIV-pos, CD4 >350 cells/µl, no ART 
HIV-pos, CD4 200–350 cells/µl, no ART 
HIV-pos, CD4 <200 cells/µl, no ART 
 
 
0.115 
0.33 
0.67 
0.94 
 
 
[0.09-0.14] 
[0.18-0.51] 
[0.49-0.82] 
[0.70-1.00]  [4,55] 
Parameters related to f 
Probability of smear-positivity, for 
incident TB cases:   
HIV-neg 
HIV-pos, CD4 >350 cells/µl, no ART 
HIV-pos, CD4 200–350 cells/µl, no ART 
HIV-pos, CD4 <200 cells/µl, no ART 
 
 
0.62 
0.45 
0.35 
0.35 
 
 
[0.42-0.80] 
[0.23-0.68] 
[0.19-0.54] 
[0.19-0.54]  [3,11,55] 
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Table 2.5. Base-case parameter values and ranges (continued) 
Description  Base-case value  Range*  Source 
Parameters related to τ 
Rate of breakdown from latent/recovered 
to active TB (per 100,000):   
HIV-neg 
HIV-pos, CD4 >350 cells/µl, no ART 
HIV-pos, CD4 200–350 cells/µl, no ART 
HIV-pos, CD4 <200 cells/µl, no ART 
 
 
0.001 
0.003 
0.085 
0.170 
 
 
[0.0003-0.0024] 
[0.001-0.006] 
[0.060-0.130] 
[0.100-0.270]  [3,4,56] 
Parameters related to α 
Rate of conversion from smear-negative to 
smear-positive active TB 
0.015  [0.010-0.023] 
[4] 
Parameters related to σ 
Rate of self-cure for active TB:   
HIV-neg 
HIV-pos, CD4 >350 cells/µl, no ART 
HIV-pos, CD4 200–350 cells/µl, no ART 
HIV-pos, CD4 <200 cells/µl, no ART 
 
0.2 
0.1 
0.0 
0.0 
 
[0.15-0.25] 
[0.06-0.16] 
— 
—  [4,5,57] 
Parameters related to    
Duration of TB treatment (     ⁄ ):   
First-line 
Mono-INH resistant 
Mono-RIF resistant 
MDR-TB 
MDR+/XDR-TB 
Non-DOTS (averaged) 
 
6 mo. 
9 mo. 
18 mo. 
21 mo. 
21 mo. 
18 mo. 
 
— 
— 
— 
— 
— 
—  [58] 
Parameters related to v 
Probability failed treatment cases are 
identified and returned to treatment 
0.5  [0.25-0.75] 
Assumed 
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Table 2.5. Base-case parameter values and ranges (continued) 
Description  Base-case value  Range*  Source 
Additional parameters related to TB strain subdivisions 
Rates of acquisition of TB drug resistance: 
Pan-sensitive  Mono-INH resistant, 
1st-line regimen 
Pan-sensitive  Mono-RIF resistant, 1st 
-line regimen 
Pan-sensitive  MDR-TB, 1st -line 
regimen 
Mono-RIF or Mono-INH resistant  
MDR-TB, appropriate 2nd-line regimen 
Mono-RIF or Mono-INH resistant  
MDR-TB, inappropriate 2nd -regimen 
MDR-TB  MDR+/XDR-TB, appropriate 
2nd -line regimen 
MDR-TB  MDR+/XDR-TB, 
inappropriate 2nd -line regimen 
Rate ratio of acquired resistance, pan-
sensitive, non-DOTS regimen 
 
0.020 
 
0.003 
 
0.010 
 
0.020 
 
0.230 
 
0.020 
 
0.230 
 
3.0 
 
[0.012-0.032] 
 
[0.002-0.005] 
 
[0.006-0.016] 
 
[0.012-0.032] 
 
[0.139-0.359] 
 
[0.012-0.032] 
 
[0.139-0.359] 
 
[1.8-4.8]  [31] 
Additional parameters related to HIV subdivisions 
HIV incidence  Time-varying  Annual 
change varied 
±5% 
UNAIDS 
unpublished 
estimates 
Rate of HIV progression for individuals not 
on ART: 
CD4 >350 cells/µl to CD4 200–350 
cells/µl 
CD4 200–350 cells/µl to CD4 <200 
cells/µl 
 
 
0.134 
 
0.505 
 
 
[0.08-0.21] 
 
[0.30-0.81] 
[59-62] 
Historical ART coverage for treatment-
eligible HIV-positive individuals 
Time-varying  —  UNAIDS 
unpublished 
estimates 
Future ART coverage for treatment-
eligible HIV-positive individuals 
0.8  [0.47-0.96] 
[32] 
Effectiveness of ART in reversing effect of 
HIV on TB natural history (all TB 
transition parameters subdivided by HIV 
status, excluding mortality) 
0.7  [0.47-0.87] 
[63-65] 
Proportion of HIV-negative individuals 
with prior HIV test result 
0.5   
[0.25-0.75]  [66-68] 87 
 
Table 2.5. Base-case parameter values and ranges (continued) 
Description  Base-case value  Range*  Source 
Additional parameters related to costs and health outcomes 
Per-test cost of Xpert  $20, $30, $40  Assumed 
fixed  [25,69,70] 
Per-test cost of smear diagnosis:   
Botswana 
Lesotho 
Namibia 
South Africa 
Swaziland 
 
$6.13 
$3.31 
$5.31 
$5.94 
$4.24 
 
[4.18-8.68] 
[2.26-4.68] 
[3.63-7.51] 
[4.06-8.39] 
[2.90-5.99]  [24,71-77] 
Per-test cost of culture:   
Botswana 
Lesotho 
Namibia 
South Africa 
Swaziland 
 
$15.83 
$8.56 
$13.72 
$15.33 
$10.94 
 
[13.07-18.99] 
[7.07-10.27] 
[11.33-16.46] 
[12.66-18.39] 
[9.04 -13.13]  [24,71,73,74,77] 
Per-test cost of chest X-ray:   
Botswana 
Lesotho 
Namibia 
South Africa 
Swaziland 
 
$16.69 
$9.03 
$14.46 
$16.16 
$11.54 
 
[11.35-23.70] 
[6.14-12.81] 
[9.83-20.52] 
[10.99-22.94] 
[7.85-16.38]  [71,76,78] 
Per-test cost of drug sensitivity testing: 
Botswana 
Lesotho 
Namibia 
South Africa 
Swaziland 
 
$81.97 
$44.32 
$71.02 
$79.37 
$56.65 
 
[61.44-
107.17] 
[33.22-57.94] 
[53.24-92.85] 
[59.50-103.77] 
[42.47-74.07]  [79,80] 
Cost of outpatient diagnostic visit:  
Botswana 
Lesotho 
Namibia 
South Africa 
Swaziland 
 
$10.32 
$2.94 
$7.99 
$10.30 
$6.21 
 
[6.09-16.40] 
[1.73-4.67] 
[4.71-12.70] 
[6.08-16.39] 
[3.66-9.87]  [81] 
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Table 2.5. Base-case parameter values and ranges (continued) 
Description  Base-case value  Range*  Source 
Cost of outpatient treatment visit:  
Botswana 
Lesotho 
Namibia 
South Africa 
Swaziland 
 
$6.85 
$1.95 
$5.31 
$6.85 
$4.13 
 
[4.04-10.89] 
[1.15-3.10] 
[3.13-8.44] 
[4.04-10.89] 
[2.44-6.57]  [81] 
Cost of inpatient care, per day:  
Botswana 
Lesotho 
Namibia 
South Africa 
Swaziland 
 
$38.99 
$8.78 
$28.76 
$39.38 
$21.91 
 
[23.00-61.99] 
[5.18-13.96] 
[16.97-45.73] 
[23.23-62.61] 
[12.93-34.84]  [81] 
Monthly TB regimen cost:   
First-line 
Mono-INH resistant 
Mono-RIF resistant 
MDR-TB 
MDR+/XDR-TB 
 
$5.86 
$18.02 
$33.91 
$119.37 
$179.06 
 
[3.46-9.32] 
[10.63-28.65] 
[20.01-53.92] 
[70.43-189.79] 
[105.64-284.7]  [41] 
Monthly frequency of treatment activities, 
averaged over treatment course:   
Clinic visits (first-line) 
Clinic visits (second-line) 
Monitoring smears (first-line) 
Monitoring smears (second-line) 
Sputum cultures (second-line) 
Chest X-rays (second-line) 
 
 
5.9 
22.3 
1.0 
1.0 
0.43 
0.14 
 
 
[3.5-9.4] 
[13.2-35.4] 
[0.6-1.6] 
[0.6-1.6] 
[0.25-0.68] 
[0.08-0.22]  [1] 
Number of months of inpatient care with 
MDR-TB treatment 
4.0  [2.4-6.4] 
[82] 
Monthly cost of ART:   
Botswana 
Lesotho 
Namibia 
South Africa 
Swaziland 
 
$104.97 
$69.63 
$94.68 
$102.53 
$81.20 
 
[84-80-128.48] 
[57.22-83.92] 
[76.78-115.52] 
[82.90-125.40] 
[66.25-98.52]  [41,83-87] 
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Table 2.5. Base-case parameter values and ranges (continued) 
Description  Base-case value  Range*  Source 
Disability weights:   
Active TB 
HIV-pos, CD4 >350 cells/µl, no ART 
HIV- pos, CD4 200–350 cells/µl, no ART 
HIV- pos, CD4 <200 cells/µl, no ART 
HIV- pos, ART initiated at CD4 >350  
HIV- pos, ART initat CD4 200–350  
HIV- pos, ART initat CD4 <200  
 
0.271 
0.135 
0.320 
0.505 
0.135 
0.151 
0.167 
 
[0.151-0.422] 
[0.078-0.213] 
[0.176-0.496] 
[0.252-0.757] 
[0.078-0.213] 
[0.087-0.238] 
[0.096-0.262]  [43,44] 
Discount rate  3.0%  [0-10%]  [88,89] 
All costs are given in 2011 US dollars 
* Ranges for parameters were derived from the literature where sufficient data existed, and otherwise 
were calculated as ± 50% of the point estimate value. 90 
 
 
Figure 2.11. Time-varying parameter inputs for TB diagnosis and treatment 
 
2.6.4.  Model calibration 
We adopted a Bayesian approach to calibrate the model, following the prior work of Raftery, 
Alkema and colleagues [90,91]. The approach enables the synthesis of multiple sources of 
information on the values of model outputs, and allows for characterization of the uncertainty in 
model results using Bayesian posterior intervals and similar metrics.  
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The disease model (M) can be considered a deterministic mapping from the parameter space of the 
model inputs (Θ) to that of the model outputs (Φ), such that M: θ → φ. For some of these outputs 
(φ1) we have external data (X) related to φ1 through a defined probability model. An example of φ1 
would be model projections of MDR-TB prevalence for 2010, and an example for X would be the 
estimate for MDR-TB prevalence obtained from a population-based survey conducted in the same 
year. For other outputs (φ2) — generally those about we would like to make inferences — we have 
no external data, but can estimate their distribution based on the prior information about θ and φ2, 
relying on the deterministic disease model to link these three sets of parameters. As we have 
probabilistic prior information on θ and φ1, we can use this information to estimate the posterior 
density of θ: 
 ( | )    ( )    ( | ) 
where p(θ) is the prior distribution of the model inputs, and  ( | ) is the likelihood function for θ 
constructed with the external data X. While this likelihood function cannot be estimated directly, we 
can transform θ into the output parameter space to estimate the likelihood: 
 ( | )    ( )    ( | ( )) 
   ( )    ( |  )   
Having obtained a posterior distribution for the model inputs, we can then estimate the posterior 
density of φ2 through the model, as  ( ( | )). An analytic solution can be difficult or impossible to 
calculate for disease models of moderate or greater complexity, but the posterior distributions can 
be approximated using numerical methods. Following Alkema et al. [90], we used a sampling / 
importance resampling (SIR) algorithm [92]: 92 
 
The prior uncertainty was quantified for each model parameter, expressed as the ranges given in 
Table 2.5. Each range was assumed to represent the 95% equal tailed interval for a log-normal 
distribution (for parameters defined over positive numbers, e.g., rates, costs) or logit-normal 
distribution (for parameters defined over the interval 0–1, e.g., probabilities, disability weights).  
For each country, a likelihood function was constructed to calibrate the model, based on (a) WHO 
estimates [29] for TB prevalence and incidence in 1990 and 2009 (the earliest and most recent 
estimates available, respectively); and (b) results from a country-level drug resistance survey, 
where available [93]. The uncertainty around prevalence and incidence estimates was assumed to 
be distributed normally, with a variance calculated from the width of the uncertainty intervals 
reported with the WHO estimates. The sample size and MDR-TB prevalence reported by the drug 
resistance surveys were used to parameterize two beta distributions (one for treatment-
experienced and one for treatment-naïve individuals), assuming a design effect of 2.0 for the survey 
sample. These likelihood functions were assumed to be mutually independent, and multiplied to 
create a joint likelihood function.  
For each country 20,000 random parameter sets were drawn via Latin hypercube sampling, and a 
separate simulation conducted for each of these parameter sets. A likelihood statistic was 
calculated for each of these model runs by applying the joint likelihood function to the model 
outputs produced by a particular parameter set. 
The 20,000 parameter sets from the first stage sample were then resampled with replacement to 
create a final array of parameter sets, using the likelihoods as sampling weights. A sample size of 
100,000 was used for this second sample as this step is not computationally intensive. 
Results were calculated by running the model for the resampled parameter sets. For each quantity 
of interest, the point estimate was calculated as the mean of the results for the second stage sample, 93 
 
and 95% posterior intervals (the Bayesian equivalent of confidence intervals) calculated from the 
2.5th and 97.5th percentiles of the simulation results for each quantity of interest. 
This procedure was conducted separately for each country. Figure 2.12 shows the results of the 
calibration for TB prevalence, incidence and MDR-TB prevalence in South Africa, overlaid with the 
WHO estimates and drug resistance survey data. Posterior distributions for health outcomes and 
costs for the southern Africa region were calculated by summing the outcomes for each country.  
 
 
Figure 2.12. Calibrated outcomes for South Africa based on sampling / importance 
resampling 94 
 
2.6.5.  Sensitivity and uncertainty analyses 
We adopted four approaches to investigate the sensitivity of results to changes in model inputs.  
2.6.5.1.  Deterministic one-way senstitivity analyses 
Traditional deterministic one-way sensitivity analyses describe how the value of a model output 
responds to deliberate changes in the value of a particular input parameter, when all other 
variables are held at their expected values. For all input parameters, we evaluated how the 10-year 
incremental cost-effectiveness ratio for Xpert vs. the status quo changed as each individual 
parameter was varied ±1 standard deviation from the mean of its posterior distribution, while all 
other variables were held at their posterior mean values. The resulting information represents a set 
of 'what-if' analyses, useful for identifying situations where the optimal policy decision might 
change if the value of an individual parameter were found to differ substantially from prior 
expectations. The main paper (Figure 2.8) reported on results for the 10 most influential 
parameters identified through this process for South Africa. A full listing of results, by country, is 
shown here in Tables 2.6-2.10. 
2.6.5.2.  Analysis of partial rank correlation coefficients 
Partial rank correlation coefficients (PRCCs) represent a complementary approach for investigating 
uncertainty, providing information on the relative influence that individual parameters have on 
model outcomes based on the results of a probabilistic sensitivity analysis [4,94,95]. We calculated 
PRCCs using the resampled parameter sets produced by the calibration proceedure. Results for the 
10 parameters having the greatest influence on the cost-effectiveness ratio for Xpert in South 
Africa, under a 10-year time horizon, are shown in Figure 2.9. 
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Table 2.6. Univariate sensitivity analysis, Botswana (base-case ICER =$1,289) 
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Transmission parameter for individuals with smear-pos 
TB in 1950  9.6  12.2  1,381  1,248 
Annual percentage decline in transmission parameter  0.004  0.010  1,236  1,394 
Infectivity of smear-neg TB, relative to smear-pos TB   0.17  0.30  1,447  1,167 
Fitness cost for drug-resistant TB strains (% of base-case)  82%  134%  1,392  1,218 
Rate of attending TB testing site, for individuals with 
active TB, DOTS, 1990 (% of base-case)  53%  174%  1,292  1,285 
Rate of attending TB testing site, for individuals with 
active TB, DOTS, 2010 (% of base-case)  90%  191%  1,071  1,561 
Rate of attending TB testing site, for individuals with 
active TB, non-DOTS, 1990 (% of base-case)  48%  136%  1,242  1,335 
Rate of attending TB testing site, for individuals with 
active TB, non-DOTS, 2010 (% of base-case)  50%  140%  1,245  1,334 
Rate ratio of TB testing, for individuals without active TB 
compared to those with active TB  0.011  0.019  1,203  1,374 
Specificity of sputum smear microscopy  0.97  0.98  1,256  1,321 
Specificity of sputum culture   0.98  0.99  1,284  1,293 
Sensitivity of Xpert for TB, smear-neg TB   0.69  0.76  1,314  1,267 
Sensitivity of Xpert for TB, smear-pos TB   0.98  0.99  1,295  1,282 
Specificity of Xpert for TB  0.99  1.00  1,316  1,261 
Sensitivity of Xpert for RIF resistance  0.96  0.99  1,280  1,297 
Specificity of Xpert for RIF resistance  0.98  0.99  1,291  1,286 
Probability of sputum culture following a negative 
sputum smear (status quo), tx-naïve patients  0.16  0.27  1,192  1,389 
Probability of sputum culture following a negative 
sputum smear (status quo), tx-experienced patients  0.75  0.85  1,289  1,288 
Probability of DST following a positive TB diagnosis 
(status quo), tx-experienced patients  0.75  0.85  1,324  1,253 
Probability of loss to follow-up between initial 
presentation and tx initiation, with prompt diagnosis  0.12  0.19  1,281  1,298 
Probability of loss to follow-up between initial 
presentation and tx initiation, with delayed diagnosis  0.18  0.30  1,343  1,238 
Tx default rate, DOTS (% of base-case)  78%  129%  1,278  1,293 
Tx default rate, non-DOTS   0.39  0.70  1,363  1,218 
Probability of tx success, individuals with pan-sensitive 
TB completing 1st-line regimen (% of base-case)  77%  125%  1,304  1,283 96 
 
Table 2.6. Univariate sensitivity analysis, Botswana (base-case ICER =$1289) (continued) 
Parameter description 
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Risk ratio of tx success, 1st-line regimen, semi-sensitive 
strain  0.79  0.87  1,296  1,282 
Risk ratio of tx success, 1st-line regimen, non-sensitive 
strain  0.32  0.56  1,303  1,278 
Risk ratio of tx success, 2nd-line regimen, sensitive strain  0.91  0.95  1,301  1,277 
Risk ratio of tx success, 2nd-line regimen, non-sensitive 
strain  0.34  0.58  1,339  1,260 
Risk ratio of tx success, non-DOTS regimen, non-MDR 
strain  0.65  0.81  1,287  1,290 
Risk ratio of tx success, non-DOTS regimen, MDR strain  0.32  0.56  1,302  1,277 
Excess mortality rate for active TB, smear-neg  0.20  0.23  1,282  1,295 
Excess mortality rate for active TB, smear-pos  0.26  0.37  1,322  1,267 
Excess mortality rate for HIV, CD4 >350 cells/µl, no ART  0.006  0.010  1,285  1,292 
Excess mortality rate for HIV, CD4 200-350 cells/µl, no 
ART  0.023  0.038  1,287  1,290 
Excess mortality rate for HIV, CD4 <200 cells/µl, no ART  0.17  0.28  1,285  1,291 
Excess mortality rate for HIV, on ART initiated at CD4 
>350 cells/µl  0.006  0.010  1,289  1,289 
Excess mortality rate for HIV, on ART initiated at CD4 
200-350 cells/µl  0.017  0.028  1,286  1,291 
Excess mortality rate for HIV, on ART initiated at CD4 
<200 cells/µl  0.038  0.062  1,275  1,302 
Excess mortality rate for advanced HIV (CD4 <200 
cells/µl) and active TB without ART  0.62  1.04  1,287  1,290 
TB tx mortality rates (% of base-case)  77%  127%  1,308  1,271 
Partial immunity afforded by prior infection, HIV-neg  0.60  0.81  1,283  1,303 
Partial immunity afforded by prior infection, HIV-pos, 
CD4 >350 cells/µl, no ART  0.35  0.58  1,291  1,287 
Partial immunity afforded by prior infection, HIV-pos, 
CD4 200-350 cells/µl, no ART  0.19  0.31  1,288  1,290 
Partial immunity afforded by prior infection, HIV-pos, 
CD4 <200 cells/µl, no ART  0.18  0.32  1,288  1,289 
Probability of fast breakdown to active TB, with new 
infection, HIV-neg  0.10  0.12  1,333  1,256 
Probability of fast breakdown to active TB, with new 
infection, HIV-pos, CD4 >350 cells/µl, no ART  0.24  0.41  1,298  1,282 
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Table 2.6. Univariate sensitivity analysis, Botswana (base-case ICER =$1289) (continued) 
Parameter description 
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Probability of fast breakdown to active TB, with new 
infection, HIV-pos, CD4 200-350 cells/µl, no ART  0.59  0.77  1,290  1,287 
Probability of fast breakdown to active TB, with new 
infection, HIV-pos, CD4 <200 cells/µl, no ART  0.87  1.00  1,289  1,288 
Probability of smear-positivity, for incident TB cases, HIV-
neg  0.56  0.74  1,190  1,428 
Probability of smear-positivity, for incident TB cases, HIV-
pos, CD4 >350 cells/µl, no ART  0.34  0.57  1,262  1,317 
Probability of smear-positivity, for incident TB cases, HIV-
pos, CD4 200-350 cells/µl, no ART  0.27  0.44  1,272  1,307 
Probability of smear-positivity, for incident TB cases, HIV-
pos, CD4 <200 cells/µl, no ART  0.26  0.44  1,273  1,305 
Rate of breakdown, latent/recovered to active TB, HIV-
neg  0.0006  0.0014  1,339  1,251 
Rate of breakdown, latent/recovered to active TB, HIV-
pos, CD4 >350 cells/µl, no ART  0.002  0.004  1,296  1,281 
Rate of breakdown, latent/recovered to active TB, HIV-
pos, CD4 200-350 cells/µl, no ART  0.08  0.11  1,305  1,275 
Rate of breakdown, latent/recovered to active TB, HIV-
pos, CD4 <200 cells/µl, no ART  0.14  0.22  1,314  1,273 
Rate of conversion, smear-neg to smear-pos active TB  0.012  0.019  1,286  1,291 
Rate of self-cure for active TB, HIV-neg  0.19  0.24  1,258  1,321 
Rate of self-cure for active TB, HIV-pos, CD4 >350 cells/µl, 
no ART  0.08  0.13  1,284  1,292 
Probability that failed tx cases are correctly identified and 
returned to tx  0.38  0.63  1,294  1,283 
Rate of acquisition of TB drug resistance (% of base-case)  77%  127%  1,179  1,414 
HIV incidence trend, post-2011 (% of base-case)  98%  103%  1,290  1,287 
Rate of HIV progression for individuals not on ART, from 
CD4 >350 cells/µl to CD4 200-350 cells/µl  0.11  0.17  1,266  1,308 
Rate of HIV progression for individuals not on ART, from 
CD4 200-350 cells/µl to CD4 <200 cells/µl  0.35  0.66  1,287  1,290 
Future ART coverage for tx-eligible HIV-pos individuals  0.66  0.93  1,180  1,371 
Effectiveness of ART in reversing effect of HIV on TB 
natural history   0.54  0.75  1,213  1,393 
Per-test cost of smear diagnosis  4.9  7.5  1,334  1,243 
Per-test cost of culture  14.4  17.4  1,301  1,276 98 
 
Table 2.6. Univariate sensitivity analysis, Botswana (base-case ICER =$1289) (continued) 
Parameter description 
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Per-test cost of chest X-ray  13.5  19.8  1,288  1,289 
Per-test cost of drug sensitivity testing  71.0  94.5  1,296  1,281 
Cost of outpatient diagnostic visit  7.7  13.1  1,321  1,256 
Cost of outpatient tx visit  5.0  9.0  1,281  1,296 
Cost of inpatient care, per day  28.6  48.8  1,246  1,331 
Monthly TB regimen costs (% of base-case)  0.74  1.27  1,267  1,310 
Monthly frequency of tx activities, averaged over tx 
course, clinic visits (1st-line)  4.3  7.5  1,299  1,278 
Monthly frequency of tx activities, averaged over tx 
course, clinic visits (2nd-line)  15.9  27.4  1,266  1,311 
Monthly frequency of tx activities, averaged over tx 
course, monitoring smears (1st-line)  0.73  1.25  1,290  1,287 
Monthly frequency of tx activities, averaged over tx 
course, monitoring smears (2nd-line)  0.74  1.26  1,288  1,289 
Monthly frequency of tx activities, averaged over tx 
course, sputum cultures (2nd-line)  0.31  0.54  1,288  1,290 
Monthly frequency of tx activities, averaged over tx 
course, chest X-rays (2nd-line)  0.11  0.18  1,288  1,289 
Number of months of inpatient care with MDR-TB tx  3.0  5.1  1,246  1,331 
Monthly cost of ART  93.3  116.0  1,227  1,350 
Disability weight, active TB  0.20  0.34  1,366  1,219 
Disability weight, HIV-pos, CD4 >350 cells/µl, no ART  0.10  0.17  1,285  1,292 
Disability weight, HIV-pos, CD4 200-350 cells/µl, no ART  0.23  0.39  1,289  1,289 
Disability weight, HIV-pos, CD4 <200 cells/µl, no ART  0.36  0.64  1,282  1,295 
Disability weight, HIV-pos, ART initiated CD4 >350   0.10  0.17  1,278  1,300 
Disability weight, HIV-pos, ART initiated CD4 200-350   0.12  0.19  1,284  1,293 
Disability weight, HIV-pos, ART initiated CD4 <200   0.13  0.21  1,271  1,307 
Annual discount rate  0  10%  1,265  1,348 
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Table 2.7. Univariate sensitivity analysis, Lesotho (base-case ICER =$1071)  
Parameter description 
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Transmission parameter for individuals with smear-pos 
TB in 1950 
9.7  12.4  1,281  942 
Annual percentage decline in transmission parameter  0.004  0.010  896  1,294 
Infectivity of smear-neg TB, relative to smear-pos TB   0.18  0.30  1,254  933 
Fitness cost for drug-resistant TB strains (% of base-case)  79%  131%  1,085  1,062 
Rate of attending TB testing site, for individuals with 
active TB, DOTS, 1990 (% of base-case) 
58%  185%  1,045  1,090 
Rate of attending TB testing site, for individuals with 
active TB, DOTS, 2010 (% of base-case) 
60%  139%  714  1,537 
Rate of attending TB testing site, for individuals with 
active TB, non-DOTS, 1990 (% of base-case) 
46%  139%  1,060  1,082 
Rate of attending TB testing site, for individuals with 
active TB, non-DOTS, 2010 (% of base-case) 
48%  152%  1,068  1,075 
Rate ratio of TB testing, for individuals without active TB 
compared to those with active TB 
0.012  0.019  931  1,212 
Specificity of sputum smear microscopy  0.97  0.98  1,058  1,085 
Specificity of sputum culture   0.98  0.99  1,070  1,073 
Sensitivity of Xpert for TB, smear-neg TB   0.69  0.76  1,101  1,046 
Sensitivity of Xpert for TB, smear-pos TB   0.98  0.99  1,077  1,067 
Specificity of Xpert for TB  0.99  1.00  1,083  1,060 
Sensitivity of Xpert for RIF resistance  0.97  0.99  1,070  1,073 
Specificity of Xpert for RIF resistance  0.98  0.99  1,072  1,071 
Probability of sputum culture following a negative 
sputum smear (status quo), tx-naïve patients 
0.16  0.27  937  1,227 
Probability of sputum culture following a negative 
sputum smear (status quo), tx-experienced patients 
0.74  0.85  1,067  1,076 
Probability of DST following a positive TB diagnosis 
(status quo), tx-experienced patients 
0.75  0.85  1,078  1,065 
Probability of loss to follow-up between initial 
presentation and tx initiation, with prompt diagnosis 
0.11  0.18  1,060  1,085 
Probability of loss to follow-up between initial 
presentation and tx initiation, with delayed diagnosis 
0.18  0.32  1,141  1,008 
Tx default rate, DOTS (% of base-case)  73%  120%  1,064  1,074 
Tx default rate, non-DOTS   0.48  0.78  1,086  1,058 
Probability of tx success, individuals with pan-sensitive 
TB completing 1st-line regimen (% of base-case) 
76%  127%  1,067  1,073 100 
 
Table 2.7. Univariate sensitivity analysis, Lesotho (base-case ICER =$1071) (continued) 
Parameter description 
L
o
w
 
p
a
r
.
 
v
a
l
u
e
 
H
i
g
h
 
p
a
r
.
 
v
a
l
u
e
 
I
C
E
R
 
w
/
 
l
o
w
 
v
a
l
u
e
 
I
C
E
R
 
w
/
 
h
i
g
h
 
v
a
l
u
e
 
Risk ratio of tx success, 1st-line regimen, semi-sensitive 
strain 
0.79  0.87  1,073  1,070 
Risk ratio of tx success, 1st-line regimen, non-sensitive 
strain 
0.36  0.58  1,071  1,072 
Risk ratio of tx success, 2nd-line regimen, sensitive strain  0.91  0.95  1,074  1,069 
Risk ratio of tx success, 2nd-line regimen, non-sensitive 
strain 
0.35  0.57  1,078  1,067 
Risk ratio of tx success, non-DOTS regimen, non-MDR 
strain 
0.66  0.81  1,066  1,077 
Risk ratio of tx success, non-DOTS regimen, MDR strain  0.32  0.56  1,073  1,070 
Excess mortality rate for active TB, smear-neg  0.20  0.23  1,066  1,078 
Excess mortality rate for active TB, smear-pos  0.27  0.39  1,046  1,104 
Excess mortality rate for HIV, CD4 >350 cells/µl, no ART  0.006  0.010  1,063  1,080 
Excess mortality rate for HIV, CD4 200-350 cells/µl, no 
ART 
0.023  0.038  1,061  1,082 
Excess mortality rate for HIV, CD4 <200 cells/µl, no ART  0.16  0.25  1,021  1,114 
Excess mortality rate for HIV, on ART initiated at CD4 
>350 cells/µl 
0.006  0.010  1,071  1,071 
Excess mortality rate for HIV, on ART initiated at CD4 
200-350 cells/µl 
0.017  0.029  1,070  1,073 
Excess mortality rate for HIV, on ART initiated at CD4 
<200 cells/µl 
0.039  0.061  1,054  1,089 
Excess mortality rate for advanced HIV (CD4 <200 
cells/µl) and active TB without ART 
0.61  1.00  1,033  1,103 
TB tx mortality rates (% of base-case)  78%  130%  1,068  1,075 
Partial immunity afforded by prior infection, HIV-neg  0.62  0.82  1,033  1,111 
Partial immunity afforded by prior infection, HIV-pos, 
CD4 >350 cells/µl, no ART 
0.33  0.57  1,069  1,074 
Partial immunity afforded by prior infection, HIV-pos, 
CD4 200-350 cells/µl, no ART 
0.18  0.31  1,069  1,074 
Partial immunity afforded by prior infection, HIV-pos, 
CD4 <200 cells/µl, no ART 
0.18  0.32  1,067  1,076 
Probability of fast breakdown to active TB, with new 
infection, HIV-neg 
0.10  0.12  1,159  1,000 
Probability of fast breakdown to active TB, with new 
infection, HIV-pos, CD4 >350 cells/µl, no ART 
0.25  0.43  1,109  1,036 
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Table 2.7. Univariate sensitivity analysis, Lesotho (base-case ICER =$1071) (continued) 
Parameter description 
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Probability of fast breakdown to active TB, with new 
infection, HIV-pos, CD4 200-350 cells/µl, no ART 
0.58  0.76  1,077  1,066 
Probability of fast breakdown to active TB, with new 
infection, HIV-pos, CD4 <200 cells/µl, no ART 
0.85  1.00  1,078  1,067 
Probability of smear-positivity, for incident TB cases, HIV-
neg 
0.53  0.72  1,043  1,120 
Probability of smear-positivity, for incident TB cases, HIV-
pos, CD4 >350 cells/µl, no ART 
0.33  0.58  1,051  1,093 
Probability of smear-positivity, for incident TB cases, HIV-
pos, CD4 200-350 cells/µl, no ART 
0.26  0.44  1,058  1,085 
Probability of smear-positivity, for incident TB cases, HIV-
pos, CD4 <200 cells/µl, no ART 
0.27  0.44  1,060  1,084 
Rate of breakdown, latent/recovered to active TB, HIV-
neg 
0.0005  0.00122  1,137  1,025 
Rate of breakdown, latent/recovered to active TB, HIV-
pos, CD4 >350 cells/µl, no ART 
0.002  0.004  1,082  1,061 
Rate of breakdown, latent/recovered to active TB, HIV-
pos, CD4 200-350 cells/µl, no ART 
0.08  0.11  1,099  1,048 
Rate of breakdown, latent/recovered to active TB, HIV-
pos, CD4 <200 cells/µl, no ART 
0.15  0.24  1,140  1,025 
Rate of conversion, smear-neg to smear-pos active TB  0.011  0.018  1,071  1,072 
Rate of self-cure for active TB, HIV-neg  0.18  0.24  1,027  1,119 
Rate of self-cure for active TB, HIV-pos, CD4 >350 cells/µl, 
no ART 
0.07  0.13  1,065  1,078 
Probability that failed tx cases are correctly identified and 
returned to tx 
0.39  0.65  1,072  1,071 
Rate of acquisition of TB drug resistance (% of base-case)  66%  108%  1,052  1,094 
HIV incidence trend, post-2011 (% of base-case)  98%  102%  1,076  1,066 
Rate of HIV progression for individuals not on ART, from 
CD4 >350 cells/µl to CD4 200-350 cells/µl 
0.11  0.18  1,092  1,066 
Rate of HIV progression for individuals not on ART, from 
CD4 200-350 cells/µl to CD4 <200 cells/µl 
0.36  0.61  1,028  1,102 
Future ART coverage for tx-eligible HIV-pos individuals  0.67  0.91  1,009  1,134 
Effectiveness of ART in reversing effect of HIV on TB 
natural history  
0.58  0.79  1,000  1,157 
Per-test cost of smear diagnosis  2.7  3.8  1,091  1,052 
Per-test cost of culture  7.7  9.4  1,078  1,065 102 
 
Table 2.7. Univariate sensitivity analysis, Lesotho (base-case ICER =$1071) (continued) 
Parameter description 
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Per-test cost of chest X-ray  7.2  10.6  1,071  1,072 
Per-test cost of drug sensitivity testing  37.9  51.1  1,075  1,068 
Cost of outpatient diagnostic visit  2.2  3.8  1,080  1,063 
Cost of outpatient tx visit  1.5  2.5  1,073  1,070 
Cost of inpatient care, per day  6.6  10.9  1,068  1,075 
Monthly TB regimen costs (% of base-case)  0.75  1.24  1,064  1,079 
Monthly frequency of tx activities, averaged over tx 
course, clinic visits (1st-line) 
4.3  7.4  1,074  1,069 
Monthly frequency of tx activities, averaged over tx 
course, clinic visits (2nd-line) 
16.9  28.0  1,069  1,074 
Monthly frequency of tx activities, averaged over tx 
course, monitoring smears (1st-line) 
0.76  1.29  1,072  1,071 
Monthly frequency of tx activities, averaged over tx 
course, monitoring smears (2nd-line) 
0.75  1.22  1,071  1,072 
Monthly frequency of tx activities, averaged over tx 
course, sputum cultures (2nd-line) 
0.32  0.54  1,071  1,072 
Monthly frequency of tx activities, averaged over tx 
course, chest X-rays (2nd-line) 
0.10  0.18  1,071  1,072 
Number of months of inpatient care with MDR-TB tx  3.0  5.1  1,067  1,076 
Monthly cost of ART  62.5  76.5  1,035  1,108 
Disability weight, active TB  0.21  0.35  1,130  1,019 
Disability weight, HIV-pos, CD4 >350 cells/µl, no ART  0.10  0.17  1,067  1,076 
Disability weight, HIV-pos, CD4 200-350 cells/µl, no ART  0.24  0.40  1,071  1,071 
Disability weight, HIV-pos, CD4 <200 cells/µl, no ART  0.36  0.64  1,064  1,079 
Disability weight, HIV-pos, ART initiated CD4 >350   0.10  0.17  1,067  1,076 
Disability weight, HIV-pos, ART initiated CD4 200-350   0.12  0.19  1,065  1,078 
Disability weight, HIV-pos, ART initiated CD4 <200   0.12  0.21  1,053  1,091 
Annual discount rate  0  10%  1,050  1,126 
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Table 2.8. Univariate sensitivity analysis, Namibia (base-case ICER =$863)  
Parameter description 
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Transmission parameter for individuals with smear-pos 
TB in 1950 
10.0  12.8  955  811 
Annual percentage decline in transmission parameter  0.003  0.007  803  942 
Infectivity of smear-neg TB, relative to smear-pos TB   0.19  0.33  992  768 
Fitness cost for drug-resistant TB strains (% of base-case)  79%  132%  916  828 
Rate of attending TB testing site, for individuals with 
active TB, DOTS, 1990 (% of base-case) 
52%  137%  864  862 
Rate of attending TB testing site, for individuals with 
active TB, DOTS, 2010 (% of base-case) 
42%  96%  688  1,088 
Rate of attending TB testing site, for individuals with 
active TB, non-DOTS, 1990 (% of base-case) 
47%  153%  839  887 
Rate of attending TB testing site, for individuals with 
active TB, non-DOTS, 2010 (% of base-case) 
44%  132%  838  890 
Rate ratio of TB testing, for individuals without active TB 
compared to those with active TB 
0.011  0.019  786  941 
Specificity of sputum smear microscopy  0.97  0.98  848  879 
Specificity of sputum culture   0.98  0.99  861  866 
Sensitivity of Xpert for TB, smear-neg TB   0.69  0.76  883  846 
Sensitivity of Xpert for TB, smear-pos TB   0.98  0.99  870  857 
Specificity of Xpert for TB  0.99  1.00  878  849 
Sensitivity of Xpert for RIF resistance  0.97  0.99  859  868 
Specificity of Xpert for RIF resistance  0.98  0.99  865  862 
Probability of sputum culture following a negative 
sputum smear (status quo), tx-naïve patients 
0.15  0.25  804  928 
Probability of sputum culture following a negative 
sputum smear (status quo), tx-experienced patients 
0.75  0.86  864  863 
Probability of DST following a positive TB diagnosis 
(status quo), tx-experienced patients 
0.75  0.86  881  846 
Probability of loss to follow-up between initial 
presentation and tx initiation, with prompt diagnosis 
0.12  0.19  858  870 
Probability of loss to follow-up between initial 
presentation and tx initiation, with delayed diagnosis 
0.19  0.31  895  834 
Tx default rate, DOTS (% of base-case)  74%  116%  858  866 
Tx default rate, non-DOTS   0.45  0.75  908  822 
Probability of tx success, individuals with pan-sensitive 
TB completing 1st-line regimen (% of base-case) 
73%  129%  873  861 104 
 
Table 2.8. Univariate sensitivity analysis, Namibia (base-case ICER =$863) (continued) 
Parameter description 
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Risk ratio of tx success, 1st-line regimen, semi-sensitive 
strain 
0.79  0.87  866  861 
Risk ratio of tx success, 1st-line regimen, non-sensitive 
strain 
0.36  0.60  866  861 
Risk ratio of tx success, 2nd-line regimen, sensitive strain  0.91  0.95  869  858 
Risk ratio of tx success, 2nd-line regimen, non-sensitive 
strain 
0.33  0.56  877  855 
Risk ratio of tx success, non-DOTS regimen, non-MDR 
strain 
0.67  0.81  861  865 
Risk ratio of tx success, non-DOTS regimen, MDR strain  0.33  0.54  869  859 
Excess mortality rate for active TB, smear-neg  0.19  0.23  851  876 
Excess mortality rate for active TB, smear-pos  0.27  0.37  886  848 
Excess mortality rate for HIV, CD4 >350 cells/µl, no ART  0.006  0.009  861  866 
Excess mortality rate for HIV, CD4 200-350 cells/µl, no 
ART 
0.022  0.036  861  866 
Excess mortality rate for HIV, CD4 <200 cells/µl, no ART  0.16  0.26  858  870 
Excess mortality rate for HIV, on ART initiated at CD4 
>350 cells/µl 
0.006  0.010  863  863 
Excess mortality rate for HIV, on ART initiated at CD4 
200-350 cells/µl 
0.017  0.028  863  864 
Excess mortality rate for HIV, on ART initiated at CD4 
<200 cells/µl 
0.037  0.061  855  873 
Excess mortality rate for advanced HIV (CD4 <200 
cells/µl) and active TB without ART 
0.61  0.97  860  866 
TB tx mortality rates (% of base-case)  78%  126%  871  857 
Partial immunity afforded by prior infection, HIV-neg  0.61  0.83  847  885 
Partial immunity afforded by prior infection, HIV-pos, 
CD4 >350 cells/µl, no ART 
0.32  0.55  863  864 
Partial immunity afforded by prior infection, HIV-pos, 
CD4 200-350 cells/µl, no ART 
0.19  0.31  862  865 
Partial immunity afforded by prior infection, HIV-pos, 
CD4 <200 cells/µl, no ART 
0.18  0.31  861  866 
Probability of fast breakdown to active TB, with new 
infection, HIV-neg 
0.10  0.12  920  819 
Probability of fast breakdown to active TB, with new 
infection, HIV-pos, CD4 >350 cells/µl, no ART 
0.26  0.43  868  860 
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Table 2.8. Univariate sensitivity analysis, Namibia (base-case ICER =$863) (continued) 
Parameter description 
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Probability of fast breakdown to active TB, with new 
infection, HIV-pos, CD4 200-350 cells/µl, no ART 
0.58  0.75  864  863 
Probability of fast breakdown to active TB, with new 
infection, HIV-pos, CD4 <200 cells/µl, no ART 
0.87  1.00  864  863 
Probability of smear-positivity, for incident TB cases, HIV-
neg 
0.54  0.72  783  981 
Probability of smear-positivity, for incident TB cases, HIV-
pos, CD4 >350 cells/µl, no ART 
0.35  0.58  855  873 
Probability of smear-positivity, for incident TB cases, HIV-
pos, CD4 200-350 cells/µl, no ART 
0.27  0.47  858  869 
Probability of smear-positivity, for incident TB cases, HIV-
pos, CD4 <200 cells/µl, no ART 
0.28  0.45  860  867 
Rate of breakdown, latent/recovered to active TB, HIV-
neg 
0.0005  0.00141  911  826 
Rate of breakdown, latent/recovered to active TB, HIV-
pos, CD4 >350 cells/µl, no ART 
0.002  0.004  866  861 
Rate of breakdown, latent/recovered to active TB, HIV-
pos, CD4 200-350 cells/µl, no ART 
0.08  0.12  871  857 
Rate of breakdown, latent/recovered to active TB, HIV-
pos, CD4 <200 cells/µl, no ART 
0.15  0.25  885  850 
Rate of conversion, smear-neg to smear-pos active TB  0.012  0.018  862  865 
Rate of self-cure for active TB, HIV-neg  0.18  0.24  831  898 
Rate of self-cure for active TB, HIV-pos, CD4 >350 cells/µl, 
no ART 
0.08  0.13  861  865 
Probability that failed tx cases are correctly identified and 
returned to tx 
0.37  0.64  866  861 
Rate of acquisition of TB drug resistance (% of base-case)  70%  113%  812  921 
HIV incidence trend, post-2011 (% of base-case)  97%  103%  863  864 
Rate of HIV progression for individuals not on ART, from 
CD4 >350 cells/µl to CD4 200-350 cells/µl 
0.12  0.19  860  870 
Rate of HIV progression for individuals not on ART, from 
CD4 200-350 cells/µl to CD4 <200 cells/µl 
0.35  0.61  858  868 
Future ART coverage for tx-eligible HIV-pos individuals  0.65  0.92  816  911 
Effectiveness of ART in reversing effect of HIV on TB 
natural history  
0.50  0.71  824  917 
Per-test cost of smear diagnosis  4.3  6.3  886  841 
Per-test cost of culture  12.5  15.2  871  856 106 
 
Table 2.8. Univariate sensitivity analysis, Namibia (base-case ICER =$863) (continued) 
Parameter description 
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Per-test cost of chest X-ray  11.7  17.0  863  864 
Per-test cost of drug sensitivity testing  61.0  80.5  867  860 
Cost of outpatient diagnostic visit  5.9  10.0  878  849 
Cost of outpatient tx visit  3.9  6.6  854  873 
Cost of inpatient care, per day  20.9  35.3  845  882 
Monthly TB regimen costs (% of base-case)  0.73  1.25  850  877 
Monthly frequency of tx activities, averaged over tx 
course, clinic visits (1st-line) 
4.4  7.2  863  864 
Monthly frequency of tx activities, averaged over tx 
course, clinic visits (2nd-line) 
16.6  28.9  852  874 
Monthly frequency of tx activities, averaged over tx 
course, monitoring smears (1st-line) 
0.75  1.22  863  864 
Monthly frequency of tx activities, averaged over tx 
course, monitoring smears (2nd-line) 
0.76  1.25  863  864 
Monthly frequency of tx activities, averaged over tx 
course, sputum cultures (2nd-line) 
0.32  0.54  863  864 
Monthly frequency of tx activities, averaged over tx 
course, chest X-rays (2nd-line) 
0.11  0.18  863  864 
Number of months of inpatient care with MDR-TB tx  3.0  5.2  845  882 
Monthly cost of ART  84.6  104.0  829  898 
Disability weight, active TB  0.21  0.34  912  820 
Disability weight, HIV-pos, CD4 >350 cells/µl, no ART  0.10  0.17  863  864 
Disability weight, HIV-pos, CD4 200-350 cells/µl, no ART  0.25  0.40  863  863 
Disability weight, HIV-pos, CD4 <200 cells/µl, no ART  0.38  0.64  861  866 
Disability weight, HIV-pos, ART initiated CD4 >350   0.10  0.17  860  867 
Disability weight, HIV-pos, ART initiated CD4 200-350   0.12  0.19  861  866 
Disability weight, HIV-pos, ART initiated CD4 <200   0.13  0.21  854  873 
Annual discount rate  0  10%  843  915 
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Table 2.9. Univariate sensitivity analysis, South Africa (base-case ICER =$986)  
Parameter description 
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Transmission parameter for individuals with smear-pos 
TB in 1950 
10.4  13.2  979  1,019 
Annual percentage decline in transmission parameter  0.003  0.007  1,012  983 
Infectivity of smear-neg TB, relative to smear-pos TB   0.17  0.28  1,087  907 
Fitness cost for drug-resistant TB strains (% of base-case)  68%  106%  1,105  903 
Rate of attending TB testing site, for individuals with 
active TB, DOTS, 1990 (% of base-case) 
51%  159%  1,027  958 
Rate of attending TB testing site, for individuals with 
active TB, DOTS, 2010 (% of base-case) 
52%  126%  903  1,085 
Rate of attending TB testing site, for individuals with 
active TB, non-DOTS, 1990 (% of base-case) 
65%  178%  918  1,055 
Rate of attending TB testing site, for individuals with 
active TB, non-DOTS, 2010 (% of base-case) 
48%  165%  905  1,070 
Rate ratio of TB testing, for individuals without active TB 
compared to those with active TB 
0.011  0.019  959  1,013 
Specificity of sputum smear microscopy  0.97  0.98  976  996 
Specificity of sputum culture   0.98  0.99  985  987 
Sensitivity of Xpert for TB, smear-neg TB   0.70  0.76  1,003  971 
Sensitivity of Xpert for TB, smear-pos TB   0.98  0.99  994  978 
Specificity of Xpert for TB  0.99  1.00  994  978 
Sensitivity of Xpert for RIF resistance  0.97  0.99  979  993 
Specificity of Xpert for RIF resistance  0.98  0.99  988  985 
Probability of sputum culture following a negative 
sputum smear (status quo), tx-naïve patients 
0.15  0.27  925  1,057 
Probability of sputum culture following a negative 
sputum smear (status quo), tx-experienced patients 
0.75  0.86  987  985 
Probability of DST following a positive TB diagnosis 
(status quo), tx-experienced patients 
0.76  0.85  1,011  961 
Probability of loss to follow-up between initial 
presentation and tx initiation, with prompt diagnosis 
0.11  0.20  987  987 
Probability of loss to follow-up between initial 
presentation and tx initiation, with delayed diagnosis 
0.20  0.32  1,014  960 
Tx default rate, DOTS (% of base-case)  67%  119%  983  986 
Tx default rate, non-DOTS   0.37  0.65  1,083  896 
Probability of tx success, individuals with pan-sensitive 
TB completing 1st-line regimen (% of base-case) 
71%  125%  1,025  973 108 
 
Table 2.9. Univariate sensitivity analysis, South Africa (base-case ICER =$986) (continued) 
Parameter description 
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Risk ratio of tx success, 1st-line regimen, semi-sensitive 
strain 
0.79  0.88  993  980 
Risk ratio of tx success, 1st-line regimen, non-sensitive 
strain 
0.32  0.54  1,029  959 
Risk ratio of tx success, 2nd-line regimen, sensitive strain  0.91  0.95  998  975 
Risk ratio of tx success, 2nd-line regimen, non-sensitive 
strain 
0.32  0.56  1,041  950 
Risk ratio of tx success, non-DOTS regimen, non-MDR 
strain 
0.67  0.81  985  987 
Risk ratio of tx success, non-DOTS regimen, MDR strain  0.33  0.55  1,016  961 
Excess mortality rate for active TB, smear-neg  0.19  0.23  983  989 
Excess mortality rate for active TB, smear-pos  0.26  0.37  1,072  922 
Excess mortality rate for HIV, CD4 >350 cells/µl, no ART  0.006  0.010  985  987 
Excess mortality rate for HIV, CD4 200-350 cells/µl, no 
ART 
0.021  0.036  986  986 
Excess mortality rate for HIV, CD4 <200 cells/µl, no ART  0.16  0.26  993  980 
Excess mortality rate for HIV, on ART initiated at CD4 
>350 cells/µl 
0.006  0.010  986  986 
Excess mortality rate for HIV, on ART initiated at CD4 
200-350 cells/µl 
0.018  0.029  986  986 
Excess mortality rate for HIV, on ART initiated at CD4 
<200 cells/µl 
0.040  0.063  988  984 
Excess mortality rate for advanced HIV (CD4 <200 
cells/µl) and active TB without ART 
0.60  1.02  983  987 
TB tx mortality rates (% of base-case)  73%  125%  1,012  962 
Partial immunity afforded by prior infection, HIV-neg  0.58  0.81  1,044  967 
Partial immunity afforded by prior infection, HIV-pos, 
CD4 >350 cells/µl, no ART 
0.33  0.54  988  985 
Partial immunity afforded by prior infection, HIV-pos, 
CD4 200-350 cells/µl, no ART 
0.18  0.30  985  987 
Partial immunity afforded by prior infection, HIV-pos, 
CD4 <200 cells/µl, no ART 
0.19  0.32  985  987 
Probability of fast breakdown to active TB, with new 
infection, HIV-neg 
0.10  0.13  988  997 
Probability of fast breakdown to active TB, with new 
infection, HIV-pos, CD4 >350 cells/µl, no ART 
0.27  0.42  986  988 
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Table 2.9. Univariate sensitivity analysis, South Africa (base-case ICER =$986) (continued) 
Parameter description 
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Probability of fast breakdown to active TB, with new 
infection, HIV-pos, CD4 200-350 cells/µl, no ART 
0.58  0.76  984  988 
Probability of fast breakdown to active TB, with new 
infection, HIV-pos, CD4 <200 cells/µl, no ART 
0.88  1.00  985  987 
Probability of smear-positivity, for incident TB cases, HIV-
neg 
0.57  0.74  876  1,134 
Probability of smear-positivity, for incident TB cases, HIV-
pos, CD4 >350 cells/µl, no ART 
0.37  0.62  956  1,020 
Probability of smear-positivity, for incident TB cases, HIV-
pos, CD4 200-350 cells/µl, no ART 
0.28  0.46  973  1,000 
Probability of smear-positivity, for incident TB cases, HIV-
pos, CD4 <200 cells/µl, no ART 
0.28  0.48  970  1,003 
Rate of breakdown, latent/recovered to active TB, HIV-
neg 
0.0005  0.00126  991  983 
Rate of breakdown, latent/recovered to active TB, HIV-
pos, CD4 >350 cells/µl, no ART 
0.002  0.004  987  985 
Rate of breakdown, latent/recovered to active TB, HIV-
pos, CD4 200-350 cells/µl, no ART 
0.08  0.11  984  988 
Rate of breakdown, latent/recovered to active TB, HIV-
pos, CD4 <200 cells/µl, no ART 
0.14  0.23  979  995 
Rate of conversion, smear-neg to smear-pos active TB  0.012  0.018  984  988 
Rate of self-cure for active TB, HIV-neg  0.18  0.23  975  998 
Rate of self-cure for active TB, HIV-pos, CD4 >350 cells/µl, 
no ART 
0.08  0.12  983  989 
Probability that failed tx cases are correctly identified and 
returned to tx 
0.38  0.62  994  978 
Rate of acquisition of TB drug resistance (% of base-case)  85%  123%  888  1,094 
HIV incidence trend, post-2011 (% of base-case)  98%  103%  986  987 
Rate of HIV progression for individuals not on ART, from 
CD4 >350 cells/µl to CD4 200-350 cells/µl 
0.11  0.17  960  1,005 
Rate of HIV progression for individuals not on ART, from 
CD4 200-350 cells/µl to CD4 <200 cells/µl 
0.37  0.63  980  990 
Future ART coverage for tx-eligible HIV-pos individuals  0.67  0.93  941  1,026 
Effectiveness of ART in reversing effect of HIV on TB 
natural history  
0.60  0.80  978  994 
Per-test cost of smear diagnosis  4.8  7.0  998  974 
Per-test cost of culture  14.2  17.1  990  982 110 
 
Table 2.9. Univariate sensitivity analysis, South Africa (base-case ICER =$986) (continued) 
Parameter description 
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Per-test cost of chest X-ray  13.6  19.3  986  986 
Per-test cost of drug sensitivity testing  66.7  89.5  989  983 
Cost of outpatient diagnostic visit  7.9  12.6  997  975 
Cost of outpatient tx visit  5.0  8.3  952  1,020 
Cost of inpatient care, per day  28.9  49.9  938  1,034 
Monthly TB regimen costs (% of base-case)  0.79  1.27  961  1,011 
Monthly frequency of tx activities, averaged over tx 
course, clinic visits (1st-line) 
4.3  7.5  977  995 
Monthly frequency of tx activities, averaged over tx 
course, clinic visits (2nd-line) 
16.0  27.9  956  1,016 
Monthly frequency of tx activities, averaged over tx 
course, monitoring smears (1st-line) 
0.77  1.21  985  987 
Monthly frequency of tx activities, averaged over tx 
course, monitoring smears (2nd-line) 
0.75  1.18  985  987 
Monthly frequency of tx activities, averaged over tx 
course, sputum cultures (2nd-line) 
0.32  0.52  985  987 
Monthly frequency of tx activities, averaged over tx 
course, chest X-rays (2nd-line) 
0.11  0.17  986  986 
Number of months of inpatient care with MDR-TB tx  3.0  4.7  945  1,027 
Monthly cost of ART  91.9  114.0  943  1,029 
Disability weight, active TB  0.20  0.32  1,037  940 
Disability weight, HIV-pos, CD4 >350 cells/µl, no ART  0.10  0.17  983  989 
Disability weight, HIV-pos, CD4 200-350 cells/µl, no ART  0.23  0.38  986  986 
Disability weight, HIV-pos, CD4 <200 cells/µl, no ART  0.38  0.63  982  990 
Disability weight, HIV-pos, ART initiated CD4 >350   0.11  0.17  983  989 
Disability weight, HIV-pos, ART initiated CD4 200-350   0.12  0.20  982  990 
Disability weight, HIV-pos, ART initiated CD4 <200   0.13  0.21  973  999 
Annual discount rate  0  10%  966  1,038 
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Table 2.10. Univariate sensitivity analysis, Swaziland (base-case ICER =$770)  
Parameter description 
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Transmission parameter for individuals with smear-pos 
TB in 1950 
9.9  12.6  819  751 
Annual percentage decline in transmission parameter  0.003  0.008  742  827 
Infectivity of smear-neg TB, relative to smear-pos TB   0.18  0.32  880  695 
Fitness cost for drug-resistant TB strains (% of base-case)  77%  130%  837  729 
Rate of attending TB testing site, for individuals with 
active TB, DOTS, 1990 (% of base-case) 
56%  182%  783  762 
Rate of attending TB testing site, for individuals with 
active TB, DOTS, 2010 (% of base-case) 
73%  193%  648  940 
Rate of attending TB testing site, for individuals with 
active TB, non-DOTS, 1990 (% of base-case) 
48%  143%  751  789 
Rate of attending TB testing site, for individuals with 
active TB, non-DOTS, 2010 (% of base-case) 
53%  153%  746  796 
Rate ratio of TB testing, for individuals without active TB 
compared to those with active TB 
0.011  0.019  731  810 
Specificity of sputum smear microscopy  0.97  0.98  764  777 
Specificity of sputum culture   0.98  0.99  770  771 
Sensitivity of Xpert for TB, smear-neg TB   0.70  0.77  784  758 
Sensitivity of Xpert for TB, smear-pos TB   0.98  0.99  774  767 
Specificity of Xpert for TB  0.99  1.00  776  765 
Sensitivity of Xpert for RIF resistance  0.96  0.99  767  774 
Specificity of Xpert for RIF resistance  0.98  0.99  772  769 
Probability of sputum culture following a negative 
sputum smear (status quo), tx-naïve patients 
0.15  0.27  713  837 
Probability of sputum culture following a negative 
sputum smear (status quo), tx-experienced patients 
0.75  0.86  771  770 
Probability of DST following a positive TB diagnosis 
(status quo), tx-experienced patients 
0.75  0.85  785  756 
Probability of loss to follow-up between initial 
presentation and tx initiation, with prompt diagnosis 
0.12  0.19  767  775 
Probability of loss to follow-up between initial 
presentation and tx initiation, with delayed diagnosis 
0.18  0.31  797  746 
Tx default rate, DOTS (% of base-case)  75%  125%  766  772 
Tx default rate, non-DOTS   0.43  0.72  807  736 
Probability of tx success, individuals with pan-sensitive 
TB completing 1st-line regimen (% of base-case) 
73%  121%  784  765 112 
 
Table 2.10. Univariate sensitivity analysis, Swaziland (base-case ICER =$770) (continued) 
Parameter description 
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Risk ratio of tx success, 1st-line regimen, semi-sensitive 
strain 
0.79  0.87  774  767 
Risk ratio of tx success, 1st-line regimen, non-sensitive 
strain 
0.35  0.58  782  763 
Risk ratio of tx success, 2nd-line regimen, sensitive strain  0.91  0.95  776  765 
Risk ratio of tx success, 2nd-line regimen, non-sensitive 
strain 
0.33  0.57  791  758 
Risk ratio of tx success, non-DOTS regimen, non-MDR 
strain 
0.65  0.81  769  772 
Risk ratio of tx success, non-DOTS regimen, MDR strain  0.33  0.55  778  764 
Excess mortality rate for active TB, smear-neg  0.20  0.23  765  776 
Excess mortality rate for active TB, smear-pos  0.27  0.39  800  748 
Excess mortality rate for HIV, CD4 >350 cells/µl, no ART  0.006  0.010  768  773 
Excess mortality rate for HIV, CD4 200-350 cells/µl, no 
ART 
0.023  0.038  769  772 
Excess mortality rate for HIV, CD4 <200 cells/µl, no ART  0.16  0.26  772  769 
Excess mortality rate for HIV, on ART initiated at CD4 
>350 cells/µl 
0.006  0.010  770  770 
Excess mortality rate for HIV, on ART initiated at CD4 
200-350 cells/µl 
0.017  0.029  770  770 
Excess mortality rate for HIV, on ART initiated at CD4 
<200 cells/µl 
0.039  0.062  769  773 
Excess mortality rate for advanced HIV (CD4 <200 
cells/µl) and active TB without ART 
0.65  1.08  759  779 
TB tx mortality rates (% of base-case)  77%  130%  784  758 
Partial immunity afforded by prior infection, HIV-neg  0.60  0.81  766  778 
Partial immunity afforded by prior infection, HIV-pos, 
CD4 >350 cells/µl, no ART 
0.33  0.56  769  772 
Partial immunity afforded by prior infection, HIV-pos, 
CD4 200-350 cells/µl, no ART 
0.18  0.31  769  772 
Partial immunity afforded by prior infection, HIV-pos, 
CD4 <200 cells/µl, no ART 
0.18  0.33  768  773 
Probability of fast breakdown to active TB, with new 
infection, HIV-neg 
0.10  0.12  795  751 
Probability of fast breakdown to active TB, with new 
infection, HIV-pos, CD4 >350 cells/µl, no ART 
0.26  0.44  789  756 
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Table 2.10. Univariate sensitivity analysis, Swaziland (base-case ICER =$770) (continued) 
Parameter description 
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Probability of fast breakdown to active TB, with new 
infection, HIV-pos, CD4 200-350 cells/µl, no ART 
0.58  0.76  771  770 
Probability of fast breakdown to active TB, with new 
infection, HIV-pos, CD4 <200 cells/µl, no ART 
0.88  1.00  772  770 
Probability of smear-positivity, for incident TB cases, HIV-
neg 
0.54  0.72  715  842 
Probability of smear-positivity, for incident TB cases, HIV-
pos, CD4 >350 cells/µl, no ART 
0.36  0.60  749  795 
Probability of smear-positivity, for incident TB cases, HIV-
pos, CD4 200-350 cells/µl, no ART 
0.27  0.45  764  778 
Probability of smear-positivity, for incident TB cases, HIV-
pos, CD4 <200 cells/µl, no ART 
0.27  0.45  763  779 
Rate of breakdown, latent/recovered to active TB, HIV-
neg 
0.0005  0.00128  779  763 
Rate of breakdown, latent/recovered to active TB, HIV-
pos, CD4 >350 cells/µl, no ART 
0.002  0.004  773  768 
Rate of breakdown, latent/recovered to active TB, HIV-
pos, CD4 200-350 cells/µl, no ART 
0.08  0.12  773  769 
Rate of breakdown, latent/recovered to active TB, HIV-
pos, CD4 <200 cells/µl, no ART 
0.14  0.24  777  769 
Rate of conversion, smear-neg to smear-pos active TB  0.012  0.018  769  772 
Rate of self-cure for active TB, HIV-neg  0.18  0.24  756  785 
Rate of self-cure for active TB, HIV-pos, CD4 >350 cells/µl, 
no ART 
0.07  0.13  765  775 
Probability that failed tx cases are correctly identified and 
returned to tx 
0.38  0.65  774  767 
Rate of acquisition of TB drug resistance (% of base-case)  70%  116%  716  833 
HIV incidence trend, post-2011 (% of base-case)  97%  102%  772  769 
Rate of HIV progression for individuals not on ART, from 
CD4 >350 cells/µl to CD4 200-350 cells/µl 
0.11  0.17  751  785 
Rate of HIV progression for individuals not on ART, from 
CD4 200-350 cells/µl to CD4 <200 cells/µl 
0.39  0.66  760  778 
Future ART coverage for tx-eligible HIV-pos individuals  0.66  0.92  722  814 
Effectiveness of ART in reversing effect of HIV on TB 
natural history  
0.56  0.78  745  802 
Per-test cost of smear diagnosis  3.4  5.0  780  761 
Per-test cost of culture  10.0  11.9  773  767 114 
 
Table 2.10. Univariate sensitivity analysis, Swaziland (base-case ICER =$770) (continued) 
Parameter description 
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Per-test cost of chest X-ray  9.4  13.5  770  771 
Per-test cost of drug sensitivity testing  48.6  64.8  773  768 
Cost of outpatient diagnostic visit  4.6  8.0  779  762 
Cost of outpatient tx visit  3.1  5.4  757  784 
Cost of inpatient care, per day  15.8  27.5  753  788 
Monthly TB regimen costs (% of base-case)  0.72  1.20  755  786 
Monthly frequency of tx activities, averaged over tx 
course, clinic visits (1st-line) 
4.4  7.4  766  775 
Monthly frequency of tx activities, averaged over tx 
course, clinic visits (2nd-line) 
16.5  27.4  761  780 
Monthly frequency of tx activities, averaged over tx 
course, monitoring smears (1st-line) 
0.76  1.29  770  771 
Monthly frequency of tx activities, averaged over tx 
course, monitoring smears (2nd-line) 
0.71  1.24  770  771 
Monthly frequency of tx activities, averaged over tx 
course, sputum cultures (2nd-line) 
0.34  0.57  770  771 
Monthly frequency of tx activities, averaged over tx 
course, chest X-rays (2nd-line) 
0.10  0.18  770  771 
Number of months of inpatient care with MDR-TB tx  2.9  5.2  753  788 
Monthly cost of ART  73.7  89.6  733  808 
Disability weight, active TB  0.21  0.35  814  731 
Disability weight, HIV-pos, CD4 >350 cells/µl, no ART  0.10  0.17  767  774 
Disability weight, HIV-pos, CD4 200-350 cells/µl, no ART  0.25  0.41  770  770 
Disability weight, HIV-pos, CD4 <200 cells/µl, no ART  0.36  0.62  766  775 
Disability weight, HIV-pos, ART initiated CD4 >350   0.11  0.17  767  774 
Disability weight, HIV-pos, ART initiated CD4 200-350   0.12  0.19  767  774 
Disability weight, HIV-pos, ART initiated CD4 <200   0.13  0.21  759  783 
Annual discount rate  0  10%  758  802 
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2.6.5.3.  Alternative scenarios relating to HIV treatment, TB diagnostic algorithms and MDR-TB 
treatment 
In addition to the one-way sensitivity analyses described above, we defined a range of additional 
scenarios that included alternative assumptions regarding HIV treatment, TB diagnostic algorithms, 
and MDR-TB treatment components. In each of these further analyses, we adjusted the model 
inputs relating to each new scenario then re-ran the whole simulation, calculating point estimates 
and posterior 95% intervals as described for the main analysis. 
The cost-effectiveness ratios from the main analysis aim to capture the major changes in health 
system resource use and health outcomes resulting from the adoption of the Xpert algorithm, 
including increases in TB treatment and HIV treatment volume. The increase in TB treatment 
volume is a direct consequence of better case-finding under the Xpert algorithm. The increase in 
ART volume is an indirect consequence of Xpert introduction, resulting from improved survival of 
TB-HIV coinfected individuals currently receiving ART or those who would go on to receive ART in 
the future. In order to disentangle the direct effect of Xpert from this secondary effect through HIV 
survival, we constructed a scenario in which access to ART under a scaled-up Xpert approach was 
constrained to be the same as in the status quo scenario (as might be the case if the future HIV 
treatment budget were fixed and did not increase as a function of HIV treatment need). While 
artificial, this scenario allowed us to estimate the cost-effectiveness of Xpert adoption separate 
from the effects on HIV treatment. In this scenario, incremental costs and DALYs averted dropped 
by 35-40% and 10-15%, respectively, compared to the main analysis, and the cost per DALY 
averted dropped to US$656 [386 - 1,115] over a 10-year analytic horizon (assuming a US$30 per-
test cost for Xpert). While this analysis is informative, we emphasize that a policy-maker aiming to 
maximize the effectiveness of the entire health portfolio should use the ICER generated in the main 
analysis unless planning to limit ART enrollment without consideration of actual treatment need.  116 
 
We also investigated the potential consequences of time-trends in ART prices. In the main analysis 
the per-patient costs of ART were assumed to be constant. Recent analyses have observed a net 
downward trend [86], although an upward trend might be possible, with the uncertainty reflecting 
a tradeoff between price reductions and increasing use of more expensive second-line therapies. 
We investigated the possible consequences of ART price reductions by recalculating the results 
under an assumption that ART costs would drop by 50% every 10 years. This change reduced the 
cost per DALY to US$812 [522-1,283] over the 10-year analytic horizon and to US$552 [320 - 
1,023] over 20 years, reductions of 15% and 30% compared to the results in the main analysis. 
Similar to ART, MDR-TB treatment is another expensive service with increased volume under the 
Xpert strategy, due to both better TB case-finding and better identification of drug resistance. 
Inpatient care adds substantially to MDR-TB treatment costs, yet there is limited evidence that it 
improves treatment outcomes [82,96]. We constructed a scenario to investigate how Xpert cost-
effectiveness would change if inpatient care were no longer required for MDR-TB treatment, 
assuming this would produce no net change in health outcomes. This change was found to reduce 
incremental health system costs of the Xpert algorithm by 15%, and to reduce the cost per DALY 
averted by the same percentage, to US$812 [522 - 1,283] over a 10-year analytic horizon. 
Our main analysis focused on an Xpert algorithm in which a negative Xpert diagnosis would be 
treated as definitive, whereas South Africa has developed local guidelines that call for more 
aggressive investigation (including culture, chest X-ray and antibiotic trial) for Xpert-negative 
individuals who have positive or unknown HIV status [97]. We compared this algorithm to the 
Xpert algorithm used in the main analysis, assuming that all truly HIV-positive individuals would be 
categorized as ‘HIV-positive or unknown’ at TB diagnosis, while 50% (range 25-75%) of all truly 
HIV-negative individuals would have a prior HIV test confirming this status, based on recent 
population based surveys [66-68]. In this comparison the South African Xpert algorithm was found 117 
 
to increase incremental costs by 60% and incremental DALYs averted by 27%, which resulted in an 
incremental cost-effectiveness ratio of US$2,128 [1,215-3,954] per DALY averted (10-year analytic 
horizon, US$30 Xpert cost) for the more aggressive strategy compared to the base-case Xpert 
algorithm. We also conducted sensitivity analyses on how the cost-effectiveness of Xpert might 
change if all individuals with a positive Xpert RIF result receive empiric MDR-TB treatment while 
waiting for the DST result to be returned (a delay estimated at 80 days [98]). This change had a 
modest effect, raising incremental costs by 8%, and resulting in a cost per DALY averted of 
US$1,038 [683-1,584] (10-year analytic horizon, US$30 year Xpert cost). 
In another set of sensitivity analyses we tested the robustness of the results to changes in the status 
quo algorithm. In the main analysis we assumed incomplete access to TB culture and DST. If instead 
we assumed 100% access to TB culture, such that all treatment-experienced patients testing 
negative with sputum smear received a confirmatory TB culture, incremental costs and DALYs 
averted by the Xpert algorithm both dropped by 3%, with little change in the cost per DALY 
averted, which was estimated as US$956 [628-1,491]. If we also assumed that 100% of treatment-
experienced patients diagnosed with TB received DST, then incremental costs and DALYS averted 
by the Xpert algorithm dropped by 15% and 4%, respectively, compared to the main analysis, and 
the cost per DALY averted dropped marginally to US$851 [570-1,323]. We also conducted a three-
way sensitivity analysis that considered a much wider range of estimates for culture and DST 
access, investigating the possibility of country-level differences in access to these diagnostic 
services. The results of these changes on incremental costs, incremental health benefits, and 
incremental cost-effectiveness ratios are shown in Figures 2.13-2.17. This figure shows that if use 
of culture under the status quo algorithm is higher than the value used in the main analysis, this 
would reduce the incremental costs and health benefits produced by adopting Xpert and result in a 
less favorable cost-effectiveness ratio. In some countries very high values of culture use would 
result in the status quo strategy dominating the Xpert strategy, i.e., having lower costs and greater 118 
 
health benefits. The coverage levels that produce such a result (80% of all treatment- naïve and 
treatment-experienced patients diagnosed via culture), however, are unlikely to be in place at 
present given current infrastructure and program constraints. Higher than expected DST access 
under the status quo would produce modest reductions in incremental costs and minimal changes 
in cost-effectiveness ratios. 
Similarly, allowing for the possibility of clinical diagnosis as part of the base case algorithm did not 
substantially alter the cost-effectiveness of Xpert. When we compared the Xpert algorithm to an 
altered status quo algorithm in which all individuals with suspected TB testing negative with 
sputum smear receive clinical diagnosis (which might include chest X-ray or antibiotic trial [49]) to 
confirm the negative diagnosis, this increased the incremental cost-effectiveness ratio for Xpert by 
approximately 10%, to US$1,052 [643 - 1,785], with both incremental costs and DALYs averted 
approximately one-third lower than estimated in the main analysis. 
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Figure 2.13. Three-way sensitivity analyses showing effects of changes in culture and DST 
coverage on major study outcomes in Botswana 
* Costs, DALYs and ICERs assessed over a 10-year analytic horizon with a US$30 Xpert unit cost. All 
other parameters held at their mean posterior values. 120 
 
 
Figure 2.14. Three-way sensitivity analyses showing effects of changes in culture and DST 
coverage on major study outcomes in Lesotho 
* Costs, DALYs and ICERs assessed over a 10-year analytic horizon with a US$30 Xpert unit cost. All 
other parameters held at their mean posterior values. 121 
 
 
Figure 2.15. Three-way sensitivity analyses showing effects of changes in culture and DST 
coverage on major study outcomes in Namibia 
* Costs, DALYs and ICERs assessed over a 10-year analytic horizon with a US$30 Xpert unit cost. All 
other parameters held at their mean posterior values. 122 
 
 
Figure 2.16. Three-way sensitivity analyses showing effects of changes in culture and DST 
coverage on major study outcomes in South Africa 
* Costs, DALYs and ICERs assessed over a 10-year analytic horizon with a US$30 Xpert unit cost. All 
other parameters held at their mean posterior values. 123 
 
 
Figure 2.17. Three-way sensitivity analyses showing effects of changes in culture and DST 
coverage on major study outcomes in Swaziland 
* Costs, DALYs and ICERs assessed over a 10-year analytic horizon with a US$30 Xpert unit cost. All 
other parameters held at their mean posterior values. 124 
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Abstract 
In this analysis I estimate the relative value of new research on various targets related to HIV 
control in South Africa. There has been growing enthusiasm for expanding HIV treatment programs 
in highly-affected settings, due to new evidence that antiretroviral therapy (ART) may reduce HIV 
transmission. Expanding ART programs would likely require substantial resources, and there is 
considerable uncertainty about the impact of such expansion on long-term outcomes. The best 
strategy for ART expansion is also unclear—policy debate has focused on relaxing ART eligibility 
criteria, but this must compete with efforts to increase enrollment among groups already eligible 
according to current guidelines. This uncertainty hinders the development of long-term HIV control 
strategy. In this analysis I used Value of Information (VOI) methods to identify the types of new 
research that would be most valuable to this policy debate, using South Africa as a case study. I 
implemented this analysis using a mathematical model of HIV epidemiology in the adult population. 
The model simulated HIV transmission through durable sexual partnerships and casual sexual 
contacts, disease progression for HIV-infected individuals, and initiation and receipt of ART. I used 
this model to project the costs and health outcomes resulting from various ART policies that might 
be adopted, and used Monte Carlo methods to quantify how uncertainty in epidemiology, 
programmatic performance, and costs translated into uncertainty about policy outcomes. These 
results were used to estimate VOI for individual parameters or groups of parameters. Issues found 
to have the highest potential value of information included issues of cost and implementation, 
relative infectiousness during late HIV and the reduction in infectiousness for individuals on ART, 
and the therapeutic health benefits of early ART initiation. These findings generally held up across 
different time horizons and other analytic assumptions. Another notable finding was the apparent 
unimportance of information about transmission during early HIV infection, despite earlier 
research suggesting that transmission during early HIV infection could substantially reduce the 
impact of ART expansion. This analysis also developed new methods for estimating VOI in the 136 
 
context of numerically calibrated models, which may be of increasing relevance as a greater 
number of analyses adopt these calibration techniques. 
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 Introduction  3.1.
Policy decisions are made under conditions of uncertainty. While rational policy makers will adopt 
policies that appear to give the best expected outcomes given the current state of knowledge, better 
information may change policy choices and improve expected outcomes. As research can improve 
information before consequential policy decisions are made, the value of research can be can 
estimated from the expected improvement in policy choices and outcomes. This approach can be 
used to guide the magnitude and direction of new research investments. 
This paper examines the value of new research related to HIV control in developing countries. In 
2011, there was $US16.8 billion spent globally on HIV control, the majority in developing countries 
[1]. Most of this funding is devoted to providing care and antiretroviral therapy (ART), with over 8 
million individuals in low and middle-income countries now receiving ART [1]. The progressive 
expansion of treatment services is seen as one of the successes of global HIV control, with many 
institutions promoting the goal of universal treatment access [2]. Despite these advances many 
countries are not yet providing treatment services to all who might benefit, and in 2011 there were 
an estimated 6.8 million individuals eligible for treatment according to current WHO guidelines 
who were not yet receiving ART [1]. Treatment programs continue to face constrained budgets, 
with both domestic and external HIV spending under increasing pressure [3]. 
While the therapeutic benefits of ART are well established [4], there has been increasing evidence 
that ART may also have a role to play in HIV prevention, building on the facts that ART reduces HIV 
viral load in treated individuals [5], and that a lower viral load is associated with reduced rates of 
HIV transmission [6]. Evidence from observational analyses supports this relationship [7,8], and 
results reported for a recent clinical trial (HPTN 052) confirm the effectiveness of ART for reducing 
transmission in serodiscordant couples, with transmission rates reduced by 96% (95% CI: 73-99%) 
[9].  138 
 
These results have important implications for HIV control in the many highly-affected countries 
with ongoing generalized HIV epidemics. Analyses have used mathematical models to explore the 
potential of expanded ART eligibility as a policyfor reducing HIV incidence at a population-level 
[10,11], and policy makers are considering an increased prioritization of ART within the HIV 
control portfolio. Expansion of ART may come at the expense of other health interventions unless 
further funding is available [12], and policy changes to extend ART eligibility beyond current 
guidelines must compete with efforts to increase enrollment among groups already eligible 
according to current guidelines. A recent study by a consortium of HIV modeling groups found that 
in 4 highly affected settings (South Africa, Zambia, India, Vietnam) improving ART coverage 
(through improved HIV testing and linkage to care) and expanding eligibility both have the 
potential to generate substantial health gains, and would be considered cost-effective according to 
conventional benchmarks [13]. This study also revealed substantial uncertainty about the projected 
resource requirements and epidemic impact of competing policies. Uncertainty about the 
appropriate timing of treatment initiation has been highlighted as a barrier to developing long-term 
HIV control strategy [14]. 
Even if ART could be scaled up to high coverage with expanded eligibility criteria, it will not be 
possible to enroll individuals with early HIV infection. These are individuals who have recently 
acquired HIV, and are therefore unlikely to be aware of their HIV status. Given the short duration 
and difficult diagnosis of early HIV, it is unlikely that this group would be affected by a policy 
aiming to use treatment of infected individuals to reduce transmission. The extremely high levels of 
viral load observed during early infection has been linked to increased transmission risk [15], and 
an observational study from Uganda has estimated that each log increment in the viral load 
produces a 2-3 fold increase in transmission risk [6]. There are few additional studies to confirm 
this finding, and this is reflected in prior modelling studies that reveal substantial uncertainty about 
the proportion of all infections attributable to transmission during early HIV infection [16]. A recent 139 
 
Malawian study used a mathematical model to examine the role of acute HIV infection in overall 
transmission dynamics, suggested that 38% (19-52%) of all transmissions could be attributed to 
individuals in the first 5 months following initial infection [17]. Uncertainty about the role of 
transmission during early HIV has relevance for the programmatic response to the HPTN 052 
results – if the proportion of new infections coming from transmission during early HIV infection is 
low, efforts to scale-up ART programs may produce substantial incidence reductions. If the 
proportion of new infections coming from transmission during early HIV infection is high, the 
prevention benefits of aggressive treatment scale-up may be less, and the cost-effectiveness of ART 
may not differ substantially from analyses focused on the therapeutic benefits alone [18–20]. 
Other information gaps add to the uncertainty around optimal ART policy. While it now seems clear 
that ART can reduce transmission, the magnitude of this effect is still uncertain. The HPTN 052 trial 
is the only randomized study to date to report on the prevention benefits of ART, and while it 
identified a 20-fold reduction in transmission risk, these findings were estimated from only 28 
transmission events within study couples [9]. There is also substantial uncertainty about the 
therapeutic benefits of early ART initiation for individuals with high CD4 cell count, with no 
randomized trials yet reported and conflicting evidence from analyses of observational data [21]. 
Finally, there is substantial uncertainty about the costs and difficulty of policy implementation, as 
ART scale-up will require identifying, enrolling, and retaining patients who may not currently know 
their HIV status or be experiencing HIV symptoms. 
This study aims to estimate the potential value of new research on the various uncertainties related 
to ART policy. Understanding the relative value of different research investments will allow 
programs to identify and prioritize high-value research and improve expected outcomes. 
This research approach—quantifying the value of research through its potential to improve 
decision-making—draws on a class of methods known as value of information (VOI) analysis [22–140 
 
24]. In the absence of further research, it is assumed that HIV control programs will allocate 
funding across the HIV control portfolio in a way that will maximize valued health outcomes on 
expectation, averaging over the joint distribution of possible costs and health outcomes for each 
possible intervention portfolio.. Given the substantial uncertainty that exists, it is possible that a 
portfolio will be chosen that achieves worse health outcomes than would be produced by other 
portfolios under consideration, but without further research this cannot be known ex ante. If new 
research is undertaken before the policy decision is made, this can reduce the uncertainty faced by 
policy-makers and reduce the probability that a suboptimal policy will be chosen. The incremental 
gains in expected outcomes (reductions in expected costs and/or improvement in expected health 
outcomes) that result from this improved policy choice can be used to estimate the value of 
undertaking the research. 
The application of VOI methods to real-world policy problems is growing [25,26]. There has so far 
been little use of VOI methods to address HIV control questions, though some recent examples 
exist: Leelahavarong et al. [27] undertake a VOI analysis as part of an examination of HIV vaccine 
cost-effectiveness in Thailand, while Maheswara and Barton [28] estimate VOI in the context of an 
analysis of TB case-finding and prevention activities for HIV-infected populations. 
In the present study the VOI analysis is operationalized in the context of a dynamic HIV 
transmission model of the South African epidemic, focusing on a decision currently facing policy 
makers: whether to expand HIV treatment services, given the growing evidence base that it may 
reduce transmission, and if so how this should be accomplished. With 5.6 million HIV-positive 
individuals [1], the HIV epidemic in South Africa is almost twice as large as in any other country, 
and represents one-sixth of the world’s HIV-infected population. South Africa also reflects 
characteristics common to other highly-affected settings, with ongoing HIV transmission in the 
general community, limited success of conventional prevention approaches, and scarce resources 141 
 
for increased HIV spending. For this reason, South Africa represents a focus of HIV research and 
policy dialogue, and insights learned in this setting will be relevant locally as well as in other similar 
settings. 
In addition to providing guidance on a substantive question—how should new HIV research 
funding be directed to maximize health gains—this study also addresses a specific methodological 
question, that of how various VOI estimates can be obtained when the distribution of model 
parameters is not available in closed-form. This situation arises in the context of common model 
calibration techniques (such as used in this analysis), where the joint distribution of model 
parameters, after they have been calibrated, is represented by a sample of parameter sets rather 
than an equation. This situation poses no problem for calculating the expected value of perfect 
information (EVPI), as this outcome can be calculated directly using the sample of parameter sets. 
In contrast, published methods for estimating the expected value of partial perfect information 
(EVPPI) [22,29] require the expected value of model outcomes (specifically, net monetary benefit 
achieved by each policy) to be estimated conditional on the value of the parameter (or group of 
parameters) that is the subject of the analysis. This can be straight-forward if the parameter 
distribution is available in closed form (particularly if the parameters are uncorrelated). In 
contrast, it is not immediately clear how to estimate EVPPI when the parameter distribution is 
represented by a fixed sample of parameter sets, as there is no way to generate new samples from 
the conditional distribution of other parameters once the value of one parameter has been fixed. 
While a ‘brute force’ solution to this problem is possible—recalibrating the model for many 
different values of a given parameter—such an approach would likely be infeasible in many 
analysis, where the computational burden of a single calibration may be large. Formal calibration 
procedures are increasingly being used to improve the predictive validity of complex disease 
models, it is therefore useful to describe methods for estimating VOI in this class of analyses. 142 
 
 Methods  3.2.
3.2.1.  General approach 
We assumed that the South African national HIV control program chooses between policies based 
on their potential costs and health benefits. The trade-off between these two goals can be 
operationalized as a willingness-to-pay (WTP) threshold, describing the maximum rate at which the 
program would be willing to expend resources in order to gain health benefits. For a given WTP 
threshold, the health and economic consequences of a policy can be summarized as net monetary 
benefit (NMB), a measure of the social welfare generated by health programs, combining both costs 
and health benefits [30]. In the absence of new research, we assumed a policy would be preferred if 
it maximizes NMB on expectation. The expected NMB (E(NMB)) obtained under this ’no research’ 
scenario can be compared to alternative scenarios in which new research is commissioned in order 
to reduce decision uncertainty. We assumed that the national program would consistently apply the 
same decision rule, choosing the policy option that maximizes E(NMB) in light of new research 
findings. The potential benefits of research can then be quantified as the difference in E(NMB) 
between ‘no research’ and alternative scenarios. 
3.2.2.  Policy options 
We characterized the policy decision facing the national program in terms of two dimensions: the 
criteria determining ART eligibility, and the intensity of HIV testing programs undertaken to 
identify HIV-positive individuals for care. This second dimension was operationalized as the rate of 
HIV testing in the general population. Three different eligibility criteria were considered: 
A.  ART eligibility for HIV-infected individuals with CD4 cell count <350 cells/µL (current 
eligibility). 
B.  ART eligibility for individuals with CD4 cell count <500 cells/µL. 143 
 
C.  ART eligibility for all HIV-positive individuals. 
Five different HIV testing scenarios were considered: 
1.  Continuation of current HIV testing rates and restriction of total ART patient volume to 
current levels, such that any patients leaving ART cohorts are replaced, but no new patient 
slots are added. 
2.  Continuation of current HIV testing rates, with individuals initiating ART per eligibility 
guidelines. 
3.  Expanded HIV testing programs raising the average rate of testing to 1.5 times its current 
level, with individuals initiating ART per eligibility guidelines. 
4.  Expanded HIV testing programs raising the average rate of testing to 2.0 times its current 
level, with individuals initiating ART per eligibility guidelines. 
5.  Expanded HIV testing programs raising the average rate of testing to 3.0 times its current 
level, with individuals initiating ART per eligibility guidelines. 
Each of these coverage scenarios was applied to each of the possible eligibility criteria, giving 15 
possible policies1. We assumed any changes in ART eligibility and coverage would be introduced 
over a 12-month period starting in 2013 and then remain in force for the duration of the analysis. 
   
                                                             
1 For convenience, the policies are labeled with a letter-number combination, such that “B1” denotes a policy 
combining the second eligibility policy and the first coverage policy. 144 
 
3.2.3.  Model overview 
We used a mathematical model to project the costs and health outcomes resulting from the various 
policy options that might be adopted by the South African national HIV control program. The model 
was developed to represent an HIV epidemic in the South African adult population, simulating 
transmission of HIV infection through durable sexual partnerships and casual sexual contacts, the 
progression of HIV disease for HIV-infected individuals, and initiation and receipt of antiretroviral 
therapy. We parameterized the model to the South African epidemic, with probability distributions 
constructed for each model parameter to represent current uncertainty about these values. We 
used a Bayesian approach to calibrate these probability distributions to agree with empirical data 
on HIV prevalence trends, distribution across CD4 count categories, and survival following HIV 
infection. We used this calibrated model to estimate future outcomes of the policy options 
described in Section 3.2.2, and then used the results to estimate VOI for individual parameters or 
groups of parameters. Finally, we compared VOI estimates for different parameters to draw 
conclusions about high-priority research targets for informing ART policy. 
3.2.4.  Model structure 
The structure of the model was based on approaches adopted by other published HIV transmission 
models [17,31–37]. The model distributes the adult population across compartments that 
distinguish HIV status, CD4 cell count categories, receipt of ART, sex, and sexual behavior 
characteristics. A schematic of the model is shown in Figure 3.1. A fraction of the population 
residing in one compartment may transition into another compartment at weekly timesteps, 
according to transition probabilities defined by model parameter values. 145 
 
 
Figure 3.1. Schematic of model compartments, transitions, and sexual interactions 
 
3.2.5.  Sexual networks 
Multiple studies have demonstrated that the nature of sexual interaction has important 
implications for the dynamics of generalized HIV epidemics [31–34,37–39]. This concern is 
particularly important when addressing the issue of early HIV infection, with Eaton and colleagues 
demonstrating that the role of early infection in HIV epidemics differs between models that assume 
random, instantaneous sexual contacts and those that capture more realistic patterns of sexual 
mixing [38]. Similarly, an earlier analysis by Kretzschmar and Dietz demonstrate that models that 
explicitly account for disease transmission within durable sexual partnerships (pair models) 
attribute a smaller fraction of overall transmission to early infection, compared to random mixing 
models [31]. A number of analyses have applied pair models to understand real epidemics, most 146 
 
notably Xiridou and colleagues in a series of studies related to homosexual [32,33] and 
heterosexual [40,41] HIV transmission in the Netherlands, and more recently Powers et al. 
(hereafter ‘Powers’) in an analysis of heterosexual HIV transmission in Lilongwe, Malawi [17]. The 
Powers analysis is particularly relevant to the current study, in that the primary goal of the analysis 
was to understand the role of early infection in a generalized heterosexual HIV epidemic that bears 
some similarities to South Africa’s. In developing the model for the current analysis we adopted 
many features of the Powers model, described in detail below.  
3.2.5.1.  Durable sexual partnerships 
We modeled sexual interaction as occurring through either durable sexual partnerships or casual 
sex. Durable sexual partnerships (pairs) were modeled explicitly, with a distinct model 
compartment devoted to each allowed type of heterosexual pairing (e.g., an HIV-negative female 
paired with an HIV-positive male with CD4<200). Following earlier approaches, the population is 
divided into distinct sexual activity strata to capture, in a simplified form, the heterogeneity in risk 
behaviors across the population. Sexual risk strata differ in the rate of formation/dissolution of 
pairs as well as other sexual behaviors. Pairs are allowed to form within each risk stratum (high-
risk and low-risk) but not across strata [17,35,37]. Within each pair, sexual activity is assumed to be 
constant over the duration of the partnership (conditional on HIV stage), and the rates of other 
model transitions (e.g., mortality, disease progression) are assumed to be unaffected by pair 
membership. 
For each timestep, let      be the total number of pairs formed by individuals in risk stratum r (high 
or low), HIV state i (as shown in the top section of Figure 3.1), and sex s, where s=w for women and 
s=m for men. Let     represent the total number of pairs formed by a particular risk stratum and 
sex. The rate that an individual in model compartment sri attempts to enter a pair relationship is 
calculated as the product of the average rate for healthy individuals in the risk stratum   , and a 147 
 
multiplier    that accounts for lower pair formation rates in individuals with advanced HIV 
infection. Empirical estimates of the pair formation rate    are unavailable, and following Powers 
we approximated    from the pair dissolution rate   , the fraction of the risk stratum in a steady 
pair relationship    , and the combined exit rate from the sexually active population (a combination 
of the background mortality rate    and the rate at which individuals age out of the sexually active 
population  )[17]: 
    
   (      (      ))
(       )
 
  (1) 
An estimate of the fraction of low-risk types in a pair relationship was derived from data on 
cohabiting couples reported in the 2001 South African census [42]. Estimates of the fraction of 
high-risk types in a pair relationship, partnership dissolution rates for high- and low-risk types, and 
relative partnership formation rate for individuals with advanced HIV infection were drawn from a 
detailed modeling study of sexual behavior and HIV risk in South Africa by Johnson and colleagues 
[34]. 
For a given sex and risk stratum, the total number of unpaired individuals attempting to enter a 
pair relationship can be calculated as the product of the pair formation rate for each HIV health 
state and the number of individuals in each HIV health state (    ), summed across HIV health 
states: 
      ∑        
   
 
  (2) 
The value of     as calculated for each sex will not necessarily match, and an adjustment factor is 
calculated within the model such that the total number of new pairs formed in risk stratum r is the 148 
 
mean of     and    . The transition rate   for an unpaired individual in compartment sri to a 
paired compartment with an unpaired individual in compartment     ̂ can be then be expressed as2: 
        ̂          
(         )
       
 
  ̂  ̂     ̂
∑   ̂  ̂     ̂  ̂   ̂
                  ̂  
  (3) 
The rate of sexual contact within pair relationships (  
 ) and the reduction in coital frequency 
associated with advanced HIV infection (  ) were drawn from Johnson et al. [34].  
3.2.5.2.  Casual sex 
Casual sex was modeled as instantaneous ‘one-off’ sexual contacts between males and females. The 
model allows for casual sex involving both paired and unpaired individuals, and across sexual risk 
strata, with individuals in each of these groups participating in casual sex at different rates. The 
Powers analysis assumed random mixing, whereby individuals exhibit no preference as to the 
characteristics of sexual partners [17]. However, other modeled analyses have shown that mixing 
patterns between subgroups with different characteristics can affect epidemic outcomes, 
suggesting that an assumption of random mixing may be inappropriate [43]. In our model the 
possibility of assortative mixing (i.e., allowing for unequal preferences regarding sexual partners of 
different types) is operationalized as a mixing matrix M, the cells of which describe the relative 
preference of an individual in a given subgroup for forming a partnership with members of other 
subgroups (Figure 3.2). Two parameters are used to specify mixing patterns: d, which determines 
the degree of assortativity between risk strata, and e, which determines the relative frequency of 
casual sex between paired individuals. The mixing matrix shown in Figure 3.2 can be understood as 
                                                             
2 In other applications a geometric mean has been to correct the different estimates of    . Sensitivity analysis 
using a geometric mean showed that the results are insensitive to this assumption. 149 
 
a linear interpolation between 4 extremes: (a) random mixing (for d=e=1), (b) complete with-like 
assortative mixing within risk strata (for d=0, e=1), (3) random mixing except with no casual sex 
between two individuals both in pair relationships (for d=1, e=0), and (4) complete with-like 
assortative mixing within risk strata and no casual sex between two individuals both in pair 
relationships (for d=e=0) [35,37]. Consistent with this interpretation, the parameters d and e are 
assumed to fall within the range [0,1]. The value of d was drawn from Johnson et al. 2009 [34]. No 
estimates were available for e, and a weakly-informative probability distribution was specified 
centered at 0.5. While HIV health state was assumed to affect the rate at which individuals 
participate in casual sex, it was assumed not to affect mixing patterns3. 
   
                                                             
3 Of note, the restriction of the model to heterosexual sex can be seen as an assumption of complete ‘with-
unlike’ mixing, ruling out sexual contact or pair formation between individuals of the same sex. Similarly, the 
assumption of pair formation within risk strata assumes complete ‘with-like’ mixing. To relax these 
assumptions would involve a substantial expansion of the state-space of the model. 
 150 
 
 
MALES 
Low-risk, 
unpaired 
Low-risk, 
paired 
High-risk, 
unpaired 
High-risk, 
paired 
F
E
M
A
L
E
S
 
Low-risk, 
unpaired  1  1  d  d 
Low-risk, 
paired  1  e  d  d*e 
High-risk, 
unpaired  d  d  1  1 
High-risk, 
paired  d  d*e  1  e 
 
Figure 3.2. Mixing matrix for casual sex (M) 
 
The total number of sexual contacts   ̃   (where subscript j indicates one of the 4 categories created 
by high- vs. low-risk, unpaired vs. paired,) attempted by each group is calculated as: 
  ̃     ∑         
           
   
 
  (4) 
In this equation, subscript j indicates one of the 4 categories created by high- vs. low-risk, unpaired 
vs. paired, and the tilde on   ̃   indicates these are attempted partnerships. As the number of 
attempted contacts for various groups will not automatically match (as described below)   ̃   is 
distinguished from     , the number of realized contacts. In addition,   
  indicates the annualized 
rate of casual sex for healthy individuals in group j,    indicates the rate of casual sex for each HIV 
health state relative to healthy individuals, and    is a time-varying parameter allowing for time 
changes in the rate of risky sexual behavior, a phenomenon identified by earlier analyses [39,44]. 
For the purposes of this analysis risky sexual behavior was defined as including casual sex as well 
as any sex involving high-risk individuals. Values for   
  were drawn from the 2003 Demographic 151 
 
and Health Survey [45], and values for    were drawn from Johnson et al. 2009 [34]. The parameter 
   is operationalized as a logistic curve with an initial value of 1.0 that declines to asymptote to a 
new, lower level at some point during the historical development of the epidemic. Values for the 
start year of this change, the time taken to reach the new level, and the magnitude of the reduction 
were drawn from Johnson et al. 2009 [34].  
The total sexual contact attempts for each group can be distributed among the 4 groups of the 
opposite sex, where        ̂ represents cells of the mixing matrix: 
  ̃      ̂        
  ̃   ̂          ̂
∑   ̃   ̂          ̂  ̂   ̂
                 ̂ 
  (5) 
As the number of sexual contact attempts will not automatically match (e.g., the number of sexual 
contacts attempted by high-risk paired men with low-risk unpaired women will not automatically 
match the number of sexual contacts attempted by low-risk unpaired women with high-risk paired 
men), these two approaches must be balanced, with the actual number of casual sexual contacts 
between groups    and   ̂ calculated as: 
      ̂   (  ̃     ̂     ̃  ̂    )
 
  
  (6) 
 
3.2.6.  HIV transmission 
3.2.6.1.  Transmission within discordant pairs 
The rate of HIV acquisition by HIV-negative members of HIV discordant pairs is determined by the 
number of sexual contacts and the per-contact transmission risk. Both of these quantities are 
allowed to vary by risk stratum and by the health state of the HIV-positive member of the pair, and 
the per-contact risk is also allowed to differ depending on the sex of the HIV-negative member of 152 
 
the pair, based on evidence of sex differentials in HIV acquisition risk [46,47]. Due to the potential 
for high numbers of sexual contacts within pairs the probability of transmission within a single 
timestep (  
  and   
  for low-risk and high-risk pairs respectively) is calculated with a Bernoulli 
model: 
  
        (                    )  
     
  (7) 
  
        (                    )  
        
  (8) 
where o is the per-act transmission risk [47],   is the relative transmission risk related to the sex of 
the HIV-negative partner [47],    is the relative transmission risk related to risk stratum (proxying 
for unmodeled differences in the prevalence of other sexually transmitted infections that increase 
transmission risk [17,48,49]),    is the relative transmission risk related to HIV health state and 
ART status of the HIV-positive partner [50,51] , and   
  is the number of within-pair sex acts per 
timestep, by risk stratum [34]. 
3.2.6.2.  Transmission through casual sex 
The rate of HIV acquisition through casual sex for a particular HIV-negative group (    
  ) is 
calculated as the sum of acquisition risk across all casual sexual partners, adjusted for individuals’ 
risk factors: 
    
    ∑∑∑
         ̂
    
                ̂     ̂
 ̂   ̂  ̂   ̂  ̂   ̂
 
  (9) 
Note that the subscript on    refers to the sex of the HIV-negative partner, the subscript on   ̂ refers 
to the HIV-positive partner, and     ̂ refers to both individuals, such that if either or both is high-
risk then the risk-ratio for to the high-risk stratum is applied. 153 
 
The total HIV acquisition rate for an individual model compartment is calculated as the sum of the 
rates from pairs and casual sex. 
3.2.7.  HIV progression 
HIV progression is modeled as the transition between discrete CD4 categories, with transition rates 
    ̂ for the transition between HIV state   and state  ̂ . Following HIV acquisition, individuals enter 
the early HIV compartment, then transition rapidly to either the CD4>500 or CD4 350-500 
compartment. The average duration of time spent with early HIV infection (and thus the sum of exit 
rates to subsequent CD4 cell count compartments) was based on a reanalysis of historical data on 
transmission during untreated HIV infection in Rakai, Uganda [50]. Following early infection, 
individuals transition to compartments representing progressively lower CD4 cell counts until they 
reach the CD4<200 compartment, in which they remain until death or ART uptake. Rates of 
transition between these CD4 compartments were based on data from observational cohorts [52–
54]. 
3.2.8.  Model entry, aging, and mortality 
Individuals enter the model as unpaired HIV-negative adults (≥15 years). Time trends in new 
entrants were calculated from annual birth estimates obtained from the UN Population Division 
[55], lagged by 15 years and adjusted for intervening mortality. The model has a simplified age 
structure that distinguishes individuals 15-49 years of age from those aged 50 years and above. It 
was assumed for simplicity that sexual transmission of HIV occurs prior to age 50 years, consistent 
with earlier studies [17]. As pairs are only modeled to capture infection risks within sexual 
relationships, the model does not track pairs at ages above 50 years. Age-based background 
mortality rates [56] for 15-49 and ≥50 age groups were derived from the Actuarial Society of South 
Africa [56]. Disease-specific mortality rates for each HIV health state were derived from 
observational cohort data [57–61]. In the model, overall mortality rates are assumed to be the sum 154 
 
of background and disease-specific mortality rates. Uncertainty in time varying parameters for 
model entry and background mortality is introduced by multiplying the time trend by random noise 
centered at 1.0. 
3.2.9.  HIV care and treatment 
In the model, individuals can transition onto ART from any HIV health state except early HIV, as it is 
assumed that the difficulty of diagnosis during this period, in addition to delays in treatment 
initiation, will prevent individuals with early HIV from starting ART. The rate of treatment initiation 
for each HIV health state (  ) is determined by eligibility policy and the number of individuals in 
that health state receiving pre-ART care, as described below. Individuals receiving ART default from 
treatment at a fixed rate   
   . For individuals initiating ART with CD4<350, this rate is based on a 
recent systematic review [62]. There are few data on which to base the default rate for individuals 
initiating ART at higher CD4 counts, but a higher rate is plausible since these individuals will lack 
first-hand experience of the reduction in HIV symptoms associated with ART, and this rate was 
assumed to be double the rate for individuals initiating ART with CD4<350. Individuals defaulting 
from ART return to their original untreated health state. 
Although pre-ART care (referred to simply as “pre-ART”) is not represented by an explicit set of 
model compartments, it is an important component of the process of identifying individuals and 
linking them to ART, mediating the rate of ART initiation following a change in ART policy. The 
resources required to provide pre-ART also represent a non-trivial component of HIV treatment 
costs [63]. For these reasons the number of individuals receiving pre-ART is tracked in the model, 
and all individuals are assumed to pass through pre-ART before initiating ART. Individuals are 
initiated on pre-ART following identification in HIV testing programs. The average rate of HIV 
testing in the untreated population (i.e., all individuals not on ART or pre-ART) was specified as a 
time-varying policy input, with historical testing rates defined to be consistent with published 155 
 
estimates of testing volume [64] and reproduce ART volume observed in prior years [65] in 
combination with historical ART eligibility criteria as described below. HIV-positive individuals are 
assumed to test at a higher rate than HIV-negative individuals based on consistent findings from 
population-based surveys [66]. Programmatic experience suggests that a substantial fraction of 
individuals testing HIV-positive will not initiate pre-ART, and the rate of primary default was 
derived from a systematic review by Rosen and Fox [67]. Individuals enrolled on pre-ART can 
subsequently default from care [67], die, or be initiated on ART. ART initiation rates prior to 2013 
were based on historical ART eligibility criteria [68–71], which restricted general ART eligibility to 
individuals with CD4<200 cells/µL until 2010, then extended eligibility to include individuals with 
CD4<350 cells/µL by 2011 and maintained at this level until 2013. After 2013, modeled ART 
eligibility is determined by the policy scenario being modeled, as described in Section 3.2.2. 
Individuals who are enrolled on pre-ART and meeting CD4-based ART eligibility criteria are 
assumed to initiate ART on average one month after becoming eligible. Mortality rates, sexual 
behavior and other transitions are assumed to be unaffected by receipt of pre-ART. 
3.2.10. Simulation  
To undertake one simulation, the model is initiated in 1975, with individuals distributed across 
model compartments to represent an uninfected population. HIV is introduced into this population 
at a random point in time, centered at 1980 (Normally distributed with an equal-tailed 95% 
interval of +/- 5 years), and historical HIV eligibility guidelines and testing rates are modeled until 
the end of 2012. One of the policy options specified in Section 3.2.2 is introduced at the beginning of 
the year 2013 and assumed to be fully adopted by the end of 2013, then maintained at a constant 
level for a further 19 years, for a total analytic horizon of 20 years. 
Simulations are limited to a 20-year analytic horizon as modeled epidemiology will be increasingly 
unreliable over longer time periods. However, restricting the analysis to this period ignores any 156 
 
subsequent health benefits and costs, particularly the life-years gained through averted HIV 
mortality and averted transmission. These delayed costs and health outcomes may be of interest to 
decision-makers. For this reason, two sets of results were calculated: one set where only outcomes 
realized over the 20 years were included in the analysis (“truncated time horizon”), and one set 
where long-term outcomes were calculated for those individuals alive at the end of the initial 20-
year simulation (“extended time horizon”). This second approach was operationalized by assuming 
no further HIV transmission, ART initiation4 or population entry, and running the model for a 
further 100 years to capture the remaining life spans of both infected and uninfected persons of all 
ages, with outcomes being aggregated over the full 120 year period. 
3.2.11. Parameter estimates and calibration 
A Bayesian approach was used to calibrate model parameters to empirical data on HIV 
epidemiology in South Africa. . Under this approach, probability distributions were first specified to 
represent current uncertainty in model parameters (the ‘prior’). A likelihood function (the 
‘likelihood’) was then created to assess the level of agreement between modeled estimates and 
empirical data. This likelihood combined evidence from three sources (time trends in national HIV 
prevalence, survival in the absence of ART, and the CD4 cell count distribution in untreated HIV-
positive individuals), with the overall likelihood calculated as the product of these three individual 
likelihoods. Finally, an iterative algorithm used to synthesis these various information sources via 
Bayes Theorem. Each of these steps is described in detail below.   
 
                                                             
4 In sensitivity analyses we tested an alternate assumption in which all HIV-positive individuals were initiated 
on ART at the end of the initial 20-year period, with qualitatively similar results.  157 
 
3.2.11.1. Parameter estimates 
The estimates used to parameterize the model are shown in Table 3.1. There is substantial 
uncertainty about many of these parameters, and this uncertainty was operationalized as a prior 
probability distribution. For each parameter the prior distribution was centered at the mean shown 
in Table 3.1, with dispersion such that 2.5% of the distribution fell outside of the upper and lower 
bounds shown in the table (analogous to an equal-tailed 95% confidence interval). The functional 
form of the prior distributions was based on the range over which the parameter is defined: for 
parameters defined over the range [0,1] a logit-Normal prior was used (e.g., probabilities, disability 
weights), and for parameters defined over non-negative numbers a log-Normal prior was used (e.g., 
rates, costs)5. 
   
                                                             
5 While alternate functional forms might be considered, the logit-Normal and log-Normal were adopted as 
they were more easily adapted to the use with incremental mixture importance resampling (IMIS) calibration 
approach. 158 
 
Table 3.1. Prior distributions for model parameters 
Parameter Description  Value (Bounds)  Source 
Sexual behavior parameters 
Rate of partnership dissolution, by risk stratum: 
Low-risk 
High-risk 
 
0.017 [0.011, 0.025] 
2.0 [1.3, 3.0]  [34] 
Fraction of population in a pair, by risk stratum: 
Low-risk 
High-risk 
 
0.63 [0.47, 0.77] 
0.88 [0.82, 0.92] 
[42] 
[34] 
Relative partnership formation rate, by HIV health 
state: 
HIV-positive, CD4<200, no ART 
HIV-positive, CD4 200-350, no ART 
HIV-positive, CD4<350, ART 
All others 
 
0.25 [0.16, 0.37] 
0.65 [0.42, 0.96] 
0.80 [0.52, 1.18] 
1.00 
[34] 
Sexual mixing parameter for casual sex between 
risk strata 
0.56 [0.13, 0.93] 
[34] 
Sexual mixing parameter for casual sex between 
paired individuals 
 
0.50 [0.10, 0.90]  Assumed 
Rate of sex acts within pairs, by risk stratum: 
Low-risk 
High-risk  
 
42 [27, 63] 
42 [27, 63]  [34] 
Rate of casual sex acts, by risk stratum and pair 
status: 
Low-risk, in pair 
Low-risk, not in pair 
High-risk, in pair 
High-risk, not in pair 
 
4.4 [2.8, 6.5] 
4.4 [2.8, 6.5] 
4.4 [2.8, 6.5] 
4.4 [2.8, 6.5] 
[45] 
Relative frequency of sexual acts , by HIV health 
state: 
HIV-positive, CD4<200, no ART 
HIV-positive, CD4 200-350, no ART 
HIV-positive, CD4<350, ART 
All others (reference) 
 
0.65 [0.42, 0.96] 
0.25 [0.16, 0.37] 
0.80 [0.52, 1.18] 
1.0 
[34] 
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Table 3.1. Prior distributions for model parameters (continued) 
Parameter Description  Value (Bounds)  Source 
Relative rate of risky sexual behavior over time, 
parameterized as a logistic curve (see Figure 3.3): 
Initial value (reference): 
Final value: 
Start year of behavior change: 
Years to reach final value: 
 
 
1.0 
0.60 [0.42, 0.76] 
1995 [1990, 2000] 
10.0 [5.9, 15.9]  [34] 
Parameters related to HIV transmission risk 
Start year of modeled HIV epidemic  1980 [1975, 1985]  Assumed 
Fraction of population HIV-positive at start year of 
epidemic (HIV seed) 
 
0.0010 [0.0006, 
0.0015]  Assumed 
Per-act transmission risk for an individual with 
asymptomatic HIV, in the low-risk stratum, for 
male-to-female transmission  
 
 
0.003 [0.001, 0.006]  [47] 
Relative HIV transmission risk, by HIV health state: 
Early HIV 
CD4>350, excl. early HIV (reference) 
CD4<350 
 
26.5 [5.1, 83.0] 
1.0 
7.3 [1.6, 21.4] 
 
 
[50] 
 
 
 
Relative transmission risk for individuals receiving 
ART, compared to untreated individuals 
0.040 [0.006, 0.144] 
[51] 
Relative HIV transmission risk, by risk stratum: 
Low-risk (reference) 
High-risk 
 
1.0 
2.0 [1.3, 3.0]  [17] 
Relative HIV transmission risk: 
Male-to-female (reference) 
Female-to-make 
 
1.0 
1.5 [1.2, 1.8]  [47] 
Parameters related to HIV progression  
Transition rates between CD4 compartments: 
Early HIV to CD4>500 or 350-500 
Fraction exiting early HIV to CD4>500 
CD4>500 to CD4 350-500 
CD4 350-500 to CD4 200-350 
CD4 200-350 to CD4>200 
 
4.1 [1.5, 9.2] 
0.70 [0.56, 0.81] 
0.15 [0.10, 0.22] 
0.41 [0.26, 0.61] 
0.41 [0.26, 0.61] 
[50] 
 
 
 
[52–54] 
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Table 3.1. Prior distributions for model parameters (continued) 
Parameter Description  Value (Bounds)  Source 
Parameters related to model entry, aging and mortality 
Adult population in 1975 (millions)  14.9  [55] 
Absolute number of new entrants to adulthood (age 
≥15years) 
Time-varying, 
see Figure 3.3  [55] 
Fraction of new entrants female  0.51 [0.50, 0.52]  [55] 
Fraction of new entrants entering low-risk stratum  0.70 [0.56, 0.81]  [34] 
Rate at which individuals age out of the sexually 
active population  
 
0.029 
By 
construction 
Background mortality by age group: 
Age 15-49 years 
Age ≥50 years 
 
Time-varying, 
see Figure 3.3  [56] 
HIV specific mortality, by HIV health state: 
No ART, early HIV 
No ART, CD4>500 
No ART, CD4 350-500 
No ART, CD4 200-350 
No ART, CD4<200 
ART, initiated at CD4>500 
ART, initiated at CD4 350-500 
ART, initiated at CD4 200-350 
ART, initiated at CD4<200 
 
0.006 [0.001, 0.020] 
0.006 [0.001, 0.020] 
0.016 [0.008, 0.030] 
0.042 [0.029, 0.058] 
0.31 [0.27, 0.35] 
0.006 [0.001, 0.020] 
0.006 [0.001, 0.020] 
0.023 [0.014, 0.037] 
0.050 [0.031, 0.076]  [57–61] 
Parameters related to service delivery 
Rate of HIV testing in HIV-negative individuals as 
compared to HIV-positive individuals  
 
0.63 [0.56, 0.71]  [66] 
Probability of primary default between HIV 
diagnosis and pre-ART 
 
0.42 [0.31, 0.53]  [67] 
Rate of default from pre-ART care, by HIV health 
state: 
CD4<350  
CD4>350  
 
0.25 [0.15, 0.40] 
0.75 [0.53, 1.03] 
[67] 
Rate of default from ART, by health state at ART 
initiation: 
CD4<350 at ART initiation 
CD4>350 at ART initiation 
 
 
0.10 [0.07, 0.15] 
0.21 [0.13, 0.30]  [62] 
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Table 3.1. Prior distributions for model parameters (continued) 
Parameter Description  Value (Bounds)  Source 
Parameters related to cost and health state valuation 
Disability weights, by HIV health state: 
No ART, early HIV 
No ART, CD4 200-350 
No ART, CD4<200 
ART 
 
0.053 [0.033, 0.081] 
0.22 [0.15, 0.31] 
0.55 [0.38, 0.71] 
0.053 [0.034, 0.079]  [72] 
Costs of health care received by individuals with 
symptomatic HIV, not on ART or pre-ART: 
No ART, CD4 350-500 (annual) 
No ART, CD4 200-350 (annual) 
No ART, CD4<200 (annual) 
 
 
13 [7, 21] 
46 [35, 60] 
167 [160, 175]  [13] 
Costs of pre-ART services (annual)  238 [161, 338]  [13] 
Costs of ART services 
ART initiation (per event) 
Antiretroviral drugs (annual) 
Non-ARV costs (annual) 
 
95 [70, 127] 
172 [127, 227] 
422 [340, 517] 
[13] 
Cost of HIV testing and counseling (per client)  20 [15, 27]  [13] 
Cost of care during terminal illness  160 [88, 268]  [13] 
Mark-up on direct service provision costs to account 
for program-level management and administrative 
support 
 
0.50 [0.29, 0.79] 
[13] 
Discount rate  0.03  [73] 
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Figure 3.3. Prior distributions for time-varying model parameters  
 
3.2.11.2. Likelihood for HIV prevalence 
Two sources of HIV prevalence data were available: annual HIV prevalence estimates from sentinel 
surveillance at antenatal care (ANC) centers [74], and national population-based seroprevalence 
surveys conducted in 2002, 2005, and 2008 [75]. The estimates from population-based surveys 
were assumed to be unbiased but their small number provides limited information on long-term 
trends. In contrast, the estimates from ANC sites are generally based on a larger sample and are 
available as a complete annual time series 1990-2010. However, data from ANC sites are thought to 
provide biased estimates of general population prevalence, with pregnant women at higher relative 
risk of HIV compared to the general community [76]. As part of its Epidemic Projection Package for 163 
 
estimating national HIV prevalence and incidence trends [77], the UNAIDS Reference Group on 
Estimates, Modelling and Projections has developed an approach for incorporating both surveys 
and ANC surveillance into a single likelihood, by assuming that the bias in the ANC data represents 
a constant additive term in probit space [78,79]. We adopt a modified version of this likelihood, 
expressed as the log-likelihood shown below: 
    (  |      )    (
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  (10) 
where: 
    = parameter set i, 
     = modeled HIV prevalence estimate for year t (t   T), produced by parameter set   , 
T  = years in which ANC sentinel surveillance was conducted (1990-2010 inclusive), 
    = probit-transformed ANC prevalence estimate in year t, 
    = variance for ANC prevalence estimate in year t, calculated as 
             (   (  ) )  (      )   , 
    = effective sample size of ANC survey in year t, calculated by dividing the reported sample size 
by a design effect of 2.0 to account for clustering6, 
    = constant term for bias in ANC prevalence estimates,  
    = prior mean for bias term  , calculated as    
∑ (     )  
  , 
    = prior variance for bias term  , calculated as     
∑ (      )  
   , 
     = probit-transformed prevalence estimate from population-based survey in year z, 
                                                             
6 While this design effect is assumed, 95% uncertainty intervals calculated using these variance estimates 
approximate the confidence intervals reported in the survey report [74].  164 
 
z   = year in which population-based survey was conducted (z   2002, 2005, 2008), 
    = variance estimate for population-based prevalence survey in year z, 
   = multiplier on   to account for selective non-participation in population-based prevalence 
surveys, and 
   = number of population-based prevalence surveys conducted (      for South Africa). 
 
By considering selective non-participation in population-based prevalence surveys (via the term d) 
the likelihood function shown in equation 10 differs from the likelihood described by Alkema and 
colleagues [78]. This change is motivated by recent re-analyses of national prevalence surveys 
using Heckman-type selection models [80,81]. In its review of the issue, the UNAIDS Reference 
Group on Estimates, Modelling and Projections concluded that appropriate consideration of this 
potential bias may extend reported confidence intervals by up to a factor of 4.5 [82]. In this analysis 
we assumed d = 2.0. 
In addition, the assumption that the bias in the ANC data (operationalized as b) would be constant 
in probit space may not hold over a wide range of prevalence. As all the population-based 
prevalence surveys (used to estimate b) were conducted at a time of high prevalence (15.6-16.9%), 
we excluded from the likelihood all years where the maximum of the likelihood function would fall 
below 1% prevalence (1990-1992). Figure 3.4 summarizes the various data used for the prevalence 
likelihood. 165 
 
 
Figure 3.4. Data used for HIV prevalence likelihood  
 
3.2.11.3. Likelihood for HIV-positive survival in the absence of ART 
Glynn and colleagues report estimates of median survival from seroconversion to death in a 
retrospective cohort of South African mine workers [83]. As this study was conducted before ART 
became widely available, the results can be used to calibrate modeled estimates of survival for 
untreated HIV-positive individuals from the time of initial infection. In this study median survival 
was 10.5 years (95% CI: 10.0-10.8). As the raw data were unavailable, a Normal likelihood was 
constructed based on this summary estimate: 
    (  |    )    
(      ) 
     
  (11)   
where: 
    = parameter set i, 166 
 
    = modeled estimate of median survival following HIV seroconversion, produced by parameter 
set   , 
   = median survival of 10.5 years reported by Glynn et al., 
   = factor to expand Normal likelihood to account for unobserved bias, value=2.0, and 
    = variance of median survival estimate, calculated as (
         
       )
 
    = 0.083. 
This study was conducted in a select population (mine workers) whose survival might differ from 
the general population. For this reason the variance of the likelihood function was expanded by a 
factor of 2.0 to account for the possibility of unobserved bias. 
3.2.11.4. Likelihood for CD4 cell count distribution in untreated HIV-positive individuals 
A number of studies report information on the distribution of CD4 cell counts in ART-naïve 
individuals. While some of these studies report on populations whose CD4 distribution will clearly 
differ from the general population7, three studies report on groups whose CD4 distribution might 
be similar to the general population. These include data collected in 2002 from a single township 
with high HIV prevalence [84], data from a 2004 national survey of public school educators [85], 
and data collected in 2005 from health care workers in two public hospitals in Gauteng province 
[86]. These data are summarized in Figure 3.5. 
   
                                                             
7 For example, Holmes et al. report on a population of ART-naïve patients attending an HIV treatment clinic 
[53]. As a consequence of attending the clinic, these individuals are more likely to be experiencing HIV 
symptoms and have lower CD4 cell counts compared to HIV-positive individuals in the general population.  167 
 
 
Figure 3.5. Data used for CD4 cell count distribution likelihood 
 
These data were summarized in the following multinomial likelihood: 
    (  | )   ∑∑
   
 
   
  (   ) 
  (12)   
where: 
    = parameter set i, 
     = modeled estimate of the fraction of the untreated HIV-positive population in CD4 stratum k 
in the year in which data were collected for study j , produced by parameter set   , 
     = number of individuals in CD4 stratum k in study j, and 
   = factor to expand multinomial likelihood to account for unobserved bias, value=2.0. 
 
The study populations on which this likelihood is based represent specific groups (a single 
township, educators, health care workers) whose CD4 distributions might differ from the general 
population. As with the survival likelihood, an additional term (d) was included in order to increase 
the dispersion of the likelihood to account for the possibility of unobserved bias. 168 
 
The likelihoods for prevalence, survival, and CD4 distribution were assumed to be independent, and 
consequently the overall log-likelihood was calculated as the sum of the individual log-likelihoods: 
                             
  (13) 
3.2.11.5. Calibration approach 
The posterior distribution of the model parameters was approximated using Incremental Mixture 
Importance Sampling (IMIS) [87]. Similar to the Markov chain Monte Carlo methods conventionally 
used for Bayesian inference, IMIS produces a table of parameter sets that represent independent 
draws from the joint posterior parameter distribution, which are obtained by updating the joint 
prior distribution p(θ) with the information contained in the likelihood function described in 
Sections 3.2.11.2-3.2.11.4. The algorithm proceeds by drawing a sample from the prior distribution 
of the model parameters, similar to Rubin’s Sampling Importance Resampling approach [88] on 
which IMIS is based, and then iteratively adds extra draws to this sample in regions of the 
parameter space that the likelihood suggests are under-sampled with respect to the posterior 
distribution. The following description closely follows the exposition provided by Raftery and Bao 
2010 [87]: 
Initial stage: 
a.  Draw a large number (  ) of parameter sets from the prior distribution  ( ).  
b.  For each of these parameter sets,    , run the model and estimate the outcomes needed to 
evaluate the likelihood function (HIV prevalence, HIV survival, CD4 distribution in 
untreated individuals).  
c.  For each parameter set    calculate the likelihood,  (  ), and use these to calculate 
importance weights   
 : 169 
 
  
   
 (  )
∑  (  )  
 
  (14) 
Importance sampling stage: for k=1,2,… repeat the following steps 
d.  Choose the parameter set with the highest importance weight,   , and use this parameter 
set as the center of a new multivariate Normal distribution,   , created to sample 
underrepresented parts of the parameter space. Estimate the variance-covariance matrix 
of this distribution,   , as the weighted covariance of the B parameter sets with the 
smallest Mahalonobis distance to   , where distances are calculated with respect to the 
covariance of the prior distribution. 
e.  Sample B new parameter sets from   . 
f.  Run the model and calculate the likelihood for each of these new parameter sets. 
g.  Combine all parameter sets and calculate importance weights for the new parameter sets: 
  
     
 (  ) (  )
  (  )
 
  (15) 
where c is a constant chosen so that the weights sum to 1, and   (  ) is the mixture 
distribution calculates as a mixture of the prior and the new multivariate Normal 
distribution: 
  ( )  
   ( )    ∑     
   
  
 
  (16) 
where             . 
h.  Evaluate the stopping criterion: that the expected fraction of unique parameter sets in the 
resample is greater or equal to    
 
  (i.e., 0.632, which is the expected fraction when the 170 
 
importance weights are all equal). The expected fraction of unique parameter sets is 
calculated as ∑ (    (      
 )
 
)
  
    .  
i.  If the stopping criterion is not met, repeat steps d to h. If the stopping criterion is met, 
resample J parameter sets with replacement from the set of all    parameter sets, using 
the importance weights as sampling weights. These J parameter sets represent a draw 
from the posterior distribution. 
   (the size of the initial sample), B (the size of each additional importance sample) , and J (the 
number of resample in the final draw), are user specified inputs, set to 5 million, 50,000, and 
100,000 respectively in this analysis. 
 The stopping criterion described above is difficult to obtain for a problem with a high-dimensional 
posterior, and for this reason an alternative approach was adopted, whereby the algorithm was 
stopped after 20 iterations and all parameter sets were retained whose likelihood was statistically 
indistinguishable from the maximum likelihood8. The resulting sample of 70,840 parameter sets 
was used for all subsequent analyses. Figure 3.6 compares the results produced by the calibrated 
model against the calibration data.   
                                                             
8 This included all parameter sets i where        (
  
       
)       , and where the 65.2 threshold for the test 
statistic is derived from a    distribution with 48 degrees of freedom and   = 0.05. 171 
 
 
Figure 3.6. Results of calibrated model vs. calibration data 172 
 
3.2.12. Estimating costs 
We adopted a health system perspective for the analysis and costs were assessed incrementally, 
such that any cost categories unaffected by the changes in ART policy examined in this analysis 
were omitted from the costing. All costs are expressed in 2012 US dollars. Costs were assessed for 
the following categories: 
(a) direct costs of care received by ART patients, 
(b) direct costs of care received by pre-ART patients, 
(c) direct costs of programs to identify and link HIV-positive individuals to care,  
(d) averted costs due to reduced health care utilization outside of the HIV program, and 
(e) costs of higher-level programmatic support. 
 
3.2.12.1. ART costs 
ART costs were subdivided into ARV drug costs and non-ARV costs. The total cost of ARV drugs in a 
given year was calculated by multiplying the number of person-years of ART in that year by the 
annual ART regimen unit cost. The ART regimen unit cost represents the average annual cost of the 
current distribution of ART regimens in South Africa, estimated as part of a recent analysis of WHO 
guideline changes [13]. This and other unit costs are shown in Table 3.1. 
Nnon-ARV costs were subdivided into ART initiation costs and established patient costs. ART 
initiation costs—accounting for the additional laboratory tests and clinic visits incurred during a 
patient’s initial months on ART [63]—were calculated by multiplying the number of individuals 
initiating ART in a given year by the ART initiation unit cost, which was obtained from an evidence 
synthesis of available costing data [13]. Established patient costs—accounting for the regular 
clinical care and laboratory monitoring received by ART patients, as well as all other site-level 
activities required for the functioning of the ART program—were calculated by multiplying the 
number of person-years of ART in a given year by the established ART patient unit cost, obtained 173 
 
from the earlier evidence synthesis. Total ART costs were calculated as the sum of ARV costs, ART 
initiation costs, and established patient costs. 
3.2.12.2. Pre-ART costs 
Pre-ART patients receive regular clinical and laboratory monitoring of ART eligibility, as well as 
routine care and prophylaxis / treatment of opportunistic infections [89]. Pre-ART costs for a given 
year were calculated by multiplying the number of patient-years of pre-ART in that year (tracked in 
the model, as described in Section 3.2.9) by the pre-ART unit cost, obtained from the earlier 
evidence synthesis. 
3.2.12.3. HIV testing costs 
HIV testing costs in a given year were calculated as the product of the number of people receiving 
HIV tests in that year (as described in Section 3.2.9) and the unit cost of HIV testing and counseling, 
obtained from the earlier evidence synthesis. 
3.2.12.4. Averted costs outside of the HIV program 
Individuals with symptomatic HIV who are not receiving care or treatment in a dedicated HIV 
program may exhibit greater utilization of care within the routine health system. These other care 
costs were subdivided into annual health care utilization costs and end-of-life care costs.  
Annual health care utilization costs were estimated for HIV-positive individuals not on pre-ART or 
ART with a CD4 count <500 cells/µL. For each CD4 count category (350-500, 200-350, <200), 
health care utilization costs in a given year were calculated as the product of the number of person-
years spent in that state and the health care utilization unit cost for that state, obtained from the 
earlier evidence synthesis. 174 
 
End-of-life care costs were assumed to be the same for all individuals, and total end-of-life care 
costs for a given year were estimated as the number of deaths in that year multiplied by the unit 
cost per death, reflecting the additional utilization and inpatient care received during terminal 
illness. 
3.2.12.5. Programmatic support  
Program costs—the costs of management, administration, supervision, training, M&E and other 
activities undertaken to support direct service provision—are frequently omitted from empirical 
costing exercises, but can represent a non-trivial fraction of total costs. Estimates of program costs 
for PMTCT services suggest that these costs can represent 4–18% of total costs, and for HIV 
education services this percentage has been estimated as 34–97% [90]. For this analysis the mark-
up on direct service provision to take account of program costs was based on the input of costing 
and programmatic experts participating in the WHO guidelines analysis described previously [13]. 
In that analysis, program costs were divided into a fixed component, invariant to changes in 
program scale, and a variable component that scaled linearly with total direct costs (excluding 
ARVs). As this was an incremental costing the fixed costs could be ignored. The variable component 
represents a fixed multiple of direct costs, and this multiple was estimated at 50% (with a wide 
uncertainty interval), such that program costs would represent 33% of total service provision costs 
(excluding ARVs) [13].  
3.2.13. Estimating health outcomes 
Health consequences were summarized as incremental DALYs averted. For each year the total 
number of DALYs averted was calculated by summing the number of person-years lived in each HIV 
health state, multiplying this total by one minus the disability weight for that state (zero unless 
listed in Table 3.1), and summing across all HIV health states. The same basic estimation approach 
was used for truncated and extended time horizons, though the period over which results were 175 
 
aggregated differed (20 years and 120 years respectively). No age-weighting was used, consistent 
with the approach used in the most recent iteration of the Global Burden of Disease (GBD) study 
[91]. However, unlike the current GBD approach, future health gains (and costs) were discounted, 
using a rate of 3% per year [73]. 
3.2.14. Value function and decision rule 
It was assumed that:   
-  Policy makers are rational in their choice of policy options (i.e., hold preferences over any 
set of policy options that are complete and transitive), 
-  Faced with uncertain outcomes, policy makers value each outcome proportional to its 
probability of occurring, consistent with Von Neumann–Morgenstern Expected Utility 
Theory, and 
-  Policy makers hold preferences consistent with a utility function that is linearly 
increasing in health benefits (as operationalized in Section 3.2.13) and linearly 
decreasing in costs (as operationalized in Section 3.2.12), that these arguments exhibit 
additive independence, and that these outcomes (health system costs and DALYS 
averted) summarize all relevant consequences of the policies in question. 
If these conditions hold, relative preference for different policy options can be summarized as Net 
Monetary Benefit (NMB) [30], where for a policy i the expected value of Net Monetary Benefit is 
given by: 
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In equation 17 j indexes for parameter sets randomly drawn from the posterior parameter 
distribution, t indexes for year following policy introduction9, B represents total health benefits (in 
DALYs averted), C represents total costs, d represents the discount rate, and   represents the policy 
makers’ rate of exchange between health benefits and cost savings.  
As a consequence of the assumptions described above, decision makers will choose the policy that 
maximizes NMB on expectation, obtaining             
 
   (    ). For the purposes of this 
analysis we also assumed that the preferences expressed by policy makers are consistent with 
general societal preferences, such that by making optimal choices according to the choice function 
described above policy makers are also maximizing social welfare. 
The NMB framework also provides a direct measure of the welfare loss from sub-optimal decision-
making, with                representing the monetized value of the welfare loss through 
choosing policy i instead of the optimal policy, and the maximum value we should be willing to pay 
to switch from i to the optimal policy. 
3.2.15. Value of information analysis 
To assess the relative value of new research investments we followed the general framework 
described by earlier authors for estimating VOI [22,23,29,92,93]. 
 
 
                                                             
9 Note that T=20 for the truncated time horizon and T=120 for the extended time horizon, as discussed in 
Section 3.2.9. 177 
 
3.2.15.1. Expected value of perfect information 
The expected value of perfect information (EVPI) represents the additional welfare that would be 
gained if all decision uncertainty were resolved before a policy is chosen, as compared to a scenario 
where no new information is collected: 
        (             )  (           ) 
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      )      
 
   (    )  
  (18) 
Within the context of the calibrated model, this can be operationalized as: 
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  (19) 
where j indexes for parameter set drawn from the posterior parameter distribution. 
Results are presented for EVPI as a function of WTP per DALY averted ( ), to understand the upper 
bound of the possible value of new research. However, this metric gives little insight as to the 
absolute or relative value of new information on specific research targets. 
3.2.15.2. Expected value of partial perfect information 
The expected value of partial perfect information (EVPPI) represents the expected value of the 
additional welfare that would be gained if the decision uncertainty around an individual parameter 
or subset of parameters were resolved before a policy is chosen, as compared to the ‘no new 
information’ scenario: 
          (                  )  (           ) 
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where   represents the parameter or set of parameters on which perfect information is gained, and 
   represents the complement of  .        would typically be calculated by (i) drawing a single 
realization of   , (ii) drawing a large sample from     conditional on the realized value of    , (iii) 
finding the maximum average     in this sample that can be achieved by choosing between the 
different policy options i, (iv) repeating steps i-iii for a large sample from    and averaging the 
results, and finally (v) subtracting  (          ) from this total [22]. The first step in this 
algorithm is difficult to operationalize in the context of the calibrated model, as for each realization 
of    in the posterior parameter distribution (the set of 70,840 parameter sets described in Section 
3.2.11.5), we have only a single realization of     , and no obvious way of generating new samples 
(aside from recalibrating the model with this parameter fixed). As all parameters are sampled from 
a continuous prior distribution, this issue remains even if a very large number of samples are 
obtained from the posterior parameter distribution. To resolve this problem, it is assumed that 
    (    |  ) will be similar to     (    |   ) for those parameter sets that lie close to     in 
   (where k indexes a single realization of   ), such that: 
   
   
     (    |(       ))       (    |   )                  
  (21) 
 
This property (that the change in     (    |  ) as a function of    is continuous) is not an 
inherent property of decision problems10, yet it is true by construction for the model developed for 
this analysis. It is also true (due to the structure of the model) that the change in     (    |  ) as 
                                                             
10 For example, this continuity property may not hold in decision problems that feature sequential decisions 
made by different actors, as when    crosses a threshold such that the first actor changes their optimal policy 
there may then be a step change in the outcomes for other actors. 179 
 
a function of    is smooth (i.e., the first derivative of     (    |  ) with respect to any parameter 
in   is continuous). Based on these properties, we can approximate     (    |  ) by fitting a 
smooth curve (or smooth surface if there is more than one parameter in  ) through     |  , as 
calculated from the 70,840 posterior draws from the calibration. The resulting function, 
  ̂   (    |  ), allows us to estimate  (    |  ) for any policy and for any specific values of    in 
the range of those represented in the posterior parameter distribution11. For each policy, this 
function is created using locally-weighted polynomial regression (LOESS), an approach to 
estimating smooth curves or surfaces by fitting low-order polynomial functions to local subsets of 
data [94,95], operationalized using the loess function in R’s stats package [96]. 
The following algorithm was used to estimate       : 
(i)  For each policy i, the function   ̂   (    |  ) was estimated by fitting a LOESS regression 
for      as a function of the parameters in  . For most analyses z consisted of a single 
parameter, but when   represented multiple parameters all interaction terms were 
included in the LOESS regression.  
(ii) For each parameter set in  , the optimal policy given perfect information about   was 
identified as the policy that maximizes the function   ̂   (    |  ) at   . The rational 
decision maker should chose this policy, and obtain the actual value of     produced by 
this policy (i.e., not the value predicted by the function). 
(iii)   These actual values are averaged across all j     , and  (          ) was subtracted from 
the result, with this difference representing       . 
                                                             
11   ̂   (    |  ) actually represents a set of functions, one for each policy i. 180 
 
EVPPI results were calculated as a function of the WTP threshold, and used to make judgments 
about the relative value of perfect information for each parameter. EVPPI represents an upper 
bound of the value of new research, because the information obtained from research studies will 
not be perfect. In addition, as research on relative infectiousness might plausibly provide 
information on multiple phases of infection, EVPPI was calculated for the group of parameters 
determining relative transmission risk during early infection, late stage disease, and for those on 
ART. 
As it examines the value of perfect information on a particular parameter, EVPPI provides an upper 
bound on the value of empirical research, which only provides sample information. While the 
expected value of partial sample information (EVPSI) can be calculated, to do so requires an explicit 
description of the practical research design that would be used to collect new information, the 
expected sampling variance, and any biases that might affect the relationship between research 
results and the population-level variables of interest. As many research approaches are possible for 
a given subject, with differing costs and informational value, one could generate a function that 
describes EVPSI for each research target as a function of the level of investment, then choose the 
level of expenditure that maximizes EVPSI minus research costs. As the EVPSI of different 
parameters may not be independent (or if the opportunity cost of increased research spending is 
not fixed), optimizing the overall research portfolio would require simultaneously choosing a level 
of investment for all research targets so as to maximize the overall NMB generated by research 
minus the total costs of this research. Such an analysis—requiring estimates of the informational 
value and costs of many different research designs on different targets— is not feasible in the 
context of the current study. Instead, the relative magnitude of EVPPI for different research targets 
was used to draw conclusions about the relative urgency of new research in different areas, and 
identify areas where new research could meaningfully influence policy.  181 
 
3.2.16. Sensitivity analyses 
3.2.16.1. Health benefits attributable to the therapeutic effects of ART 
Sensitivity analyses were undertaken to estimate the fraction of health benefits that were 
attributable to the therapeutic effects of ART (c.f. the effects of reduced HIV transmission by ART 
patients). For each policy option, this fraction was calculated by comparing the number of DALYs 
averted by that policy in the main analysis (i.e., including both therapeutic and preventive benefits 
of ART) to the number of DALYs averted by that policy in an analysis in which future HIV infection 
risk is unaffected by ART policy, with all scenarios following the same HIV incidence trend as the 
current policy (policy A2, with ART eligibility of CD4 <350, and continuation of current testing 
rates).  
3.2.16.2. Different assumptions about discount rates 
Sensitivity analyses were undertaken to test the robustness of policy choices to changes in the 
discount rate applied to costs and health benefits. Three analyses were undertaken: one in which 
the discount rate for both costs and health benefits was set to 0% (i.e., no discounting), one in 
which this rate was set to 6%, and one in which costs were discounted at 3% (as in the main 
analysis) but health benefits were not discounted. 
3.2.16.3. Changes in the choice set  
For the value of information analysis, a sensitivity analysis was undertaken to understand the 
sensitivity of the VOI results to changes in the choice set. In this sensitivity analysis, the VOI results 
were recalculated under the assumption that the choice of coverage policy was already determined, 
representing continuation of current testing policy and continued ART enrollment (i.e., the choice 
set only includes policies A2, B2, and C2).  
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3.2.16.4. Fraction of transmission attributable to early infection 
A sensitivity analysis was undertaken to test whether the VOI results obtained for the parameter 
for increased transmission risk during early infection was sensitive to changes in the fraction of all 
transmission occurring during early infection. This sensitivity analysis was undertaken using a 
Bayesian melding approach [97], by adding an additional prior on this outcome (i.e., the fraction of 
all transmission attributable to individuals with early infection). This additional prior was 
operationalized as a Normal distribution with mean and standard deviation based on the estimate 
reported by Powers (38% (19-52) of all transmission attributable to early infection). This 
sensitivity analysis was implemented by reweighting the parameter sets, with weights proportional 
to the density of this additional prior when evaluated at the value of this outcome (fraction of 
transmission attributable to early infection) generated by each parameter set. The result of this 
reweighting was a 70% increase in the fraction of transmission attributable to early infection, to 
25% (15-39%). 
 
 Results  3.3.
3.3.1.  Epidemiological estimates and projections 
Figure 3.7 presents modeled results for various epidemiological outcomes over the period 1985-
2032, with future projections calculated under the assumption that current ART access and 
eligibility policies would be maintained (corresponding to policy A2, as described in Section 3.2.2). 
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Figure 3.7. Epidemiological outcomes, 1985-2032, with current ART eligibility and coverage 
policy 
 
The top left panel of this figure shows the rapid increase in HIV prevalence between 1990 and 
2005, followed by a delayed and more gradual rise in the HIV population with CD4 cell count <350 
cells/µL, the current ART eligibility threshold. The numbers of individuals receiving ART rises 
rapidly from 2005 to 2012 but subsequently plateaus as the majority of eligible individuals are 
initiated on treatment. The top right panel shows time changes in the distribution of the HIV-184 
 
positive population across CD4 cell count categories, initially dominated by early HIV during the 
early exponential growth of the epidemic, then with increasing numbers of individuals with low 
CD4 cell count as the epidemic matures. The bottom left panel shows HIV incidence and HIV 
mortality (defined as deaths of HIV-positive individuals), revealing the large lag in HIV mortality 
until 2005, after which the two curves move together, matching the rapid rise and subsequent 
plateau in HIV prevalence seen in the top right panel. The lower right panel explores the 
contributions of early and late HIV infection to overall HIV transmission, revealing a transition from 
early in the epidemic where most transmission is from individuals with early HIV, to late in the 
epidemic where almost half of all transmission is from individuals with CD4<350 (transmission 
from individuals in other disease stages not shown). This panel also reveals substantial uncertainty 
in this distribution of transmission across disease states, suggesting that a wide variety of values 
are compatible with the calibration data. These results—with 15% (7-26)12 of all current 
transmission from individuals with early HIV—can be compared to the analysis of Powers and 
colleagues, who found 38% (19-52) of all transmission in 2010 in Lilongwe Malawi to derive from 
individuals in their first 5 months following infection. The other modeled results for sub-Saharan 
Africa summarized by Cohen et al. [16] provide additional points of comparison, with the fraction of 
new infections attributable to early HIV ranging from 10-30% when the Powers result is excluded. 
Figure 3.8 shows summary epidemiological outcomes after 5 and 20 years for each of the 15 policy 
options assessed in the analysis. The policies are labeled with a letter-number combination, with 
the letter indicating ART eligibility threshold (“A” for CD4<350, “B”, for CD4<500, and “C” for all 
HIV-positive) and the number indicating coverage scenario (“1” for testing at current rates with 
fixed ART volume, “2” for testing at current rates, “3” for testing at 1.5x current rates, “4” for testing 
                                                             
12 Ranges in parentheses represent equal-tailed 95% posterior intervals. 185 
 
at 2x current rates, and “5” for testing at 3x current rates). Both cumulative incidence and 
cumulative mortality are seen to drop as coverage is expanded (holding eligibility constant), and as 
eligibility is expanded (holding coverage constant). The one exception to this relationship is in the 
set of policies where the number of ART slots is constrained to its 2012 level (policies A1, B1, C1). 
For these policies that assume a fixed capacity constraint on ART volume, an eligibility policy that 
expands ART eligibility to all HIV-positive individuals (policy C1) will reduce cumulative HIV 
incidence over 20 years to 5.9 (4.5-7.5) million individuals compared to 6.2 (4.8-7.8) new infections 
with current eligibility (policy A1), a 5.1% (1.9-10.1) reduction. However, this policy change would 
marginally increase cumulative HIV mortality over the same period, from 6.9 (5.5-8.4) to 7.0 (5.6-
8.6) million, a 1.9% (-0.2-3.9) increase in total deaths, due to relatively healthy individuals 
crowding out symptomatic individuals from limited ART slots. 186 
 
 
Figure 3.8. Major epidemiological outcomes at 5 and 20 years after policy introduction* 
* Policies are labeled with a letter-number combination, with the letter indicating ART eligibility 
threshold (“A” for CD4<350, “B”, for CD4<500, and “C” for all HIV-positive) and the number indicating 
coverage scenario (“1” for testing at current rates with fixed ART volume, “2” for testing at current rates, 
“3” for testing at 1.5x current rates, “4” for testing at 2x current rates, and “5” for testing at 3x current 
rates. 
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Over 20 years, compared to continuation of current eligibility and ART coverage (policy A2), the 
policy with most aggressive ART expansion (policy C5) is estimated to reduce cumulative HIV 
incidence by 3.1 million (2.4-3.9) new infections, a reduction of 58% (44-68), and reduce 
cumulative HIV mortality by 2.0 million (1.6-2.6), a reduction of 34% (29-38). The reductions in 
incidence and mortality that result from more aggressive eligibility and coverage policy will have 
countervailing effects on HIV prevalence. The third column of Figure 3.8, which shows the 
reduction in HIV prevalence compared to 2012 levels13, suggests there would be a net reduction in 
prevalence as both ART eligibility and coverage are expanded, despite the improved survival of 
HIV-positive individuals initiated on ART. The most aggressive ART expansion policy (policy C5) is 
projected to reduce prevalence by 5.9% (3.5-7.6) between 2012 and 2032, as compared to 2.5% 
(1.2-3.6) for the current policy (policy A2). 
Figure 3.9 shows the total DALYs averted by each policy, as compared to the status quo (policy A2). 
This figure presents results for the main analysis, when both preventive and therapeutic benefits of 
ART are taken into account, compared to a sensitivity analysis that considers only therapeutic 
health benefits by artificially holding HIV incidence equal for all policies. The fraction of total health 
benefits attributable to the therapeutic effects of ART are substantially higher under the truncated 
time horizon (representing all DALYs averted within the 20 year following policy introduction) as 
compared to the extended time horizon, which also includes lifetime health consequences for those 
alive at the end of the 20-year time horizon. This finding is consistent with the benefits of ART in 
averting transmission being substantially delayed relative to other outcomes, as newly infected 
individuals may live for many years (especially in an environment of good ART access) before the 
onset of substantial morbidity or early death. However, if these delayed health benefits are 
                                                             
13 Prevalence in 2012 is estimated to be 16.2% [14.2-18.4]. 188 
 
considered, these results suggest the prevention benefits of ART are substantial compared to the 
therapeutic benefits. It is also notable that the fraction of total health benefits attributable to the 
therapeutic effect of ART are lower in policies that expand ART eligibility alone (e.g., under the 
truncated time horizon 63% of DALYs averted by policy C2 are attributable to therapeutic effects, 
and 34% under the extended time horizon), as compared to policies that expand coverage alone 
(e.g., under the truncated time horizon 89% of DALYs averted by policy A5 are attributable to 
therapeutic effects, and 49% under the extended time horizon). This suggests that the ratio of 
prevention benefits to therapeutic benefits will be higher for individuals initiating ART at higher 
CD4 cell counts, as compared to individuals initiating ART at low CD4 cell counts (i.e., early 
initiation of ART may be more important for preventing transmission than extending survival).  189 
 
 
Figure 3.9. Total DALYs averted, and DALYs averted by therapeutic effects alone (i.e., 
excluding prevention benefits) for each policy compared to to policy A2* 
* Policies are labeled with a letter-number combination, with the letter indicating ART eligibility 
threshold (“A” for CD4<350, “B”, for CD4<500, and “C” for all HIV-positive) and the number indicating 
coverage scenario (“1” for testing at current rates with fixed ART volume, “2” for testing at current rates, 
“3” for testing at 1.5x current rates, “4” for testing at 2x current rates, and “5” for testing at 3x current 
rates. Estimates for DALYs averted from therapeutic health benefits alone are based on analyses where 
HIV infection risk is held constant at values generated by policy A2. ‘Pct. IHB’ represents the percentage 
of DALYs averted from therapeutic health benefits as compared to total health benefits (as calculated in 
the main analysis). Policy A2 used as the reference category. 190 
 
3.3.2.  Cost projections 
The effect of changing policy on costs differed across cost categories. Figure 3.10 shows the 
incremental difference in mean annual costs over the period 2012-2032 for a subset of four policy 
options, in order to illustrate the effects of different types of policy as compared to continuation of 
current policy (A2). 
Policy A1, in the top left panel of Figure 3.10, represents a very conservative approach to ART scale-
up, with ART eligibility held at CD4<350 (as in the status quo), and with ART volume capped at 
2012 levels. The cap on ART volume results in lower ART costs compared to the status quo (from 
both ARVs and non-ARV services), which are partially offset by increased pre-ART and other care 
costs (other care being care received outside of the HIV program). Policy C2, in the top right panel, 
is identical to the status quo except with greatly expanded ART eligibility (to all HIV-positive 
individuals), while policy A5, in the bottom left panel, is identical to the status quo except with 
greatly expanded ART coverage. Both changes result in higher overall costs. For policy C2, 
increased ART costs are partially offset by savings in pre-ART. In contrast, policy A5 results in 
increases in both ART and pre-ART costs, as well as large increases in testing costs, only modestly 
offset by savings in costs outside of the HIV program. These cost savings are realized because 
individuals with symptomatic HIV, who had previously been receiving care in the routine health 
system, would instead receive care through the HIV program (ART or pre-ART depending on 
eligibility). The combined effect of these factors is that the overall incremental costs under policy 
A5 appear much higher than policy C2 over all years (all panels use the same vertical scale). The 
lower right panel of Figure 3.8 shows the consequences of expanding HIV eligibility to include all 
HIV-positive individuals as well greatly expanded HIV testing programs (policy C5). Cumulative 
incremental costs are highest under this policy scenario, though the time trend in incremental costs 191 
 
decreases after the initial years, potentially due to decreased long-term incidence trends compared 
to current policy. 
 
 
Figure 3.10. Disaggregation of total incremental costs by year and by cost category, for four 
policy options as compared to continuation of current eligibility and coverage (policy A2)* 
* Policies are labeled with a letter-number combination, with the letter indicating ART eligibility 
threshold (“A” for CD4<350, “B”, for CD4<500, and “C” for all HIV-positive) and the number indicating 
coverage scenario (“1” for testing at current rates with fixed ART volume, “2” for testing at current rates, 
“3” for testing at 1.5x current rates, “4” for testing at 2x current rates, and “5” for testing at 3x current 
rates. 
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Figure 3.11 presents summary estimates of total undiscounted costs for all policies over the 20 
years since policy introduction, as compared to continuation of current eligibility and coverage 
(policy A2). As can be seen in the figure, those policies that assume ART volume is constrained at 
2012 levels (policies A1, B1, and C1) produce cost-savings compared to the status quo, while 
policies that involve expanding eligibility and coverage result in higher overall costs. This is 
particularly true for increases in coverage (e.g., policy A5, lower left), whereas expansions in ART 
eligibility (e.g., policy C2, upper right) produce relatively modest increases in total costs over the 
whole 20 years. 
 
 
Figure 3.11. Summary estimates of total incremental costs over 20 years for competing 
policies, compared to continuation of current ART eligibility and coverage (policy A2)* 
* Policies are labeled with a letter-number combination, with the letter indicating ART eligibility 
threshold (“A” for CD4<350, “B”, for CD4<500, and “C” for all HIV-positive) and the number indicating 
coverage scenario (“1” for testing at current rates with fixed ART volume, “2” for testing at current rates, 
“3” for testing at 1.5x current rates, “4” for testing at 2x current rates, and “5” for testing at 3x current 
rates. 
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3.3.3.  Decision-making with no new information 
Absent the opportunity to seek or act on new information, decision uncertainty can be ignored and 
policy choices made based on the expected values of uncertain outcomes14 [92,98–100]. Expected 
incremental costs (2012 US dollars, millions), health benefits (DALYs averted, millions) and 
incremental cost-effective ratios (ICERs) for competing ART policies are presented in Table 3.2, and 
cost-effectiveness results summarized graphically in Figure 3.12. All outcomes are discounted at 
3% per year. 
Results are presented for two time horizons: a truncated time horizon including only those costs 
and health outcomes realized within 20 years following policy introduction, and a extended time 
horizon that includes lifetime outcomes for all individuals alive at the end of the 20 year time 
horizon, in order to fully capture the value of reductions in mortality and HIV incidence (as 
described in Section 3.2.10). 
   
                                                             
14 Following the assumptions described under Section 3.2.14. 194 
 
Table 3.2. Incremental costs, DALYs averted, and cost-effectiveness ratios (US dollars per 
DALY averted) of competing policy options, assessed over both extended and truncated time 
horizons* 
Policy 
Option 
Truncated time horizon: excludes 
health benefits and costs realized after 
20 year horizon 
Extended time horizon: includes health 
benefits and costs realized after 20 
year horizon 
Cost 
Inc.   
Cost 
DALYs 
Averted 
Inc. 
DALYs 
Averted  ICER  Cost 
Inc.    
Cost 
DALYs 
Averted 
Inc. 
DALYs 
Averted  ICER 
C1  ---  ---  ---  ---  ---  ---  ---  ---  ---  --- 
B1  196  196  2.04  2.04  96  575  575  0.30  0.30  [1] 
A1  407  211  2.60  0.56  380  1,135  1,135  -0.90  -0.90  [2] 
A2  5,074  4,667  8.48  5.88  793  7,447  7,447  13.93  13.93  [1] 
B2  6,897  1,823  10.30  1.82  1,004  9,063  9,063  22.15  22.15  [1] 
C2  9,854  2,957  11.37  1.08  [1]  11,830  11,830  33.17  33.17  357 
A3  11,800  4,903  10.88  0.59  [2]  15,010  3,176  21.28  -11.89  [2] 
B3  14,320  7,421  13.65  3.36  2,210  17,110  5,279  32.06  -1.11  [2] 
C3  16,840  2,522  14.55  0.90  2,805  19,110  7,284  43.85  10.68  682 
A4  17,760  923  12.86  -1.69  [2]  21,450  2,339  26.66  -17.19  [2] 
B4  20,220  3,379  15.70  1.15  [1]  23,290  4,181  38.37  -5.48  [2] 
C4  22,350  5,515  16.45  1.90  2,902  24,700  5,585  50.35  6.50  859 
A5  27,680  5,326  15.15  -1.30  [2]  31,870  7,169  33.08  -17.28  [2] 
B5  30,030  7,672  18.04  1.59  [1]  33,310  8,611  45.86  -4.50  [2] 
C5  31,640  9,281  18.59  2.13  4,350  33,950  9,253  57.75  7.40  1,251 
[1] Dominated by extended dominance   [2] Dominated by strong dominance 
* Costs represent 2012 US dollars, both costs and outcomes are discounted at 3%. Policies are labeled with a 
letter-number combination, with the letter indicating ART eligibility threshold (“A” for CD4<350, “B”, for 
CD4<500, and “C” for all HIV-positive) and the number indicating coverage scenario (“1” for testing at current 
rates with fixed ART volume, “2” for testing at current rates, “3” for testing at 1.5x current rates, “4” for 
testing at 2x current rates, and “5” for testing at 3x current rates. 195 
 
 
Figure 3.12. Cost-effectiveness of competing policies, assessed over extended and truncated 
time horizons* 
* Policies are labeled with a letter-number combination, with the letter indicating ART eligibility 
threshold (“A” for CD4<350, “B”, for CD4<500, and “C” for all HIV-positive) and the number indicating 
coverage scenario (“1” for testing at current rates with fixed ART volume, “2” for testing at current rates, 
“3” for 1.5x current rates, “4” for 2x current rates, and “5” for 3x current rates.  196 
 
Figure 3.12 shows that, under the truncated time horizon (top panel), a large number of eligibility-
coverage combinations lie on the efficient frontier. However, under the extended time horizon 
(bottom panel) it appears that policies that allow ART eligibility for all HIV-positive individuals 
(policies C1-C5) together dominate the other policies. The relative impacts of expanding coverage 
and expanding eligibility are shown in Figure 3.13, which plots the progression of costs and health 
benefits as eligibility is expanded under each coverage policy (top panels), and as coverage is 
expanded under each eligibility policy (bottom panels). For example, the base of the blue arrow in 
the lower panels represents a policy with ART eligibility at CD4<500 and a fixed cap on ART volume 
(policy B1). Following the arrow towards the tip represents the change in costs and health 
outcomes as coverage policy is progressively expanded while eligibility policy is fixed at CD4<500, 
to the point where the tip of the arrow represents policy B5, with ART eligibility still at CD4<500 
but with very aggressive HIV testing programs. 197 
 
 
Figure 3.13. Change in costs and health benefits as one policy dimension is expanded while 
the other is held fixed, for both truncated and extended time horizons*  
* Policy dimensions are labeled with letters and numbers, with the letter indicating ART eligibility 
threshold (“A” for CD4<350, “B”, for CD4<500, and “C” for all HIV-positive) and the number indicating 
coverage scenario (“1” for testing at current rates with fixed ART volume, “2” for testing at current rates, 
“3” for 1.5x current rates, “4” for 2x current rates, and “5” for 3x current rates.  
 
Under the truncated time horizon (panels on left), expansions in both eligibility and coverage have 
approximately similar slopes, and both exhibit decreasing returns to continued expansion, though 198 
 
the magnitude of effects is greater with coverage expansion15. In contrast, under the extended time 
horizon (panels on right) expansions in coverage appear to produce substantially greater health 
gain per unit expenditure, without evidence of decreasing returns. The difference in results 
between the two time horizons can be linked back to the 20-year prevalence results shown in 
Figure 3.8, where policies expanding ART eligibility to all HIV-positive individuals (policies C1-C5) 
appear most effective at reducing prevalence relative to the other policies, mainly as a result of the 
incidence reductions associated with these policies. Reducing incidence is particularly influential in 
this extended time horizon, with each averted HIV infection producing substantial benefits in both 
cost savings and DALYs averted. The exact magnitude of these benefits will depend on the eligibility 
and coverage policy in place, but at one extreme in a scenario with no access to HIV-specific care or 
treatment the consequence would be 17.0 (16.1-17.7) DALYs averted and $825 (680-1019) in cost 
savings for each infection averted (discounted from the time the infection is averted). At the other 
extreme, in a scenario with immediate access to ART for all HIV-positive individuals, the 
consequences of preventing one HIV infection would be 3.5 (2.3-5.6) DALYs averted and $15,400 
(12,000-19,400) in cost-savings for each infection averted16. In either case the benefits of incidence 
reduction are substantial, and only fully realized under the extended time horizon. This reinforces 
the findings shown in Figure 3.9, which compares the therapeutic and total benefits of ART under 
different time horizons. 
                                                             
15 Expanding eligibility with constrained ART volume (policies A1, B1, and C1) behaves differently, with 
results reflecting the increased competition for ART slots as increasingly health individuals become ART-
eligible.  
16 These results are obtained by comparing discounted lifetime costs and health benefits for a newly infected 
HIV-positive individual with the same outcomes calculated for an HIV-negative individual, under different 
health care access scenarios.  199 
 
Given that the consequences of ART policy change accumulate over many years, the choice of 
discount rate could be influential for decision-making. Figure 3.14 shows the cost-effectiveness of 
competing policies under different discounting schemes. In the top panel, the use of a 0% discount 
rate implies that equal weight is given to all outcomes independent of when they occur. In contrast, 
the middle panel shows results calculated with a 6% discount rate, greatly down-weighting the 
value of consequences occurring many years in the future. Perhaps surprisingly, there is little 
change in the policies appearing on the efficient frontier under either scenario, or their ordering. 
However, the cost-effectiveness ratios for a given policy comparison are substantially higher as the 
discount rate increases (for example, under the extended time horizon the ICER for moving to 
policy C3 from policy C2 is 3.7 times larger with the 6% discount rate as compared to no 
discounting). This finding results from the health benefits of expanded ART access being 
experienced substantially later than the costs incurred to produce them. For a decision maker with 
a high rate of time preference, these results suggest that a more conservative approach to ART 
expansion will be optimal for a given willingness-to-pay for health benefits. 
The lower panel of Figure 3.14 describes the cost-effectiveness of competing policies in a scenario 
where costs are discounted at a conventional 3% discount rate while health benefits are 
undiscounted. To present health benefits undiscounted is consistent with recent methodological 
changes made by the Global Burden of Disease Study that developed DALYs [91]. Perhaps more 
importantly, to discount costs but not health benefits implies that the relative value of averting a 
DALY increases by 3.1% each year. While this assumption might be implausible in a stable 
economy, it can be justified in the context of economic growth [101]. If one accepts that the 
marginal utility of averting DALYs is constant as the overall level of health increases, while the 
marginal utility of other consumption is decreasing, an increasing share of overall consumption 
should be devoted to averting DALYs as an economy grows (in per-capita terms). Per-capita GDP in 
South Africa rose at an average annual rate of 6% between 1960 and 2012, and 12% over the last 200 
 
10 years [102]. It is not clear that the potential continuation of these growth rates supports a 3.1% 
annual increase in the value of averting DALYs, but it is not impossible. As with other sensitivity 
analyses shown in this figure, this discounting approach leads to little change in the identity and 
ordering of the policies on the efficient frontier, but does produce a substantial reduction in the 
ICERs for a given policy comparison. If a decision maker were to hold beliefs and preferences 
consistent with this discounting scheme, these results suggest that a more aggressive approach to 
ART expansion will be optimal for a given willingness-to-pay for health benefits. 
   201 
 
 
Figure 3.14. Cost-effectiveness of competing policies with different discount rates applied to 
future costs and health benefits* 
* Policies are labeled with a letter-number combination, with the letter indicating ART eligibility 
threshold (“A” for CD4<350, “B”, for CD4<500, and “C” for all HIV-positive) and the number indicating 
coverage scenario (“1” for testing at current rates with fixed ART volume, “2” for testing at current rates, 
“3” for 1.5x current rates, “4” for 2x current rates, and “5” for 3x current rates.   202 
 
3.3.4.  Decision uncertainty 
The cost-effectiveness results described above specify the optimal policy choice for a given WTP 
threshold. Cost-effectiveness acceptability curves (CEACs) are one approach to understanding the 
uncertainty in these results, plotting the probability that each policy is optimal as a function of the 
WTP threshold [103]. Figure 3.15 presents CEACs for both truncated and extended time horizons. 
These plots reinforce the finding of Section 3.3.3 – that while a multitude of policies have non-
negligible probability of being optimal under the truncated time horizon, the policies with eligibility 
for all HIV-positive individuals appear to be optimal with high probability under the extended time 
horizon.  203 
 
 
Figure 3.15. Cost-effectiveness acceptability curves for competing policies*  
* Policies with P(Cost-Effective)<0.05 are not shown. Policies are labeled with a letter-number 
combination, with the letter indicating ART eligibility threshold (“A” for CD4<350, “B”, for CD4<500, and 
“C” for all HIV-positive) and the number indicating coverage scenario (“1” for testing at current rates 
with fixed ART volume, “2” for testing at current rates, “3” for 1.5x current rates, “4” for 2x current rates, 
and “5” for 3x current rates. 204 
 
The CEACs also provide information relevant to the value of information. Under the framework 
adopted for the VOI analysis, information is only valuable to the extent that it allows decision 
makers to choose a policy that they would previously have avoided, such that a policy appearing 
sub-optimal with prior information is proven optimal once new information is obtained. If, based 
on prior information, we know that there is no chance that collecting new information will lead us 
to change our policy decision, then there is no value to new research. This appears to be the case for 
all but a narrow band of WTP values under the extended time horizon, where if WTP is less than 
~$100 per DALY averted, or greater than ~$2,000 per DALY averted, the policy deemed optimal 
based on expected values is almost certain to be cost-effective were full information available. In 
contrast, under the truncated time horizon there is substantial uncertainty as to the optimal policy 
over a wide range of WTP values. 
3.3.5.  Value of information 
3.3.5.1.  Expected value of perfect information 
Figure 3.16 plots the expected value of perfect information—the net monetary benefit that would 
be obtained through complete resolution of all decision uncertainty—as a function of WTP. While 
not providing information on how to direct new research, the EVPI results show that there is 
potential for substantial value from new research that would reduce decision uncertainty. As noted 
earlier, under the extended time horizon this possibility is limited to situations where WTP is less 
than $2,000 per DALY averted. 
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Figure 3.16. Value of perfect information, and probability that new information will lead to a 
different policy being chosen, as a function of willingness-to-pay and under truncated and 
extended time horizons  
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3.3.5.2.  Expected value of partial perfect information 
Figure 3.17 presents the expected value of partial perfect information (EVPPI) for selected 
individual model parameters. The figure shows the ten parameters with the highest EVPPI values as 
well as the relative transmission risk for early HIV (not in the top 10), given pre-specified interest 
in this parameter. EVPPI provides information on the value of resolving all uncertainty around a 
particular parameter, and in this analysis is used to understand the relative value of competing 
research targets. Though findings differ depending on the time horizon, parameters related to 
service provision (unit costs, default rates) are prominent. Parameters relating to HIV transmission 
risks do appear in the top ten, though the relative transmission risk associated with early HIV does 
not (but is included in the figure for purposes of comparison). Also notable from these results is the 
critical importance of the WTP threshold both for the absolute VOI as well as the relative ranking of 
different parameters. This feature results from characteristics of the policies that have non-zero 
probability of being optimal at a given WTP threshold (these probabilities are plotted in Figure 
3.16). The local maxima observed in Figure 3.17 generally correspond to WTP values where two 
policies are equally optimal on expectation. For example the first major set of peaks under the 
extended time horizon occur at a WTP of $357, which is the threshold between policies C1 and C2 
(representing a change in policy from fixed ART volume to a policy of continued ART scale-up based 
on current testing volume, with all individuals eligible for ART) being optimal (on expectation). At 
this point, EVPPI is highest for non-ARV ART costs, the relative transmission risk associated with 
ART, and pre-ART costs, suggesting the incremental difference between E(NMB) for C1 and C2 is 
most sensitive to these parameters. In contrast, the choice between policy C4 and C5 (raising the 
rate of HIV testing to very high levels, with all individuals eligible for ART), represented by the 
peaks at $1,251, appears most sensitive to HIV testing costs, the multiplier on costs to account for 
programmatic support, and the probability of primary default following HIV testing. 207 
 
 
Figure 3.17. Expected value of partial perfect information for individual model parameters  
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While Figure 3.17 describes VOI for individual parameters, it is likely that some research designs 
would inform multiple parameters simultaneously. This is particularly true of research on relative 
infectiousness during different disease stages. Earlier work has described how the sum of VOI 
calculated for individual parameters is not necessarily equal to the joint VOI for the group of 
parameters [22], which could be either sub- or super-additive depending on the context. For this 
reason further analyses were undertaken to estimate EVPPI for the group of parameters relating to 
relative infectiousness during different disease stages (relative transmission risk for early HIV vs. 
CD4>350, relative transmission risk for CD4<350 vs. CD4>350, and relative transmission risk for 
ART vs. no ART). These results are shown in Figure 3.18, along with VOI results for these 
parameters individually. The joint EVPPI for all three parameters is superimposed on top of the 
naïve sum of EVPPI for the three parameters individually, showing that VOI of the individual 
parameters is approximately additive, though appears to be super-additive for WTP values where 
two policies are equally optimal on expectation (and decision uncertainty high), and sub-additive 
otherwise. It is also clear from the figure that while there would be substantial VOI from resolving 
uncertainty around relative transmission risk during later-stage HIV (CD4<350) and while on ART, 
there is comparatively little value in further improving our understanding of relative infectiousness 
during early HIV.  209 
 
 
Figure 3.18. Expected value of partial perfect information on relative infectiousness by 
disease stage 
 
Describing VOI as a function of WTP provides insight into the relationship between VOI and the 
specific policies with a positive probability of being optimal at a given WTP threshold, and 
highlights the importance of WTP to both absolute VOI and the relative importance of different 
parameters. However, it is also useful to summarize results based on current understanding of WTP 
in this setting. There is currently a poor understanding about WTP for health gains in developing 
countries such as South Africa, and active discussion is occurring regarding the criteria upon which 
WTP estimates should be based [104]. If WTP estimates are based on our understanding about 210 
 
what countries should be willing to pay to improve health, a number of international agencies 
suggest thresholds based on small multiples of per capita GDP or GNI [105–107]. The most 
commonly cited of these are the thresholds proposed by the WHO-CHOICE initiative, suggesting 1x 
per capita GDP per DALY averted as an upper bound for interventions to be described as ‘very cost-
effective’, and 3x per capita GDP per DALY averted as an upper bound for interventions to be 
described as ‘cost-effective’ [107]. For South Africa, these thresholds would be $7,500 and $22,500 
respectively, based on per capita GDP in 2012 [108]17. In contrast, thresholds motivated by 
concepts of affordability tend to be lower, reflecting that fact that total spending on health is often 
less than might be suggested by the GDP based thresholds described above [109]. Earlier World 
Bank and WHO publications have suggested thresholds of US$100 per DALY averted as an upper 
bound for describing ‘highly attractive interventions’, and US$500 per DALY averted for describing 
‘attractive interventions’ in middle-income countries such as South Africa [110,111]. While inflation, 
economic growth, and the expansion of donor-funded health aid would suggest a threshold based 
on affordability concerns may be higher today, it is still likely that affordability and budgetary 
concerns will impose additional constraints, and dictate a lower WTP than that suggested by the 
WHO-CHOICE per-capita GDP approach. Given this uncertainty, summary results were calculated 
by assuming WTP would fall somewhere between $0 and $7,500 per DALY averted, with all values 
within this region being equally probable. The ten parameters for which EVPPI is highest by this 
approach are shown in Figure 3.19, for both truncated and extended time horizons. Included in this 
ranking is the joint EVPPI for the three parameters for relative transmission risk by disease stage. 
                                                             
17 The WHO-CHOICE thresholds were originally described in terms of international dollars per DALY averted, 
reflecting concerns about purchasing power parity when regional thresholds are used. However, within a 
single country setting the calculation of both threshold and ICERs in US dollars (or other monetary unit) 
represents a simple currency conversion and does not affect the decision-making in any way. 211 
 
While absolute values are shown in this figure, these values should be interpreted as upper bounds 
to the value of any research, given the impossibility of resolving all uncertainty around a particular 
parameter. 
 
 
Figure 3.19. Expected value of partial perfect information, summary rankings 
  
The results shown in Figure 3.19 generally confirm the findings reported in earlier figures, with 
parameters related to cost and service provision figuring prominently. The relative importance of 
resolving uncertainty around the three transmission risk parameters appears to be high (rank 2nd 
under the truncated time horizon, 3rd under the extended time horizon), though given the results 212 
 
shown in Figure 3.15, this value stems largely from the resolution of uncertainty around 
transmission risk during later HIV and while on ART, rather than during early HIV. For the 
individual parameter for relative transmission risk during early HIV, the ranking is 46 out of 71 
under the truncated time horizon, and 27 out of 71 under the extended time horizon. In both cases 
this parameter accounts for approximately 1% of the value of information estimated for the most 
valuable research targets shown in Figure 3.19. 
It is possible that the low EVPPI estimated for relative transmission risk during early HIV is a 
consequence of the relatively small fraction of new infections estimated to come from early HIV, as 
described under Figure 3.7. To test this possibility, a sensitivity analysis was undertaken in which 
the fraction of transmission attributable to early infection was increased to 25% (15-39%), 
approximately 1.7 times its value in the main analysis18. When the VOI results are recalculated for 
this new scenario, EVPPI for the relative transmission risk during early HIV increases by 50-100%. 
However, this change is not sufficient to change the overall finding that EVPPI of relative 
transmission risk during early HIV is comparatively low, and the higher value obtained in this 
sensitivity analysis is still 50 times smaller than the highest values shown in Figure 3.19. 
Additional sensitivity analyses were undertaken to assess the robustness of the results to changes 
in the choice set, by rerunning the cost-effectiveness analysis and VOI analysis under the 
assumption that testing policy was fixed (i.e., the current approach would be continued), and that 
the only policy changes being considered involved expansions in eligibility (i.e., policies A2, B2, and 
C2).  
                                                             
18 This change was achieved by recalibrating the model with an additional calibration target specified for the 
fraction of transmission attributable to early infection, as described in Section 3.2.16.4. 213 
 
 
Cost-Effectiveness Ratios and Efficient Frontier 
 
Cost-Effectiveness Acceptability Curves 
 
Figure 3.20. Cost-effectiveness results for a choice set including only policies A2, B2 and C2 
 
The cost-effectiveness results obtained in this new analysis are shown in Figure 3.20, and the 
qualitative findings generally mirror those of the main analysis, though with all three policies now 
on the efficient frontier. EVPI results for this restricted choice set are shown in Figure 3.21 plotted 
as a function of WTP, and compared to the EVPI results obtained in the main analysis. As in that 
analysis, the local maxima coincide with WTP values where two policies appear equally optimal 
based on current information, and where new information would be most valuable for discerning 214 
 
which policy is truly optimal. EVPI is generally lower if the choice set is restricted in this way 
(compared to the main analysis), and this can be understood by comparing the cost-effectiveness 
acceptability curves shown in Figures 3.15 and 3.20. In the main analysis (Figure 3.15) the range of 
WTP values where there is uncertainty as to the optimal policy is much wider, and the number of 
policies with a non-trivial probability of being optimal is larger. The VOI approach adopted for this 
analysis assumes that information is more valuable if it helps us resolve uncertainty about which 
policy will provide the best outcomes. A consequence of this approach is that greater decision 
uncertainty will lead to greater value of information, and this is relationship is reflected in the 
results of this sensitivity analysis. It should be noted that EVPI is not universally lower for the 
restricted choice set, as EVPI with the restricted choice set is higher under the extended time 
horizon if WTP is less than approximately $300 per DALY averted. In the main analysis under the 
extended time horizon, policy C1 (a fixed cap on ART scale-up with eligibility for all) is found to be 
optimal with high probability if WTP is less than $300 per DALY averted (Figure 3.15). In contrast, 
policy C1 is not available with the restricted choice set, and there is non-trivial uncertainty as to 
which of the three policies is optimal, particularly at a WTP of $200 per DALY averted, where all 
three policies have an approximately equal probability of being optimal. Thus the higher EVPI for 
the restricted choice in this particular context reinforces the relationship between decision 
uncertainty and VOI.  
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Figure 3.21. EVPI for a choice set including only policies A2, B2 and C2, compared to EVPI 
calculated for the original choice set 
  
Figure 3.22 presents EVPPI estimates for the same 11 parameters shown in Figure 3.17, now 
calculated for the restricted choice set in which testing intensity is fixed. The EVPPI estimates from 
the main analysis are shown in grey for purposes of comparison. The qualitative findings from the 
comparison of EVPI results also apply here, with EVPPI generally lower in the analysis with the 
restricted choice set, though not universally so. It is notable that EVPPI for better information on 
HIV testing costs, found to be substantial in the main VOI analysis, appears to be zero with the 
restricted choice set. This is consistent with the idea that the value of information on HIV testing 
programs will be substantially reduced whren changes in HIV testing policy are no longer being 
considered.   216 
 
 
Figure 3.22. EVPPI for a choice set including only policies A2, B2 and C2, compared to EVPI 
calculated for the original choice set*  
* Parameters shown in figure are those with the highest EVPPI estimated in the main analyses (Figure 
3.17). Grey lines represent the EVPPI estimates from the main analysis, for purposes of comparison. 217 
 
 Discussion  3.4.
This analysis finds that scaling-up ART in South Africa, either through expanded ART eligibility 
criteria or through more aggressive HIV testing programs, would lead to substantial reductions in 
the burden of disease associated with HIV. Expanded ART provision is shown to substantially 
reduce HIV-associated mortality, and absent other effects the improved survival of HIV-positive 
individuals would lead to increased HIV prevalence. However, results suggest that the net effect of 
expanded ART will be to reduce HIV prevalence over the long term, as the increase in prevalence 
due to reduced HIV mortality is outweighed by reductions in transmission. Over a extended time 
horizon, the DALYs averted through the preventative effects of ART represent over half of the total 
health benefits generated by ART. These prevention-related health benefits—representing the 
gains in quality and length of life among HIV-negative individuals who would otherwise be infected 
with HIV—are a delayed consequence of expanded ART, and might be incompletely captured by 
analyses that aggregate results over a truncated time horizon. In an analysis where health outcomes 
experienced after 20 years are ignored, the therapeutic effects of ART are the major driver of health 
impact, and the overall health benefits of expanded ART are substantially smaller.  
Expanded ART also requires large increases in health system costs, with higher costs within HIV 
programs being only modestly offset by savings in routine health services. Policies involving more 
aggressive HIV testing programs appear to add substantially to overall costs. These cost increases 
come not only from the HIV testing programs but also from higher pre-ART costs for the larger 
cohort of individuals in care but not yet eligible for ART, as well as higher ART costs. In contrast, 
under policies involving expanded ART eligibility, higher ART costs are partially offset by 
reductions in pre-ART costs, as previously enrolled pre-ART patients are shifted onto ART. 
The cost-effectiveness findings of this analysis suggest that expanding ART access in some way, 
either through raising CD4 cell count-based eligibility criteria or through more aggressive testing 218 
 
programs, would be cost-effective under a wide range of assumptions. This finding appears robust, 
despite substantial uncertainties about important features of the epidemic and intervention 
policies. Over a extended time horizon, policies involving expanded ART eligibility criteria appear 
particularly effective at producing health benefits at comparatively low cost. This result is 
surprising, given that the therapeutic benefits of early ART initiation will be lower than providing 
ART to symptomatic individuals who otherwise would not receive it (as might be accomplished by 
expanded HIV testing programs). This result reflects the importance of HIV prevention to long-term 
health outcomes, as well as the comparatively lower costs of this ART scale-up approach, as 
discussed above. One condition under which this finding—that expanding ART access is cost-
effective—may not apply is where policy makers operate under time horizons far shorter than 
those adopted here. Because spending on ART programs precedes the benefits it generates, the 
health benefits of ART may not accumulate sufficiently under a short time horizon to justify the 
costs in an acutely resource-constrained setting. Of course, in this situation the demand for new 
research will also likely be low, as the lag between investment and pay-off may be even longer for 
research. 
The results describing epidemiologic and economic outcomes are broadly consistent with other 
analyses investigating the long-term costs and population health outcomes of ART expansion in 
South Africa [11,13,112,113], though not finding the possibility of long-term cost-savings suggested 
by some authors [112]. These results form the basis of a value-of-information analysis to identify 
priority targets for new HIV research. 
Perhaps the most notable finding of the VOI results is the apparent unimportance of information 
about transmission during early HIV infection. Resolving uncertainty for this parameter (the 
relative risk of transmission during early HIV infection) accounts for approximately 1% of the value 
of information estimated for the most valuable research targets under both truncated and extended 219 
 
time horizons. One possible explanation for this finding is that the estimated fraction of all new 
infections attributable to individuals with early HIV infection is smaller in our analysis than in some 
other analyses, particularly Powers et al. [17], who also adopted a pair model. In the Powers 
analysis, the majority of HIV transmission occurred within high-risk pairs with very high rates of 
partner turnover, so the potential for newly-infected individuals to be sequestered within pair 
relationships (a defining feature of pair models) may not have been realized. In addition, the 
Powers model had an average duration of early HIV of 4.8 months, while our analysis used a mean 
value of 2.9 months from Hollingsworth et al. [50], and these differences in the definition of early 
HIV could also affect the fraction of total infections coming from this group. In sensitivity analyses 
that increased the fraction of transmission attributable to early infection by 70%, to a point 
approximately half way between the original value and that reported by the Powers analysis, the 
VOI of information about transmission during early HIV infection rose by 50-100% of its original 
value. While confirming the intuition that this VOI would rise as the fraction of transmission 
attributable to early infection increased, this new value was insufficient to produce any meaningful 
change in the relative importance of this parameter relative to other model parameters. Even if this 
analysis were adjusted to obtain a fraction of transmission attributable to early infection similar to 
that reported by Powers, it is unlikely the VOI analysis would find information about transmission 
during early HIV infection to be a priority research target. 
While there are important differences between this analysis and that conducted by Powers et al., it 
is possible that the conclusion of the VOI analysis—that relative infectiousness during early HIV is 
effectively irrelevant for ART policy—might be a general feature of HIV epidemics. A heuristic 
approach to motivate this idea is to consider transmission during early HIV as a multiplier applied 
to any new HIV transmission – thus if an intervention is able to avert one primary infection, it might 
end up averting 1.5 infections in total if one counts the subsequent secondary transmissions that 
occur while the primarily infected individual is experiencing early HIV. In a scenario where 220 
 
transmission during early HIV represents a large fraction of all new infections, the fraction of all 
transmission that could be averted by treatment of individuals in other disease stages will be 
smaller, and so ART would prevent fewer primary transmissions. However, the number of 
secondary transmissions averted for each primary transmission will be higher (e.g., instead of 1.5 
the multiplier might be 1.8). Conversely, if early HIV contributes a small fraction of all infections, 
then although a greater fraction of all transmissions could be averted by expanding ART access to 
individuals in later disease stages, the number of secondary infections averted will be smaller (e.g., 
instead of 1.5 the multiplier might be 1.3). In sum the total change in HIV incidence following a 
change in ART policy may be different between these two scenarios, but this difference will be 
smaller than originally anticipated. 
In contrast to early HIV infection, the issues found to have the highest potential value of 
information include (1) issues of cost and implementation, (2) relative infectiousness during late 
HIV and the reduction in infectiousness for individuals on ART, and (3) the therapeutic health 
benefits of ART for individuals with CD4 cell counts above current eligibility guidelines. The 
prevention benefits of ART are the subject of an increasing volume of research. The most notable 
trial reported thus far is the HPTN 052 trial, which found compelling reductions in HIV 
transmission for individuals initiated on ART [9]. A number of similar trials and observational 
studies are planned or ongoing, investigating different population groups and aspects of 
implementation [114,115], and for this reason we are likely to have improved information about 
the relative infectiousness of ART patients in the near future. These and other trials [116,117] will 
also provide information on the therapeutic benefits of early ART initiation. There has been less 
systematic investigation of HIV intervention costs beyond small single-center studies, though 
examples exist [118], particularly focused on the costs of HIV treatment [63,119–121]. One 
challenge for new research on HIV costs is generalizability: while the knowledge generated by trials 
of ART effectiveness may generalize broadly, the costs of service provision are a consequence of 221 
 
complex social and institutional interactions, and might change substantially across settings or as 
intervention approaches change. Despite these difficulties, the findings of this analysis—that 
reducing uncertainty around the costs of competing policies is a high priority relative to other 
concerns—suggest that greater investment in understanding HIV intervention costs may be 
warranted. Similarly, operational issues—such as improved understanding of the pathways for 
diagnosis and treatment initiation—will also likely differ substantially across settings, yet may 
benefit from greater research funding.  
The decision to highlight comparative VOI results (as opposed to the absolute dollar values) reflects 
the belief that that comparative findings will be more robust to some the limitations of the analysis. 
Among the limitations of using the absolute EVPPI estimates is the fact that the analysis was 
conducted in a single setting (South Africa), yet the information generated by new research would 
likely aid decision-making in other settings, and therefore the total global value may be much 
higher than the absolute values estimated in this analysis. Even within South Africa, there are likely 
a large number of policy decisions, big and small, to which new information might be applied. While 
likely not simply additive, the more decisions for which research might be relevant (and the more 
influential those decisions), the greater will be the value of that information. It is important to 
consider those research targets—such as an improved understanding of the population growth 
rate—that will be relevant to a large number of decision problems but have a small impact on any 
single decision. Research targets with these characteristics will be systematically undervalued by 
the approach adopted for this analysis, which by necessity focused on a single policy decision in 
great detail. For this reason, the VOI estimates for broadly applicable issues like population growth 
or background mortality rates should be interpreted with caution. In addition, the fact that these 
VOI results focus on perfect information means that any new research is likely to produce lower-
value information, and the absolute EVPPI estimated reported in this study will not be attainable. 222 
 
The application of VOI methods requires a formal description of the mechanism by which 
information about candidate policies is translated into a single policy choice. This choice function is 
a mathematical summary of the policy-making process, yet while the choice function adopted for 
this analysis reflects presumably reasonable assumptions—that policy makers will favor policies 
that improve health outcomes, and avoid policies that increase costs, that they will pay more 
attention to near term outcomes than outcomes realized in the distant future, that they will respond 
rationally to new information by updating their beliefs about policy outcomes—the relative 
weighting of different concerns has a central impact on the VOI results. This can be seen in the 
sensitivity of the VOI findings to changes in policy parameters such as the WTP threshold, the 
discount rate, and the time horizon. Because different policy makers might adopt different values of 
these parameters, results are presented for a range of different values for these parameters. Even 
where findings appear robust to a range of different assumptions about these values, there may be 
complex features of the ‘true’ choice function that are not explored by changing these values. For 
example, a concern for equity—which might be expressed as equity in total experience of health, 
equity in the distribution of health gains, or equitable access to care—would require different 
inputs from those currently considered in the choice function, as well as explicit mathematical 
specifications of how these equity concerns would be traded off against concerns for aggregate 
health gains and costs. Another example relates to WTP, which is operationalized as a single value, 
ignoring the possibility that the opportunity cost of spending may depend on the purpose to which 
spending is devoted (major donors may have preferences for certain health interventions, and 
funding may not be entirely fungible across budget categories), or on the absolute value of total 
spending, with progressively more valuable interventions forgone as total ART spending is 
increased. While not reflected in the results shown here, these concerns will impact actual decision-
making.  223 
 
Another simplification made to operationalize this analysis is the focus on a single policy decision. 
In reality the pattern of possible decisions may be more complicated than allowed for in this 
analysis. For example, it is likely that major policy decisions could be delayed, with a country like 
South Africa learning from the experience of other countries more willing to pursue aggressive ART 
scale-up. Similarly, even once a policy is chosen, this decision could be revised in the future as 
accumulating surveillance data and routine program reports provide empirical evidence of policy 
outcomes. Such sequential decision-making could be operationalized within the VOI approach used 
here, but would require additional assumptions about the rate at which programs generate 
evidence useful for decision makers, the points at which policy choices might be reviewed, and the 
implementation costs of policy change. 
Just as importantly, it is clear that a technocratic representation of health care resource 
allocation—that policies are chosen based on a single social welfare function, and that policy 
makers are sensitive to the changing state of knowledge about competing policies—is a crude 
approximation of the real policy-making process in many settings, and that explanations focusing 
on structural elements of the decision process, such as the interaction of key stakeholder groups, as 
well as a broader understanding of the priorities that motivate decision makers, may have greater 
explanatory power. This is exemplified by the unprecedented investment in global HIV control by 
western donors since 2000. It is difficult to interpret this as the outcome of a cost-effectiveness 
analysis, and contemporary accounts, both critical and supportive, emphasis political explanations 
for these policy choices [122,123]. If real-world decision-making differs substantially from a 
normative model of decision-making such as used in this analysis, then the implications for VOI are 
unclear. One possibility is that VOI will fluctuate over the course of time, with research much more 
valuable if it is available during those windows of opportunity when major policy change can be 
considered [124], and less valuable otherwise. In this circumstance, conventional VOI analyses may 
still give reasonable estimates of the long-term average value of research. Another possibility is that 224 
 
conventional analyses will systematically overestimate the overall value of research: if it is accepted 
that sub-optimal policy-making is only partly attributable to inadequate information, such that sub-
optimal policies will still be chosen or retained after decision uncertainty is resolved, then the value 
of resolving that decision uncertainty may well be lower. It is important to note that this is not a 
necessary consequence: one can conceive of a situation where factors promoting sub-optimal 
decision-making (such as a policy maker’s desire to please narrowly focused interest groups) play a 
much greater role in decisions when there is a poor understanding of policy outcomes. Essentially, 
when it is unclear which policy will best improve social welfare, the policy maker has greater 
liberty to adopt policies that promote other objectives. In contrast, when decision uncertainty is 
resolved, the task of justifying sub-optimal policy becomes more difficult. In this circumstance, the 
improvement in social welfare generated by research may be greater than predicted by 
conventional VOI approaches, as the discrepancy between actual decision-making and optimal 
decision-making (measured in relevant units of social welfare loss) may be smaller once decision-
uncertainty is reduced. 
In addition to addressing substantive questions about relative value of new research targets, this 
analysis also developed methods for the application of VOI methods in the context of calibrated 
models. These methods are more demanding than conventional approaches, yet will be of 
increasing relevance as a greater number of analyses adopt numerical methods to calibrate 
complex disease models, as it is the lack of an analytic representation of this calibrated parameter 
distribution that necessitates these new methods. While this analysis did not calculate measures of 
partial sample information (EVPSI), as would be required to understand the value of new 
information produced by realistic study designs, it is anticipated that the approach used in this 
analysis could be extended to estimate these quantities, by reweighting the parameter sets in light 
of the anticipated distribution of new information (as described in Section 3.2.16.4), and this 
extension will be addressed in future work.    225 
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Abstract 
Cigarette smoking causes out of every five deaths in the U.S., and both state and federal 
governments have introduced cigarette excise taxes to limit cigarette consumption. Many states 
have raised these taxes in recent years, with the real value of the average state cigarette tax rising 
by over 200% between 1996 and 2013.  
In this study we developed a mechanistic model of smoking behavior and associated health 
outcomes in the 50 U.S. states and District of Columbia, and used this model to assess the impact of 
state cigarette taxes introduced over the 17 years from 1996 to 2013. This analysis allowed 
separate effects on smoking initiation, smoking intensity, and quitting behavior, and estimated 
these effects in the context of a demographic model directly linking smoking behavior with 
mortality risks. Causal effects of cigarette taxes were estimated with data from the 1996-2012 
rounds of the CDC’s Behavioral Risk Factor Surveillance System. Our analyses made use of inter-
state variation in the timing and magnitude of new cigarette taxes to identify causal effects.   
Our analyses suggest that average national cigarette consumption by the beginning of 2013 was 
4.4% (95% posterior interval: 3.7, 5.3) lower among men, and 3.6% (2.6, 4.2) lower among women, 
compared to a counterfactual scenario in which no new state cigarette taxes were introduced after 
1996, for an overall reduction of 4.0% (3.3,4.6). The behavioral effects of tax increases were 
projected to be larger over a longer time horizon, with the average number of years spent smoking 
estimated to drop by 10 (7, 12) months for the 2013 birth cohort if exposed to 2013 vs. 1996 tax 
levels, for a 6.1% (4.5, 7.8) reduction in overall consumption. Estimates of the price elasticity of 
demand implied by these results varied from -0.14 to -0.39 depending on sex and the time horizon. 
These elasticities are smaller than conventional estimates for cigarette taxes and cigarette 
consumption, but are in line with other studies of inter-state tax variation. 238 
 
Our analyses suggest 27 thousand (22, 34) deaths have been averted by state cigarette taxes 
introduced over the period 1996-2013, for an extra 119 thousand (92, 151) life-years lived. While 
these mortality reductions are relatively small, projections of future health outcomes under 
scenarios that compared 2013 and 1996 tax levels suggest that health benefits will largely accrue in 
future decades, with over a million extra life-years lived in the decade 2020-2029. We estimate a 
2.0 (1.4, 2.7) month overall gain in life expectancy for the 2013 birth cohort due to state tax 
increases since 1996, with larger gains for men. 
These analyses provide further evidence about the magnitude and distribution of effects of recent 
state cigarette taxes on smoking behavior and related mortality. Our analytic approach closely 
integrates the task of causal inference about cigarette taxation with the task of estimating final 
health outcomes. We hope that this analysis contributes to the knowledge base about cigarette 
taxation by providing a more nuanced understanding of the long-term consequences of cigarette 
tax policy.    239 
 
 Background   4.1.
Both the federal government and individual U.S. states impose excise taxes on the sale of cigarettes. 
These taxes are assessed at the point of sale as a fixed mark-up on the quantity of cigarettes sold. 
Levying taxes on tobacco products serves multiple objectives for states, but a primary goal is to 
reduce smoking rates and in so doing reduce the risks of lung cancer and other adverse health 
effects associated with smoking [1,2]. Since 1995, individual states have raised the excise tax on 
cigarettes in 136 instances, with the average state excise tax rising from $0.31 (interquartile range 
= $0.19-$0.41) at the beginning of 1995 to $1.49 ($0.61-$2.00) by the end of 2012, more than four 
times its 1995 level. Over this same period, the federal excise tax rose from $0.24 to $1.01. State 
excise taxes produce the majority of tax revenue from cigarette sales in the United States, with 
$17.3 billion collected in the year ending June 30, 2011, as compared to $15.5 billion for federally 
imposed taxes and $0.4 billion for taxes imposed by municipalities [3]. 
Cigarette smoking is known to cause or aggravate a large number of health problems, leading to 
substantial mortality and morbidity [4–6]. In the United States, smoking is estimated to cause one 
quarter of all deaths between the ages of 35 and 70 [7], with smokers facing a life expectancy 
shortened by more than 10 years compared to individuals who have never smoked [4]. Individuals 
who quit smoking have been shown to regain much of this loss in life expectancy, especially those 
who quit at younger ages [4,8], and reduced smoking intensity is also associated with health 
benefits [5]. 
A large body of research suggests that raising cigarette taxes will reduce cigarette consumption [9], 
either through reducing smoking initiation, increasing quitting, or reduced smoking frequency. 
Many studies have investigated the relationship between taxation and smoking behavior, and the 
price elasticity of demand is generally found to be in the range of -0.4, implying that a 10% price 
increase would produce a 4% reduction in demand, with greater elasticity estimated for younger 240 
 
age groups [10]. A number of studies have focused on state excise taxes in the U.S., with variation in 
these taxes between states and over time used to separate the causal effect of excise taxes from 
other influences on smoking behavior [11–20]. There is also reason to believe that the effects of 
these state-level tax changes may differ from changes in the federal tax, given the greater 
opportunity for smokers to avoid the effect of state-level tax increases by shifting purchasing to 
states with lower tax rates [21,22]. Evidence on the impact of state cigarette taxes on smoking 
behavior is mixed, with effect sizes estimated by previous studies smaller and less robust [11–20] 
than would be predicted from the broader evidence base on tax effects. 
In general, analyses of state excise taxes focus on individual aspects of smoking behavior (e.g., 
smoking initiation, smoking prevalence, smoking intensity) and do not directly estimate the change 
in health outcomes resulting from changes in tax policy. Where these health impacts are estimated, 
it is commonly through simple multiplicative calculations used to explore possible ramifications of 
changes in smoking behavior, with a lower level of rigor than is applied to the analysis of behavioral 
outcomes. One exception to this is in the context of the California Tobacco Control Program, where 
Fichtenberg and Glantz were able to identify statistically significant reductions in the mortality 
associated with heart disease following the introduction of the program in 1989 [17]. The California 
program combined a $0.25 per pack increase in the state tobacco tax with an aggressive anti-
smoking media campaign and additional programs fostering a smoke-free environment, and it is 
difficult to attribute the changes in cardiovascular mortality to tax changes alone. This is especially 
true given the partial rebound in cardiovascular mortality observed after the non-tax elements of 
the program were cut back in 1992 [17].  
The present analysis takes a different approach to estimating the effects of cigarette excise taxes on 
mortality risks. The causal effects of cigarette excise taxes on smoking behavior are quantified in 
the context of a mechanistic population model, which directly relates individual age, sex, and 241 
 
smoking behavior to mortality rates. This model simulates the distribution of smoking behaviors 
across the U.S. population, and calibrates the parameters determining this model—including 
parameters describing the effect of tax changes on smoking behavior—to observed patterns of 
smoking behavior reported by the Behavioral Risk Factor Surveillance System (BRFSS) between 
1996 and 2013 [23]. With this analytic approach, it is possible to distinguish the separate effects of 
state cigarette taxes on smoking initiation, cessation, and smoking intensity, and to estimate the 
consequences for summary health outcomes such as mortality and life expectancy. These outcomes 
are available for individual states as well as individual sex and age groups. This analysis is used to 
estimate the effects of recent increases in state cigarette taxes on smoking behavior and on 
smoking-related mortality over the period 1996-2013, and to predict changes in long-term trends 
in smoking behavior and related mortality attributable to the state cigarette taxes. 
 
 Methods  4.2.
4.2.1.  General approach 
A mathematical model was constructed to predict changes in smoking behavior as a function of 
individual characteristics and multiple state-level predictors. Model parameters were estimated 
using a likelihood function that summarized BRFSS survey data collected between 1996 and 2013, 
with the estimation approach designed to identify the causal effect of state-level cigarette tax 
changes on smoking behavior. The fitted model was then used to predict changes in smoking 
behavior and related mortality under various tax scenarios, in order to describe the health 
consequences of changes in state-level cigarette tax policy. 
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4.2.2.  Identification strategy 
States with higher cigarette excise taxes tend to have a lower prevalence of smoking behavior. 
However, this empirical relationship cannot be interpreted as causal, given the possibility of other 
state characteristics that determine both tax policy and smoking behavior. Randomized 
experiments allow stronger identification of causal effects, yet experiments to address issues of tax 
policy are rare, and the more rigorous studies of cigarette policy within the U.S. generally adopt 
quasi-experimental designs to estimate the causal effects of tax policy from observed variation in 
cigarette taxation. A common approach is to include state and year fixed effects as part of a 
regression of some indicator of smoking behavior on tax rates and other predictors [11,15,24,25]. 
This identification strategy assumes that the average year-on-year change in the smoking outcome 
would be the same in states that introduce cigarette taxes as those that do not, were no taxes 
introduced. If these trends are found to systematically differ in states that raise cigarette taxes, as 
compared to those that do not, this difference is attributed to the tax change.  
While appealing the inclusion of state and year fixed effects can introduce challenges, due to the 
shear number of predictors used to fit the model. Arguing that state anti-smoking sentiment is the 
key confounder of the observed relationship between tax policy and smoking behavior, DeCicca et 
al. proposed a new indicator of state-level anti-smoking sentiment [12] as an alternative to state 
and year fixed effects. They calculated this measure from a factor analysis of attitudes towards 
tobacco control and smoking behavior reported in the Community Population Survey. They found 
that inclusion of this anti-smoking indicator in regression equations performs similarly to the state 
and years fixed effects specification, and use this identification strategy to investigate the 
relationship between cigarette prices and smoking behavior among youths [12] and older adults 
[11]. The present analysis adopts the identification approach developed by DeCicca et al., by 
including a measure of state-level anti-smoking behavior in the model equations used to predict 243 
 
smoking initiation, smoking intensity, and quitting behavior. Figure 4.1 shows a directed acyclic 
graph describing the causal relationships assumed in this analysis. 
 
Figure 4.1. Directed acyclic graph describing causal relationships assumed in this analysis 
 
4.2.3.  Simulation model 
A mathematical model was developed to represent successive cohorts of the total U.S. population 
(distinguished by sex, year of age, and state of residency), and describe how the smoking behavior 
of each cohort changes over time. A schematic of the compartments and transitions of this model is 
shown in Figure 4.2. These compartments are structured to match the categorization of smoking 
behavior in the BRFSS, as well categories used by Thun et al. [5] to define smoking-attributable 
mortality risks. The use of an approach that allows for different effects on various aspects of 
smoking behavior expands on work by DeCicca et al., who report analyses that explicitly allow for 
changes in smoking initiation and cessation behavior to explain overall changes in smoking 
participation as a result of tax changes [13]. The model developed for this analysis also bears 
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similarities to simulation models used to estimate health outcomes based on exogenous estimates 
of tax effects [14,26–28]. 
 
 
Figure 4.2. Schematic of simulation model, showing model compartments and transitions for 
a single cohort* 
* Capital letters (e.g., N) indicate the number of individuals in each model compartment. Lower case 
letters (e.g., nc) indicate transition probabilities. Former smokier compartments 0 though 9 represent 
time since quitting. 
 
The analysis is initiated with individuals distributed across the different model compartments to 
reflect the existing distribution in the population at the beginning of 1996. The distribution of 
individuals across model compartments is then updated each quarter, with individuals 
transitioning to different compartments based on transition probabilities which are themselves 
updated each quarter. Individuals in the ‘Never’ compartment remain in this compartment unless 245 
 
they begin smoking. Those who start smoking transition to the ‘Current’ smoker compartments. 
Current smokers are divided in those who smoke ‘Some Days’ those who smoke ‘Every Day’, to 
allow for differences in smoking intensity within the smoking population. Current smokers can 
transition between these two intensity levels or quit smoking, with those who quit transitioning to 
the first ‘Former’ compartment. Former smokers progress through Former compartments 0 
through 9 to track time since quitting (representing <1, 1, 2-4, 5-9, 10-14, 15-19, 20-29, 30-39, 40-
49, and ≥50 years since quitting, respectively). Individuals in any of the Former smoker 
compartments can relapse, returning to the Current smoker compartments. In addition, individuals 
in any compartment can die and transition to the ‘Dead’ compartment, with mortality risks 
determined by age and smoking behavior, as well as by time trends in background mortality. 
A separate cohort is formed to represent each year of age for all individuals alive in 1996 (ages 0-
99, for 100 age categories), each state (including the District of Columbia, for 51 state categories), 
and each sex, producing a total of 100 x 51 x 2 = 10,200 cohorts. The distribution of individuals in 
each cohort across smoking behavior categories is updated every quarter from the beginning of 
1996 to early 2013 (70 quarters in total), representing the total time period during which survey 
responses were being collected for BRFSS rounds 1996 to 2012.  
4.2.4.  Parameterization 
The outcomes of the model (changes in smoking prevalence and related mortality) are determined 
by transition probabilities that describe the rates at which individuals move between different 
model compartments. These transition probabilities are described in detail below. In Figure 4.2 and 
in the description below, the number of individuals in each compartment is specified by capital 
letters (N for never smokers, S for current smokers who smoke some days, E for current smokers 
who smoke every day (C representing the sum of all current smokers), and F0 through F9 for 
former smokers categorized by time since smoking), with subscripts atgi for age a (in whole years), 246 
 
calendar time t (in quarters since the beginning of 1996), sex g, and state i. The transition 
probability between two compartments is specified as a lower case combination of the first letter of 
the names of each compartment. For example, esatgi indicates the transition probability from the 
Every compartment to the Some compartment for a particular age, time, sex and state. 
4.2.4.1.  Smoking initiation 
The probability of smoking initiation is determined by the parameter       . This parameter is 
assumed to be a function of individual age, calendar time, sex, and the state in which an individual 
resides. The effects of age and time on the smoking initiation probability are allowed to vary 
smoothly, each operationalized as a penalized B-spline with knots every 10 years1 [29,30]. The 
effect of state of residence is assumed to operate through a set of independent variables, including a 
measure of state-level unemployment, indicators for the presence or absence of state-level clean air 
laws (for workplaces, bars, and restaurants separately), the indicator of anti-smoking sentiment 
described by DeCicca et al. [12], and the state cigarette tax, in 2013 constant dollars. 
Unemployment, clean air laws, and tax rates are all time-varying variables, while anti-smoking 
sentiment is assessed in 1995-1996, the year before the BRFSS time series begins. For each state, 
the tax variable is set equal to zero in 1995, such that the variable represents absolute increases in 
                                                             
1 These splines are operationalized with cubic basis splines and a 2nd degree difference penalty. For age, a 
total of 10 knots are used (every 10 years from age 0 to age 100) requiring 13 basis splines and thus 13 spline 
parameters. For calendar time, a total of 3 knots are used (every 10 years at 1996, 2006, and 2016), requiring 
5 basis splines. As two independent splines are used, a model thus specified would effectively have two 
intercept terms. To resolve this issue, the value of the year spline is fixed at zero at the beginning of the time 
series in 1996, by specifying the first spline parameter     as function of the 2nd and 3rd spline parameters: 
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the state cigarette tax since this time point. As transition probabilities are defined over the interval 
[0, 1], the logit of the transition probability is modeled as a linear function of these predictors. The 
model is estimated separately for each sex. 
      (      )        (     )         (     )                                                
                                  [1] 
         : quarterly probability of smoking initiation for individuals with age a in quarter t, sex g, and 
state i 
    : age (in quarters) 
   : calendar time (in quarters) 
      : unemployment rate, in quarter t and state i  
      : indicator variable for laws restricting smoking in workplaces, in quarter t and state i 
       : indicator variable for laws restricting smoking in restaurants, , in quarter t and state i  
       : indicator variable for laws restricting smoking in bars, , in quarter t and state i  
       : measure of state anti-smoking sentiment for state i 
      : cigarette excise tax in quarter t in state i, in dollars per pack  
             : a set of penalized B-splines allowing smooth curves to be fitted to age and time 
As the survey data used to fit the model are collected from individuals >18 years of age, age-related 
changes in smoking initiation risks will be poorly identified in younger age groups. To prevent 
implausible results, smoking initiation probabilities are set to zero for all individuals younger than 248 
 
10 years old. In addition, given the cross-sectional nature of the BRFSS data, it is impossible to 
distinguish whether newly initiating individuals begin smoking with higher or lower intensity 
relative to other smokers. For this reason new smokers are assumed to enter the Some and Every 
compartments proportionally to the distribution of individuals already in those compartments, 
operationalized as the parameters        and        for the transition probabilities from Never to 
Some and Never to Every respectively: 
                 
     
           
  [2] 
                 (   
     
           
)  [3] 
 
4.2.4.2.  Smoking intensity 
Individuals transition between Some and Every compartments as determined by the parameters 
       and        (transition probabilities for Every to Some, and from Some to Every respectively). 
The rate at which individuals move between levels of smoking intensity (i.e., the true values of 
       and       ) is not identifiable from the BRFSS data, which only provides information on 
overall changes in distribution between these two categories2. Instead, these transition 
probabilities are operationalized as a function of the distribution across the two compartments, for 
a particular age, year, and state. Where  (      |      ) represents the probability of being in the 
Every compartment, conditional on being in one of the Current smoker compartments, the values of 
       and        were calculated using the following equations: 
                                                             
2 In addition, there is no evidence that this information would be relevant to subsequent smoking behavior or 
mortality risks. 249 
 
          (      |      )  [4] 
         (     (      |      ))  [5] 
These equations implicitly assume that any changes in the predictors of smoking intensity will have 
an instantaneous effect on the distribution between Some Day and Every Day smokers3.  
As with        , the logit of  (      |      ) is estimated as a linear function of age, calendar time, 
and multiple state-level predictors: 
     ( (      |      ))        (     )         (     )                                  
                                                [6] 
 (      |      ) : the fraction of current smokers in the who smoke every day, for individuals with 
age a in quarter t, sex g, and state i 
    : age (in quarters) 
   : calendar time (in quarters) 
      : unemployment rate, in quarter t and state i  
      : indicator variable for laws restricting smoking in workplaces, in quarter t and state i 
       : indicator variable for laws restricting smoking in restaurants, , in quarter t and state i  
       : indicator variable for laws restricting smoking in bars, , in quarter t and state i  
                                                             
3 While it is plausible that smoking intensity could change slowly in response to these determinants, it is 
unlikely that such effects could be identified with the cross-sectional data used for this analysis. 250 
 
       : measure of state anti-smoking sentiment for state i 
      : cigarette excise tax in quarter t in state i, in dollars per pack  
             : a set of penalized B-splines allowing smooth curves to be fitted to age and time 
4.2.4.3.  Smoking cessation and relapse 
Individuals transition between the Current smoking compartments and the Former smoking 
compartments as determined by the parameters         (which describes the probability of 
quitting for current smokers) and         through         (which describe probabilities of relapse 
for former smokers as a function of time since quitting). The parameters         and         are 
calculated using a similar approach to that used to model changes in smoking intensity, with the 
parameter  (      |                ) defined as the number of current smokers (for a particular 
combination of age, time, sex and state), divided by the number of current smokers plus those who 
have quit within the last 12 months4.  
           (      |                )  [7] 
          (     (      |                ))   [8] 
These equations implicitly assume that any changes in the predictors of smoking cessation will 
have an instantaneous effect on the distribution between the Current compartment and the first 
Former compartment. Lower values of  (      |                ) will indicate higher rates of 
quitting and transition out of the Current compartments. As the Current compartments are 
                                                             
4 This can be thought of as the fraction who elected not to quit, of those smoking 12 months ago. 251 
 
subdivided into Some and Every, the transition parameters for these compartments need to be 
defined: 
                    
      
             
  [9] 
                   (   
      
                
)   [10] 
                                 [11] 
This assumes that individuals who reinitiate smoking are distributed across the Some and Every 
compartments based on the current distribution between these compartments, and that individuals 
in the Some and Every compartments share the same probability of transition to the first Former 
compartment. 
As with other transition probabilities, the logit of  (      |                ) is estimated as a linear 
function of age, calendar time, and multiple state-level predictors: 
     ( (      |                ))        (     )         (     )                            
                                                       
  [12] 
 (      |                ) : the fraction of current smokers, out of all individuals who smoke or quit 
within the last 12 months for individuals with age a in quarter t, sex g, and state i 
    : age (in quarters) 
   : calendar time (in quarters) 
      : unemployment rate, in quarter t and state i  252 
 
      : indicator variable for laws restricting smoking in workplaces, in quarter t and state i 
       : indicator variable for laws restricting smoking in restaurants, , in quarter t and state i  
       : indicator variable for laws restricting smoking in bars, , in quarter t and state i  
       : measure of state anti-smoking sentiment for state i 
      : cigarette excise tax in quarter t in state i, in dollars per pack  
             : a set of penalized B-splines allowing smooth curves to be fitted to age and time 
Probabilities of smoking relapse for individuals who have quit for >12 months (Former 
compartments 1 - 9) are estimated using a proportional hazards assumption, whereby the rate of 
reinitiating smoking is assumed to represent a fixed multiple of the rate estimated for those who 
have quit in the last 12 months (this rate being a transformation of the probability         ). The 
decline in the rate of smoking relapse as a function of time is modeled using a Weibull distribution 
(previously used by other analyses to model hazards of smoking relapse [31]). The survival 
function associated with the Weibull distribution,  ( )  can be used to compute  (   )  the 
probability of relapse between the time when an individual enters a particular Former 
compartment ( ), and the time when an individual moves to the next Former compartment ( ). 
 (   )   
 ( )  ( )
 ( )    
 
 ( 
 )
 
  
 ( 
 )
 
 
 ( 
 )
          (     )   
   [13] 
This probability can be used to calculate the average relapse rate for the compartment,   ̅(   ): 
  ̅(   )   
   (   (   ))
      
   (  (   
 (     )   
))
        
     
(   )    [14] 253 
 
The ratio of these average relapse rates (where      represents the rate ratio of relapse for Former 
compartment j relative to the first Former compartment) can be used to calculate the transition 
probabilities for smoking relapse for all Former compartments as a function of         and the 
Weibull parameter k (note that Weibull parameter λ drops out of the equation). 
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(     )      
(  
    
 )(     )
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 )(     )  [15] 
                  (         )              
  (         )
(  
    
 )(     )
(  
    
 )(     )                        [16] 
4.2.4.4.  Progression through former smoker states 
Former smokers who do not die or relapse will progress through Former compartments 0 to 9 in 
sequence. The transition probabilities for this progression are defined deterministically as the 
inverse of the number of quarters each state represents. Thus the transition probability from the 
first to the second Former compartment (f01) is equal to ¼, producing an average sojourn time of 1 
year for individuals in the first Former compartment who do not die or relapse. 
4.2.4.5.  Mortality 
Mortality risks are operationalized as a function of age, calendar time, sex, and smoking behavior 
compartment: 
                 
      
                                                         [17] 
       : quarterly mortality risk for individuals in compartment j, age a, quarter t, and sex g 
    
     : smoking-deleted background mortality rate for age a, quarter t, and sex g 254 
 
      : mortality rate ratio for sex g and compartment j, relative to a never smoking population of 
the same sex (i.e.,          ) 
4.2.4.6.  Model formulae 
The model is implemented as a set of difference equations. These formulae operationalize the 
description given above5.  
         (         )(                   )  [18] 
        (          )(           )(          )     (         )           (         )(           )      
  ∑    
 
   
 (          )        
[19] 
         (         )(           )(          )     (         )           (         )(           )      
  ∑    
 
   
 (          )        
[20] 
           (          )(                     )(       )     (         )            (        )         [21] 
           (          )(                     )(       )      (          )(                     )     [22] 
           (          )(                     )(       )      (          )(                     )     [23] 
           (          )(                     )(       )      (          )(                     )     [24] 
           (          )(                     )(       )      (          )(                     )     [25] 
           (          )(                     )(       )      (          )(                     )     [26] 
                                                             
5 These equations implicitly assume a single value for each transition probability for all individuals of a given 
age/time/sex/state subgroup, while in reality we would expect that individuals within a particular subgroup 
might differ in their propensity to begin smoking, to quit smoking, to relapse, etc. For this reason the model 
can be seen as an approximation that calculates subgroup-level averages for each of the model parameters, 
but that individual level outcomes (for example, the change in smoking initiation risk associated with a 
change in cigarette tax rates) may differ from these group-level averages. 255 
 
           (          )(                     )(       )      (          )(                     )     [27] 
           (          )(                     )(       )      (          )(                     )     [28] 
           (          )(                     )(       )      (          )(                     )     [29] 
           (          )(                     )(       )      (          )(                     )     [30] 
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In these equations, subscript z indicates a particular subgroup atgi, and z+1 indicates the next 
quarter for the same subgroup (i.e., where both a and t have been incremented up by 1). 
4.2.5.  Data sources 
4.2.5.1.  Data on smoking behavior 
The CDC’s Behavioral Risk Factor Surveillance Survey (BRFSS) is a large telephone survey of 
Americans aged >18 years, conducted annually to monitor national and state-level prevalence of 
behavioral risk factors for premature morbidity and mortality [23]. Since being initiated in 1984, 
the BRFSS has asked respondents several questions related to smoking behavior, including current 
smoking status, past smoking status, time since quitting, and smoking intensity. A major change in 
the question about smoking intensity occurred between 1995 and 1996 surveys, and for this reason 
the analysis is restricted to the period 1996-2013, over which smoking-related survey questions 
were largely unchanged. 
Current smoking status: one set of questions allows respondents to be categorized by current 
smoking status, specifically those who report having never smoked, current smokers who report 
smoking “some days”, current smokers who report smoking “every day”, and former smokers. This 
set of questions has been asked each year from 1996 to 2013. The data from these questions were 256 
 
used to construct a likelihood function for the distribution of individuals across compartments N, S, 
E, and the sum of compartments F0-F9.  
Smoking intensity: differences in smoking intensity are associated with differences in smoking 
attributable mortality risks, and Thun et al. report mortality risk ratios for current smokers as a 
function of the number of cigarettes smoked per day [5]. While the categorization of current 
smokers in the BRFSS (those who smoke “some days” vs. those who smoke “every day”) indicates 
qualitative differences in smoking intensity, these descriptions need to be mapped to a quantitative 
measure of cigarette consumption in order to calculate the appropriate mortality risks. To provide 
a cross-walk from the survey responses to the Thun et al. mortality estimates we use additional 
data from survey questions on the number of cigarettes smoked each day. These questions were 
posed to individuals who reported smoking “every day” in survey years 1996 to 2000. Figure 4.3 
shows the relationship between the average number of cigarettes smoked each day for individuals 
reporting smoking every day, as a function of age, sex, and survey year.  
 
  
Figure 4.3. Average number of cigarettes smoked each day for individuals reporting smoking 
every day, as a function of age, sex, and BRFSS survey year 
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As can be seen in Figure 4.3, smoking intensity varies somewhat between different ages, and also 
between men and women. However, these differences are relatively minor, and were ignored for 
the purposes of calculating the fraction of “every day” smokers who fell into different categories of 
cigarettes smoked per day. These percentages were calculated as 13% smoking <10 cigarettes per 
day, 32% smoking 10-19 cigarettes per day, 47% smoking 20-39 cigarettes per day, and 8% 
smoking ≥40 cigarettes per day. No such questions was asked for individuals reporting smoking 
only “some days”, and these individuals were assumed to smoke <10 cigarettes per day (the lowest 
risk category) for the purposes of estimating smoking mortality rate ratios for each model 
compartment. 
Time since quitting: an additional set of questions allows former smokers to be categorized 
according to time since quitting. These questions have changed over the years, allowing the 
following categorization: 
Survey years 1996-2000  <1 year6, 1-4 years, 5-14 years, and 15+ years since quitting 
Survey years 2001-2005  <1 year, 1-4 years, 5-9 years, and 10+ years since quitting 
Survey years 2006-2008  Question not asked 
Survey years 2009-2013  As in 2001-2005 
   
For the years when these questions were asked, data were used to construct a likelihood function 
for the distribution of individuals across former smoker states, with modelled former smoker 
categories grouped to fit the categorization used in the survey questions. 
                                                             
6 The survey questions allow the group reporting <1 year since quitting to be broken up into several smaller 
categories, but this level of granularity was ignored for the analysis.  258 
 
Survey weighting: the BRFSS publishes weights to be used to adjust for known biases in the BRFSS 
sampling frame, such that summary estimates calculated using these weights should be 
representative of the adult U.S. population. Using probability weights will have consequences for 
the uncertainty represented by the likelihood, and although these issues have been apparent for 
many years [32,33], the methodological difficulties have not yet been fully resolved [34]. While 
regression methods for the analysis of weighted data are better developed, the appropriate use of 
weights in an analysis such as required for the present study is not immediately apparent. If 
weights are used directly when constructing a likelihood, the implied sample size (and hence the 
relative dispersion of the likelihood) may not reflect the strength of information in the data7. If 
these weights are not used, the likelihood may not be reflective of the general U.S. population and 
parameter estimates will be biased. A revised weighting scheme was developed to satisfy these two 
concerns: 
(i)  For each combination of age (in whole years), quarter, sex, and state, the distribution of 
survey respondents across smoking behavior categories (never, current some days, current 
every day, and former) was calculated using the published weights. 
(ii)  For each combination of age (in whole years), quarter, sex, and state, the effective sample size 
(ESS) was calculated, where       (∑        )  (∑   
 
    ) ⁄  for the vector of survey weights w 
and observations      . 
(iii)  The distribution across smoking behavior categories calculated in (i) was scaled by a common 
factor such that the sum matched the ESS calculated in (ii). For each combination of age, 
                                                             
7 With unequal weights, the effective sample size will always be less than the original sample size. At the 
extreme, a set of probability weights equal to 1.0 for one observation and 0.0 otherwise will always have an 
effective sample size of 1.0, irrespective of the original sample size. 259 
 
quarter, sex, and state, this adjustment can be considered as a new weight   ̂  applied to the 
raw survey data: 
  ̂   
  (∑        )  
(∑        )(∑   
 
    )  [33] 
 
The survey dataset, once processed in this way, preserves the weighted distribution across smoking 
behavior categories while also reflecting the reduction in effective sample size associated with non-
equal weights. The same approach was used to adjust the survey data describing time since quitting 
among former smokers. 
Finally, the respondent-level data were summarized into total counts by age, sex, state, quarter, and 
smoking behavior category. This allowed the large datasets to be manipulated more efficiently 
during analysis while retaining the same informational content. 
4.2.5.2.  Data on smoking-related mortality risks 
Several recently published studies summarize smoking-related mortality risks in different 
populations [4–6]. The present analysis utilizes estimates reported by Thun et al., who synthesize 
data from multiple large observational cohorts to estimate relative risks of smoking mortality as a 
function of sex, current smoking behavior, smoking frequency, and time since quitting [5].  
4.2.5.3.  Data on smoking-deleted background mortality 
Smoking is known to cause a non-trivial fraction of total U.S. mortality [35,36]. For this reason, the 
background mortality estimates used for this analysis must have smoking-attributable mortality 
removed, to prevent double counting of this mortality risk and overestimation of total mortality 
rates. While the National Center for Health Statistics publishes cause-deleted life tables for various 260 
 
health concerns [37], smoking is not included in these estimates. Smoking-deleted mortality 
estimates were created for this analysis following an approach described by Levy et al. [27].  
For a given age (a), sex (g), and time (t), the all-cause mortality rate (    
    ) can be related to the 
smoking-deleted mortality rate (    
  ), the relative risks associated with each smoking behavior 
category (    for smoking category j), and the distribution of smoking behavior in the population 
(where       represents the fraction of the population in smoking state j for a particular age, sex, 
and time): 
    
      ∑             
           [34] 
This can be rearranged to express smoking-deleted mortality as a function of the other terms: 
    
   
    
   
∑             
  [35] 
This relationship was used to estimate smoking-deleted mortality rates for both men and women, 
for each single year of age, for years 1996-2013. To do so, yearly all-cause mortality estimates were 
derived from life tables published by the U.S. Centers for Disease Control [38,39]. As single-year life 
tables were not available for the year 1996 and had not yet been published for years 2009-2013, 
mortality rates for these years were obtained by extrapolating time trends during the period 1997-
2008. Data on relative mortality risks for different smoking categories were taken from Thun et al. 
[5] as described above, and estimates of the prevalence of smoking behaviors by age, year, and sex 
were created by fitting smooth curves8 to the BRFSS survey data described earlier. The BRFSS does 
not collect information on individuals <18 years old, and it was assumed that smoking behavior 
                                                             
8 These curves were estimated using local polynomial regression via R’s LOESS package. 261 
 
imparted no excess mortality risk in this population. Calculations described under Section 4.2.5.1 
(smoking intensity) were used to provide a crosswalk between descriptions of smoking intensity 
found in the BRFSS and those used by Thun et al. For former smokers, the categories used by the 
BRFSS and Thun et al. do not completely align in terms of time since quitting, and the mortality 
rates for each of these former smoking categories was calculated as the average across the relevant 
categories in the Thun et al. estimates. Table 4.1 summarizes the approach used to calculate relative 
risks for each BRFSS smoker category, and also shows the relative mortality risks produced. 
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Table 4.1. Crosswalk between smoking categories used in the BRFSS and those reported in 
Thun et al., for the purposes of estimating smoking deleted mortality rates 
Category from BRFSS 
Smoking category from Thun et al. 
used to estimate relative mortality 
risk (vs. never smokers) 
Relative mortality risk 
calculated from Thun et al.  
Current smoker, 
smoke some days 
Current smoker, smoke <10 cigarettes 
per day 
Male: 2.21  Female: 2.27 
Current smoker, 
smoke every day 
Weighted average across current 
smoker categories, with weight based 
on distribution in BRFSS:  
<10 cigarettes per day (wt=0.13) 
10-19 cigarettes per day (wt=0.32) 
20-39 cigarettes per day (wt=0.47) 
≥40 cigarettes per day (wt=0.08) 
Male: 3.00  Female: 3.14 
Former smoker, quit 
0-1 months 
 <2 years since quitting  Male: 2.77  Female: 2.34 
Former smoker, quit 
1-3 months 
 <2 years since quitting  Male: 2.77  Female: 2.34 
Former smoker, quit 
3-6 months 
 <2 years since quitting  Male: 2.77  Female: 2.34 
Former smoker, quit 
6-12 months 
 <2 years since quitting  Male: 2.77  Female: 2.34 
Former smoker, quit 
1-5 years 
2-4 years since quitting  Male: 2.65  Female: 2.02 
Former smoker, quit 
5-15 years* 
Average of 5-9 and 10-19 years since 
quitting 
Male: 2.08  Female: 2.02 
Former smoker, quit 
15+ years* 
Average of 20-29, 30-39, 40-49, and 
≥50 years since quitting 
Male: 1.18  Female: 1.11 
Former smoker, quit 
5-10 years** 
5-9 years since quitting  Male: 2.16  Female: 2.25 
Former smoker, quit 
10+ years** 
Average of 10-19, 20-29, 30-39, 40-
49, and ≥50 since quitting 
Male: 1.34  Female: 1.24 
*BRFSS question format used until 2000.  ** BRFSS question format used from 2000 onwards. 
  
These various data were combined using equation 35 to estimate smoking-deleted background 
mortality rates for each sex, age, and calendar year, which were then used in the main analysis. 263 
 
Cohorts were modeled from the age at which they started in the model until 100 years of age, at 
which point a mortality risk of 1.0 was imposed. 
While not required for parameter estimation, projections of future smoking-deleted mortality rates 
are needed to estimate health consequences realized in future years. Mortality rates for future 
years were obtained by adjusting the historical estimates described above for anticipated trends in 
all-cause mortality for each sex and year of age derived from future life tables published by the U.S. 
Social Security Administration [40]. 
4.2.5.4.  Data on population size and distribution in 1996 
Estimates of the 1996 population, disaggregated by age, sex, state, and smoking behavior category 
were required to initially populate the model (i.e., for t=0). These values were estimated by 
obtaining U.S. Census Bureau data on population size for each year of age, sex, and state in January 
1996 [41]. These population totals were distributed across smoking behavior categories based on 
1996 data from the BRFSS. 
4.2.5.5.  Data on births from 1996 onwards 
While not required for parameter estimation, data on births from 1996 onwards are required to 
reconstruct a full cross-section of the population for estimating total changes in smoking behavior 
and mortality outcomes. Historical data on births by sex, year, and state were obtained from the 
National Vital Statistics System [42]. Estimates for future years were obtained from the U.S. Census 
Bureau’s 2012 National Population Projections [43]. As these projections are only available at a 
national level, they were used to calculate the projected percentage change in total births over 
future years, which were then applied to the historical state-level births data in order to estimate 
annual state-level births for future years. 
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4.2.5.6.  Data on predictors of smoking behavior 
State cigarette taxes: Data on time changes in state cigarette excise taxes were obtained from a 
historical compilation of tobacco tax data [3]. For each state the value of the tax at the beginning of 
1996 was subtracted from the time series, so that the variable represented absolute changes in the 
state cigarette tax since this time point. All values were converted to 2013 constant dollars using 
the CPI [44]. 
State unemployment rates: Data on seasonally-adjusted state-level unemployment rates were 
obtained from the U.S. Bureau of Labor Statistics [45].  
State clean air laws: Summary data on state clean air regulations were obtained from the American 
Non-Smokers’ Rights Foundation’s Tobacco Control Laws Database [46]. These summaries 
categorize the strength of clean air regulation on a 4 point scale from no coverage to 100% smoke-
free. For each type of clean air regulation, a variable was created by dichotomizing this scale at its 
midpoint, equal to 1.0 if a state’s regulations were 100% smoke-free, or smoke-free with minor 
qualifications, and 0.0 otherwise. 
State anti-smoking sentiment: estimates of state-level anti-smoking sentiment in 1995-96 were 
drawn from DeCicca et al. [12]. This measure is a synthetic index created from a factor analysis of 
multiple TUS-CPS survey questions describing an individual’s level of support for various anti-
smoking measures, promotion of tobacco products, and household rules about smoking in the 
home. More negative values on this index represent stronger state-level anti-smoking sentiment. 
The values used in the present analysis (i.e., estimates for 1995-96) had a mean of -0.01 and a 
standard deviation of 0.16. Values for each state are shown in Table 4.2.   265 
 
Table 4.2. Value of anti-smoking sentiment index for each state* 
State  ANTIi  State  ANTIi  State  ANTIi 
Utah  0.40  New Hampshire  0.06  Illinois  -0.06 
California  0.32  North Dakota  0.04  Louisiana  -0.08 
Maine  0.19  Iowa  0.04  Delaware  -0.08 
Idaho  0.19  South Dakota  0.04  Pennsylvania  -0.09 
Oregon  0.18  New York  0.03  Arkansas  -0.10 
Vermont  0.17  Nebraska  0.03  Michigan  -0.11 
Washington  0.17  Rhode Island  0.02  Oklahoma  -0.11 
Hawaii  0.16  DC  0.02  Virginia  -0.12 
Arizona  0.12  Colorado  0.00  Tennessee  -0.16 
Minnesota  0.09  Montana  0.00  Indiana  -0.18 
Connecticut  0.07  New Jersey  0.00  Ohio  -0.22 
Florida  0.07  Georgia  -0.03  Missouri  -0.23 
Massachusetts  0.07  Mississippi  -0.04  South Carolina  -0.23 
Texas  0.07  Alabama  -0.05  Nevada  -0.26 
Maryland  0.06  Kansas  -0.05  West Virginia  -0.27 
New Mexico  0.06  Wyoming  -0.06  North Carolina  -0.38 
Alaska  0.06  Wisconsin  -0.06  Kentucky  -0.45 
* States ordered by values of the index. More negative values on this index represent stronger 
state-level anti-smoking sentiment. 
 
All independent variables were standardized (demeaned and scaled to a standard deviation of 1.0) 
prior to analysis to allow more efficient estimation of results. 
4.2.6.  Parameter estimation 
A Bayesian approach was used to estimate the parameters determining smoking behavior, which 
include all parameters in equations 1, 6, and 12, and parameter k from equation 16. Prior 
distributions were specified for all model parameters and a likelihood function created for the 
BRFSS data. A modified version of the incremental mixture importance sampling (IMIS) algorithm 266 
 
[47] was used to estimate the posterior parameter distribution. All analyses were undertaken using 
the R statistical computing environment [48], with the model itself coded in C++ using the Rcpp 
package [49]. 
4.2.6.1.  Prior distributions for model parameters 
Prior distributions were specified for parameters describing smoking behavior (Table 4.3). For 
coefficients on unemployment rates, anti-smoking sentiment, clean air laws and cigarette taxes 
(this includes parameters αqg, βqg, δqg, and q, which appear in equations 1, 6 and 12), weakly-
informative priors were adopted, based on a Normal distribution with mean zero and standard 
deviation of 10. The smoothness penalties on the age and year splines were calculated using an 
approach described by Lang and Brezger [50], whereby a Normal prior distribution was adopted 
for the 2nd difference of the spline coefficients, with mean zero and the standard deviation itself 
estimated as part of the analysis. The hyper-prior for this standard deviation was based on a half-
Cauchy distribution [51] with mean zero and standard deviation 5. The 2nd differences used to 
assess smoothness were calculated directly from the spline coefficients. For example, for the spline 
on age used to model the parameter        (equation 1), these 2nd differences are calculated as 
   (                    ) for j ∊ [1,2,…11]. A non-informative prior was assumed for parameter k, 
which is used to estimate the decline in relapse risk as a function of time since quitting (equation 
16). This prior was operationalized as a Beta distribution with both parameters equal to 1 
(equivalent to a uniform distribution over the interval [0,1])9. Priors for mortality rate ratios for 
different smoking behavior compartments were based on the Gamma distribution. The parameters 
                                                             
9 By construction the domain of k is restricted to real positive numbers. However, this domain is further 
restricted to the [0,1] interval to reflect the empirical finding that smoking relapse hazards decrease over 
time [31,61], consistent with values of k<1.0. 267 
 
for these distributions were estimated from the Thun et al. results described earlier [5], by 
identifying Gamma distribution parameters that recreated published means and confidence 
intervals. These mortality rate ratios were held constant at their mean estimate during parameter 
estimation, but allowed to vary when projecting outcomes under different cigarette tax scenarios10. 
Table 4.2 summarizes prior distributions for all model parameters. 
   
                                                             
10 It is conventional to allow all uncertain parameters to vary during parameter estimation, as even 
parameters with informative priors may be updated by the likelihood. However, when these mortality rate 
ratios were allowed to vary as part of parameter estimation, it was found that the posterior modes for these 
parameters were shifted far from their original values. While this might be appropriate in some 
circumstances, it is unlikely that the information available in BRFSS data provides evidence to update our 
current understanding of smoking-related mortality risks. Further investigation revealed that these changes 
were related to the likelihood for time since quitting among former smokers. In effect, the number of 
individuals represented in the BRFSS data was so large, and the likelihood so strong, that the estimation 
procedure was obtaining a better fit to the survey data via changes in the mortality rates, despite the 
relatively strong prior. This bias would likely be resolved by introducing further flexibility to the model, yet to 
do so could threaten the feasibility of the estimation approach as well as the identification strategy. Instead, 
this bias to the mortality rate ratios was resolved by holding them fixed during parameter estimation. This 
approach implicitly assumes (i) that the BRFSS data provide no evidence for updating the information on 
smoking mortality risks estimated by Thun et al., and (ii) there is no important dependence between these 
parameters and the other model parameters. 268 
 
Table 4.3. Prior distributions for model parameters 
Name  Description 
Functional 
form  Parameterization 
Implied mean and 
95% bounds 
αqg, βqg, and δqg, 
for q in [3 - 8] 
and g in [men , 
women] 
Coefficients on variables 
for unemployment rate, 
clean air laws, anti-
smoking sentiment, and 
tax rates  
Normal    Mu  Sigma 
  0.0  10.0 
 
Mean (bounds) 
0.0 (±19.6) 
 
α1g, β1g, δ1g, for g 
in [men , 
women] 
Spline parameters for 
age. Each represents a 
vector of 13 values. 
Prior constructed 
around vector of 2nd 
differences (11 values) 
Normal      Mu  Sigma 
α1g,   0.0       
β1g  0.0       
δ1g  0.0       
Mean (bounds) 
0.0 (±            ) 
0.0 (±            ) 
0.0 (±            ) 
α2g, β2g, δ2g, for g 
in [men , 
women] 
Spline parameters for 
year. Each represents a 
vector of 5 values. 
Prior constructed 
around vector of 2nd 
differences (3 values) 
Normal     Mu  Sigma 
α2g,   0.0       
β2g  0.0       
δ2g  0.0       
Mean (bounds) 
0.0 (±            ) 
0.0 (±            ) 
0.0 (±            ) 
    ,     ,     ,
     ,     , 
and     , for g in 
[men , women] 
Standard deviation of 
2nd differences of spline 
parameters 
Half-
Cauchy 
  Mu  Scale 
  0.0  5.0 
Mean (bounds) 
Undefined (0.2, 127) 
kg , for g in [men 
, women] 
Parameter determining 
relative hazard of 
smoking relapse in 
former smokers 
Beta    Alpha  Beta 
  1.0  1.0 
 
Mean (bounds) 
0.5 (0.025, 0.975) 269 
 
Table 4.3 Prior distributions for model parameters (continued) 
Name  Description 
Functional 
form  Parameterization 
Implied mean and 
95% bounds 
ρgj for j in [n, s, 
e, f0-f9] and g 
in [men , 
women] 
Mortality rate ratios for 
smoking behavior 
compartments 
Gamma          MEN               WOMEN 
  Scale  Rate   Scale Rate 
ρs  1303  589  2740  1207 
ρe  1468  488  1001  318 
ρf0  307  111  821  351 
ρf1  307  111  821  351 
ρf2  510  192  1185  587 
ρf3  796  369  1470  653 
ρf4  2105  1058  4023  2260 
ρf5  2105  1058  4023  2260 
ρf6  2489  1778  3255  2485 
ρf7  2287  1874  2905  2641 
ρf8  1536  1397  2012  1954 
ρf9  1088  1078  909  909 
                MEN                    WOMEN 
  Mean (bounds)   Mean (bounds) 
  2.21 (2.09, 2.33)  2.27 (2.19, 2.36) 
  3.01 (2.86, 3.17)  3.14 (2.95, 3.34) 
  2.77 (2.47, 3.09)  2.34 (2.18, 2.50) 
  2.77 (2.47, 3.09)  2.34 (2.18, 2.50) 
  2.65 (2.42, 2.89)  2.02 (1.91, 2.14) 
  2.16 (2.01, 2.31)  2.25 (2.14, 2.37) 
  1.99 (1.91, 2.08)  1.78 (1.73, 1.84) 
  1.99 (1.91, 2.08)  1.78 (1.73, 1.84) 
  1.40 (1.35, 1.46)  1.31 (1.27, 1.36) 
  1.22 (1.17, 1.27)  1.10 (1.06, 1.14) 
  1.10 (1.05, 1.16)  1.03 (0.99, 1.08) 
  1.01 (0.95, 1.07)  1.00 (0.94, 1.07) 
 
4.2.6.2.  Likelihood function 
The survey data, weighted and summarized into total counts for each age, sex, quarter, state, and 
smoking category (as described in Section 4.2.5.1) were used to create likelihood functions for the 
modeled distribution of the population across smoking behavior categories. Likelihood functions 
were constructed for each age, sex, quarter, and state for which data were available, with each 
individual likelihood function summarizing the distribution of surveyed individuals across smoking 270 
 
behavior categories in a given age/sex/year/state subgroup. A generalized multinomial likelihood11 
was used, and constant terms of the log-likelihood dropped to allow more efficient computation. 
The functional form for this log-likelihood is shown below, for modeled outcomes      , given 
survey data       . 
   (     |      )   ∑   (     
  )        
 
       [36] 
In this equation   represents modeled outcomes produced by a parameter set θ (i.e.,  ( )    ), 
     
   represents the observed count in smoking behavior category j for the model subgroup with 
age a, time t, sex g and state i, and      
   represents the fraction of the cohort in compartment j, for 
that same subgroup, as estimated by the model. Separate log-likelihoods were constructed for the 
different data sources described in Section 4.2.5.1, with      describing the distribution across 
current smoking compartments (4 categories: N ,S, E and the sum of F0 to F9),       describing the 
distribution of former smokers by time since quitting according to the BRFSS question format used 
before 2000 (four categories: F0, F1+F2, F3+F4, and the sum of F5 to F9), and       describing the 
distribution of former smokers by time since quitting according to the BRFSS question format used 
from 2000 onwards (four categories: F0, F1+F2, F3, and the sum of F4 to F9). All these separate 
likelihoods were assumed to be independent, conditional on a given set of parameter values. As a 
parameter set defines a unique value for every model outcome, the overall log-likelihood for a 
                                                             
11 The conventional multinomial likelihood is restricted to positive integers. However, following survey 
weighting adjustment (Section 4.2.5.1) the data for this analysis included fractions, and consequently the 
likelihood needed to be defined for all positive real numbers. The likelihood used here represents a 
generalization of the standard Multinomial likelihood, though the functional form of the log-likelihood is 
identical to the log-likelihood of the conventional multinomial once constant terms have been dropped. 271 
 
particular parameter set was calculated as the sum across the three likelihoods for all 
age/time/state subgroups (note: as parameters are estimated separately for men and women, no 
single likelihood was constructed across both sexes). 
   (  |   )   ∑ ∑ ∑ ∑     (     |      )                                                  [37] 
4.2.6.3.  Computation 
The posterior parameter distribution was estimated using a modified IMIS algorithm [47]. As 
originally described, this algorithm begins by drawing a first sample from the prior distribution. 
Next, further samples are drawn from new importance sampling distributions iteratively created to 
explore under-sampled regions of the parameter space. This iterative creation of and sampling 
from new importance sampling distributions proceeds until the total set of samples approximates 
the posterior distribution of interest. This approach is particularly useful in situations where it is 
expected that parameters will be correlated in the posterior (these situations have been found to 
impair the performance of conventional Markov chain Monte Carlo approaches).  
One complication for the present analysis is that the prior is sufficiently diffuse, and the likelihood 
sufficiently strong, that a random sample from the prior (even if very large) is unlikely to fall 
anywhere near the mode of the posterior distribution. While the published version of IMIS would 
likely still succeed in this situation, the algorithm would be very slow in locating and sampling from 
the region of maximum likelihood. In order to more efficiently operationalize this analysis, a 
revised version of IMIS was implemented whereby an optimization approach was used to identify 
the mode of the posterior, and then the curvature of the log-posterior at this location used to create 
the variance-covariance matrix of the first importance sampling distribution (which is based on a 272 
 
multivariate Normal)12. Using an optimization approach to identify the posterior mode brings with 
it a risk of being caught in a local maximum, and for this reason the optimization was undertaken 
10 times, each time initialized at randomly chosen starting points. A new importance sampling 
distribution was constructed around the results of each of these optimizations, similar to the ‘IMIS-
opt’ approach described by Raftery and Bao [47]. The analysis then followed the IMIS algorithm as 
originally described, until stable estimates were achieved. Figure 4.4 presents the progression of 
estimates for the mean and posterior intervals of key parameters and outcomes for successive 
iterations of the IMIS algorithm, and shows no systematic change in mean estimates or width of 
posterior intervals. Study results were estimated following 27 iterations of the algorithm. 
 
   
                                                             
12 This revision to the IMIS algorithm was discussed with Adrian Raftery (Adrian Raftery, personal 
communication, October 27th 2013). 273 
 
 
Figure 4.4. Estimates for the mean and posterior intervals of major parameters and 
outcomes for successive iterations of the IMIS algorithm 
 
4.2.7.  Validation 
Smoking behaviors and health outcomes estimated by the fitted model were compared to a number 
of independent datasets to ensure the analysis was consistent with available evidence. The 
distribution of smoking behavior at different time points, as estimated by the model, was compared 
to estimates derived from the Current Population Survey’s Tobacco Use Supplement (TUS-CPS). The 
TUS-CPS is an occasional supplement to Current Population Survey that uses a similar question 
format to the BRFSS to collect information on cigarette smoking and related behaviors [52]. 
Population demographics, describing the distribution of the population by state, age, and sex, were 
compared to estimates from the 2010 U.S. Census [53]. Modeled estimates for total mortality were 
compared to 2010 estimates produced by the CDC’s National Vital Statistics System [54].  
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4.2.8.  Comparison of alternative cigarette tax scenarios 
Two cigarette taxation scenarios were compared using the fitted model. These comparisons were 
used to estimate the causal effect of recent state cigarette tax increases during the period of the 
analysis 1996-2013.  
Status quo scenario (taxes introduced): under this scenario, cigarette taxes in each state follow their 
historical trajectory, as described previously. 
Counterfactual scenario (no new state taxes since 1996): under this counterfactual scenario, state 
cigarette taxes are assumes to stay at their 1996 values. 
In both scenarios, all other determinants of smoking behavior were assumed to follow their 
historical trajectory, as in the main analysis. This implicitly assumes that changes in state cigarette 
taxes have no causal effect on other determinants of smoking behavior. The comparison of these 
two scenarios allows us to explore the implications of increased state cigarette taxes on smoking 
behavior, total cigarette consumption13, and health outcomes realized between 1996 and 2013. 
Additional analyses were undertaken to explore the long-term consequences of these tax changes 
beyond 2013. In the first of these analyses the scenarios described above were extended for a 
further four decades into the future, to understand how the changes in smoking behavior and 
                                                             
13 Calculations for total consumption required estimates of the relative cigarette consumption of Some Day vs. 
Every Day smokers. For this analysis it was assumed that Some Day smokers consumed cigarettes at 0.21 the 
rate of Every Day smokers, based on the distributions of smoking intensity for Some Day and Every Day 
smokers described in Table 4.1. Estimates of total consumption were robust to different assumptions about 
this value. It was also assumed that any change in smoking intensity induced by tax changes was fully 
captured by the change in distribution between Some Day vs. Every Day smokers. 275 
 
health outcomes associated with the 1996-2013 tax increases would accumulate over time. For 
these analyses, background mortality rates and birth rates were assumed to follow long-term 
secular trends based on published estimates [40,43] , but all other variables were held at their final 
values, and taxes were fixed at their 2013 values under both status quo and counterfactual 
scenarios. As these assumptions require the value of the tax to be fixed in 2013 constant dollars, 
these scenarios can be thought of as including ongoing minor tax increases to offset the effect of 
inflation in reducing the real value of the tax.  
A third set of analyses calculated life expectancy for the 2013 birth cohort if exposed to status quo 
or counterfactual tax scenarios. For this analysis, a single birth cohort was simulated from birth to 
death under the two competing tax regimes, with all other variables, including background 
mortality rates, held constant at their 2013 values (consistent with conventional approaches for 
estimating life expectancy). Taxes were assumed fixed in 2013 constant dollars, so that the real 
value is maintained over the lifetime. 
In addition to producing estimates of behavioral and health outcomes, analyses were undertaken to 
estimate the price elasticity of demand associated with the tax increases. For a particular 
comparison, these elasticity estimates (e) were calculated as shown in equation 38, where A 
indicates the status quo scenario (taxes introduced), B represents the counterfactual scenario 
(taxes fixed at 1996 levels), Q represents total national consumption estimated under a particular 
scenario, and P represents average pack price for that same scenario.     was taken to be the 2013 
average national pack price net of sales taxes14, equal to $5.74 [55], and    was taken to be 
                                                             
14 For the large majority of states, sales taxes on tobacco products are applied as a percentage mark-up after 
state and federal excise taxes have been added, thus the absolute price increase produced by an increase in 276 
 
    minus the national average value for state cigarette taxes imposed since 1996, which was 
calculated as part of the analysis. This approach assumes that cigarette prices, net of taxes, are not 
affected by the taxes themselves. In sensitivity analyses we tested an alternate assumption whereby 
the pass-through of taxes to prices was assumed to be 1.11 [56]. 
   
     
  
   
     
  
  [38] 
Elasticity estimates were calculated for men and women as well as overall, for the period 1996-
2013. Long-run elasticity estimates were also calculated in the context of the life-expectancy 
analysis, given that decreased smoking initiation behavior, if this were a consequence of tax 
increases, would have a delayed effect on overall smoking prevalence. These delayed effects could 
result in long-run elasticity estimates that are greater than those estimated over a shorter time 
horizon. 
 
  Results  4.3.
4.3.1.  Fit to BRFSS smoking data 
Figures 4.5-4.7 compare modeled estimates of smoking behavior to the BRFSS data used to fit the 
model. Figure 4.5 presents the distribution of the national population across smoking behaviors as 
a function of age, year, and sex, and there appears to be a close calibration to the BRFSS data. Figure 
                                                                                                                                                                                                    
 
the excise tax will be larger than the tax itself. For this reason the correct elasticity estimates are obtained by 
removing the sales taxes before the elasticities are computed. 277 
 
4.6 further disaggregates these estimates by state, and while in general there is close agreement 
with the survey data, there are a small number of states where modeled estimates diverge from 
those estimated directly from the BRFSS data. For example, for men in both Georgia and Oklahoma, 
the model fails to capture observed reductions in the fraction of never smokers, as well as increases 
in former smokers, over the early 2000s. These discrepancies indicate that estimated outcomes for 
some individual states should be interpreted with caution, but in general the fit to the observed 
distribution across smoking behaviors is good. 
Figure 4.7 disaggregates former smokers by time since quitting. Again, the fit to the survey data 
appears acceptable, despite changes in question format following 2000, and despite survey data on 
time since quitting not being collected in 2006-2008.   278 
 
 
Figure 4.5. Comparison of modeled estimates to BRFSS data on smoking behavior, as a 
function of age and year* 
* Size of plotting symbols for survey data proportional to square root sample size. Estimates shown for 
2013 Q1 represent data collected during the 2012 round of the BRFSS. 279 
 
 
Figure 4.6. Comparison of modeled estimates to BRFSS data on smoking behavior, as a 
function of year and state* 
* Size of plotting symbols for survey data proportional to square root sample size. Survey data and 
modeled estimates for state populations aged ≥18 years old.   280 
 
 
Figure 4.7. Comparison of modeled estimates to BRFSS data on time since quitting in former 
smokers, as a function of age and year* 
* Size of plotting symbols for survey data proportional to square root sample size. Survey question 
categorization for time since quitting revised in 2001 (indicated by different plotting color). Questions 
on time since quitting not asked 2006-2008. Estimates shown for 2013 Q1 represent data collected 
during the 2012 round of the BRFSS. 281 
 
4.3.2.  Validation 
Model projections were compared to several independent data sources. To validate smoking 
prevalence estimates, modeled results were compared to data from successive rounds of the TUS-
CPS collected between 1999 and 2011. These comparisons are shown in Figure 4.8. Compared to 
the model estimates, the TUS-CPS data generally show a similar prevalence of current smoking 
behavior, but a lower prevalence of individuals reporting former smoking, with this difference 
made up by an increased fraction reporting having never smoked. The differences between 
modeled estimates and TUS-CPS data are largest in younger age groups, where the modeled 
estimates predict higher fractions of both current and former smokers. Given the close fit of model 
estimates to the BRFSS data, these discrepancies likely reflect differences associated with the 
instruments or the sampling frame of these two surveys.  
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Figure 4.8. Comparison of modeled estimates to independent data on smoking prevalence 
from the Tobacco Use Supplement of the Current Population Survey* 
* Unless stated otherwise, modeled estimates and TUS-CPS estimates relate to the population ≥15 years 
old (top and middle panels). 
 
Figure 4.9 presents modeled estimates of all cause mortality in 2010 for discrete age groups, as 
compared to estimates for the same quantities published by the CDC’s National Vital Statistics 
System. This comparison examines whether the approach used to create smoking-deleted life 
tables, then reintroducing smoking-attributable mortality risks, correctly recovers all-cause 
mortality rates. There is almost exact agreement with the published estimates for all age groups.  283 
 
 
Figure 4.9. All-cause mortality rate for 2010 by age group and sex, comparing modeled 
estimates to published estimates from the CDC’s National Vital Statistics System 
 
Figure 4.10 compares modeled estimates of the size and distribution of the U.S. population with 
results from the 2010 census. For a number of age categories the modeled estimates appear to 
underestimate both female and male population size (top panel). This is particularly true between 
ages 15 and 40. This difference may be due to immigration, which is not captured in the model. The 
size of this difference, with modeled estimates of the total population on 2010 approximately 20 
million smaller than census estimates, is consistent with Census Bureau estimates of immigration 
over this period (though at the high end). In addition, the age groups with the greatest discrepancy 
match the age groups with the highest observed levels of immigration [57]. A consequence of 
underestimating total population size is that absolute estimates of health outcomes reported in 
later sections of the results (e.g., life-years saved, or deaths averted) will represent a modest 
underestimate. The discrepancy between modeled population and census estimates is not evenly 
distributed by state, with Arizona, Florida and Nevada exhibiting the greatest relative difference. 284 
 
 
Figure 4.10. Population size and distribution in 2010, comparing modeled estimates to data 
from the 2010 U.S. Census 
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4.3.3.  Parameter estimates for predictors of smoking behavior 
Table 4.4 presents posterior mean and 95% posterior intervals for predictors of smoking behavior. 
Coefficients on the TX variable are generally negative, suggesting a reduction in smoking behavior 
associated with cigarette tax increases. However, the interpretation of these values for overall 
smoking prevalence and health outcomes is difficult, as smoking behavior will be determined by 
multiple parameters simultaneously. Whether changes in individual predictors are associated with 
meaningful and or statistically significant changes in smoking behavior and health outcomes is best 
understood by comparing results when the model is re-estimated under alternative taxation 
scenarios. These alternative scenarios are examined in Section 4.3.4. 
 
Table 4.4. Posterior mean values for predictors of smoking behavior* 
 
Risk of smoking initiation 
(nc) 
Probability of smoking every 
day, in current smokers 
(P(E|C)) 
Probability of continued 
smoking, among current 
smokers (P(C|F0C))) 
 
Men  Women  Men  Women  Men  Women 
Unemployment rate 
(UN) 
-0.010 
(-0.028,0.003) 
-0.061 
(-0.069,-0.054) 
-0.025 
(-0.029,-0.020) 
-0.020 
(-0.024,-0.017) 
0.025 
(0.019,0.029) 
0.028 
(0.025,0.030) 
Smoking restricted 
in workplaces (WP) 
-0.015 
(-0.057,0.057) 
0.079 
(0.036,0.116) 
-0.017 
(-0.046,0.056) 
-0.013 
(-0.028,-0.002) 
0.038 
(0.017,0.053) 
0.050 
(0.040,0.063) 
Smoking restricted 
in restaurant (RST) 
-0.241 
(-0.271,-0.197) 
-0.242 
(-0.272,-0.210) 
0.075 
(0.056,0.095) 
0.059 
(0.046,0.071) 
0.015 
(0.005,0.028) 
-0.012 
(-0.020,-0.003) 
Smoking restricted 
in bars (BAR) 
0.076 
(0.016,0.125) 
-0.211 
(-0.256,-0.168) 
-0.022 
(-0.081,0.017) 
-0.034 
(-0.050,-0.019) 
-0.043 
(-0.078,0.003) 
-0.061 
(-0.074,-0.047) 
Anti-smoking 
sentiment (ANTI) 
-0.538 
(-0.649,-0.447) 
-0.651 
(-0.698,-0.608) 
-0.759 
(-0.804,-0.706) 
-0.679 
(-0.716,-0.635) 
-0.240 
(-0.285,-0.193) 
-0.258 
(-0.284,-0.236) 
State cigarette tax 
increases (TX) 
-0.056 
(-0.088,-0.032) 
0.007 
(-0.015,0.028) 
-0.020 
(-0.037,-0.006) 
-0.025 
(-0.035,-0.014) 
-0.055 
(-0.065,-0.045) 
-0.066 
(-0.072,-0.060) 
* Parameters for age and year splines not shown. Coefficients for continuous variables 
(unemployment rate, anti-smoking sentiment, cigarette tax) transformed to original scale. 95% 
posterior intervals shown in parentheses. 286 
 
4.3.4.  Causal effects of state cigarette taxes introduced over the period 1995-2013 
4.3.4.1.  Effect on smoking behavior 
All results in this section compare the recent history of increasing state cigarette taxes with a 
counterfactual scenario in which these taxes were not introduced (i.e., all state cigarette taxes 
assumed to remain at their 1996 values). By comparing the incremental differences between these 
two scenarios we can understand the change in smoking behavior and other outcomes caused by 
the increase in state cigarette taxes since 1996.  
Figure 4.11 shows the change in various measures of smoking behavior due to the recent tax 
increases, averaged at a national level. The cigarette taxes are seen to have caused improvements in 
most indicators of smoking behavior. By the end of 2012, male smoking prevalence in the United 
States is estimated to be 4.0% (3.3, 4.8)15 lower that it would have been in the absence of the state 
cigarette taxes introduced since 1996, and female smoking prevalence is estimated to be 2.8% (1.8, 
3.5) lower. Other indicators of smoking behavior—the fraction of the population who have ever 
smoked and the fraction of smokers who smoke every day—exhibit smaller changes. In the case of 
women, the fraction of the population who have ever smoked is estimated to rise, though the 
posterior 95% interval for this outcome includes zero. These various changes contribute to total 
cigarette consumption, which is estimated to be 4.4% (3.7, 5.3) lower among men and 3.6% (2.6, 
4.2) lower among women (for a 4.0% (3.3, 4.6) overall reduction) by the end of 2012 compared to 
the counterfactual scenario that held taxes at their 1996 levels. 
   
                                                             
15 Values in parentheses represent equal-tailed 95% posterior intervals.  287 
 
 
Figure 4.11. Change in various measures of smoking behavior (national-average) due to 
increases in state cigarette taxes over the period 1996-2013* 
*All estimates are assessed in the total population, by sex. Reduction in every day smokers represents 
change in the fraction of current smokers who smoke every day.  
 
Figure 4.12 presents results for the reduction in smoking prevalence due to recent cigarette taxes 
broken down by state. The cigarette tax for each state, in nominal dollars, is also plotted for 
comparison. As can be seen, reductions in smoking prevalence accrue in proportion to the 
magnitude of tax increases for a given state, with these reductions spread over the years following 
the tax increase. These changes in smoking prevalence are marginally larger for men than for 
women, consistent with the results presented in Figure 4.11.  
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Figure 4.12. Reductions in state-level smoking prevalence due to increases in state cigarette 
taxes over the period 1996-2013* 
*All estimates are reported for the total population of each state, by sex.  
 
4.3.4.2.  Effect on population health outcomes 
Over the entire period 1996-2013, increases in state cigarette taxes are estimated to have reduced 
the total time spent smoking by 10.9 million (9.6, 12.4) person-years when summed nationally (6.3 
million (5.2, 7.4) years among men and 4.6 million (3.9, 5.3) year among women). Smoking 
predisposes individuals to a large number of health conditions that could lead to premature 
mortality, and reductions in smoking behavior are estimated to have produced improvements in 289 
 
health outcomes. Overall during the period 1996-2013, the increase in state cigarette taxes is 
estimated to have reduced the number of deaths by 14.4 thousand (9.9, 19.7) among men and 13.0 
thousand (9.9, 16.8) among for women, for a total of 27.4 thousand (21.8, 34.1) deaths averted. 
These reductions in mortality were associated with an extra 61 thousand (39, 85) years of life lived 
by men and an extra 58 thousand (44, 78) years of life lived by women, for a total of 119 thousand 
(92, 151) life-years saved. Figure 4.13 disaggregates the total change in person-years smoking, 
deaths averted, and life-years saved by age group. Though the major reductions in years spent 
smoking are estimated to accrue during ages 20-59 the impact on mortality is felt in later years, 
with most deaths averted between ages 60-79. The same pattern can be observed for the additional 
life-years lived due to the tax increases. 
 
 
Figure 4.13. Changes in major behavioral and health outcomes over 1996-2013 due to 
increase in state cigarette taxes, disaggregated by age group* 
* Figure compares a scenario in which state cigarette taxes follow their historical trajectory to a 
counterfactual scenario in which taxes are held constant at their 1996 values. 
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The results described above and in Figure 4.13 relate to the period 1996-2013. However, part of the 
benefits of the taxes introduced over this period will not be felt for many years, as tax-related 
changes in smoking initiation and cessation rates will take time to affect overall smoking 
prevalence, and subsequent changes in survival will be even further delayed. Figure 4.14 extends 
the analysis for an additional four decades into the future to understand how changes in smoking 
behavior and health outcomes might accumulate over a longer timeframe16. For each major 
outcome—reductions in years spent smoking, deaths averted, and life-years saved—the effect of 
the taxes increase in each successive decade. For estimates of the total years spent smoking, this 
increase slows over time, but the number of deaths averted increases approximately linearly until 
2030-2039, after which point the reduction in mortality tapers as those who avoided smoking-
related mortality begin to succumb to other ailments later in life. The number of life-years gained 
are estimated to increase with each successive decade, with over 6 million life-years saved over the 
next four decades compared to a scenario in which no new state cigarette taxes were introduce 
after 1996.  
                                                             
16 This analysis compares a scenario in which state cigarette taxes are held at their 1996 values for the entire 
projection period, to one in which state cigarette taxes follow their historical trajectory and then remain 
constant at their current value for the remaining projection period. Projected trends in births and background 
mortality are based on published estimates, and all other variables (e.g., unemployment rates) are held at 
their 2013 values. 291 
 
 
Figure 4.14. Projected changes in major behavioral and health outcomes over the next four 
decades due to increase in state cigarette taxes introduced between 1996 and 2013, by 
decade* 
* Figure compares a scenario in which state cigarette taxes follow their historical trajectory and then 
hold constant at 2013 values to a counterfactual scenario in which taxes are held constant at their 1996 
values. 
 
The long term improvement in health outcomes can also be understood through changes in lifetime 
smoking patterns and life expectancy. We projected lifetime smoking patterns and life expectancy 
for the 2013 national birth cohort under the assumption that the cohort would be exposed to state 
cigarette taxes in force at the beginning of 2013. We compared these values to estimates calculated 
under the counterfactual scenario where individuals are exposed to 1996 cigarette tax levels. With 
taxes at their 1996 levels, the average number of years spent smoking over the lifetime is 13.6 
(12.4, 15.0), and this value drops to 12.8 (11.8, 14.2) under the 2013 tax scenario. In combination 
with changes in smoking intensity, these reductions in years spent smoking are estimated to 
produce a 6.1% (4.5, 7.8) reduction in average lifetime cigarette consumption compared to the 
counterfactual scenario. The effect of these changes in smoking behavior is estimated to increased 
overall life expectancy from 78.7 (78.4, 79.0) years under the 1996 tax scenario to 78.9 (78.5, 79.1) 
years under the 2013 tax scenario, a gain in life expectancy equal to 2.0 (1.4, 2.7) months when 292 
 
averaged over the entire 2013 birth cohort, representing a total of 2.7 million (1.9, 3.6) extra life-
years lived. These life expectancy gains are predominantly due to greater survival at older ages, 
with 90% of the additional life-years lived being enjoyed by individuals over 60 years of age. These 
results are summarized in Table 4.5 for each sex, with men enjoying greater gains in life expectancy 
compared to women. 
Table 4.5. Changes in lifetime smoking behavior and life expectancy for the 2013 national 
birth cohort exposed to 1996 tax levels as compared to 2013 tax levels* 
    Outcomes calculated 
for 1996 state 
cigarette tax levels 
Outcomes calculated 
for 2013 state 
cigarette tax levels 
Incremental 
difference 
Average no. 
years spent 
smoking 
Men  12.9  (11.6, 14.2)  11.8  (10.7, 13.1)  -1.1  (-1.4,-0.8) 
Women  14.3  (12.4, 16.7)  13.9  (12.0, 16.5)  -0.4  (-0.7,-0.1) 
All  13.6  (12.4, 15.0)  12.8  (11.8, 14.2)  -0.8  (-1.0,-0.5) 
Life expectancy  Men  77.0  (76.6, 77.3)  77.2  (76.9, 77.5)  0.25  (0.18, 0.34) 
Women  80.5  (79.9, 80.9)  80.6  (79.9, 81.0)  0.09  (0.01,0.14) 
All  78.7  (78.4, 79.0)  78.9  (78.5, 79.1)  0.17  (0.11, 0.22) 
*Difference calculated as value from 2013 tax scenario minus value from 1996 tax scenario. 95% 
posterior intervals shown in parentheses. 
 
4.3.5.  Price elasticity of demand 
Estimates of the price elasticity of demand were estimated using two approaches. In the first 
approach, elasticities were calculated based on the price changes and behavioral outcomes 
estimated for the period 1996-2013. With this approach, the elasticity was estimated to be -0.18 (-
0.22, -0.15) for men and -0.14 (-0.16, -0.10) for women, producing an overall elasticity of -0.16 (-
0.18, -0.13). The second approach attempted to estimate long-run elasticities, given the delayed 
effect of changes in smoking initiation rates and quitting rates on overall cigarette consumption. 
These long-run elasticity estimates were calculated in the context of the life-expectancy analysis, 293 
 
comparing changes in price to predicted changes in lifetime cigarette consumption. Under this 
second approach, elasticity was estimated as -0.39 (-0.50, -0.30) for men, and -0.16 (-0.25, -0.06) for 
women, for an overall long-run elasticity of -0.27 (-0.35, -0.20). 
4.3.6.  Sensitivity analyses 
We tested the robustness of the results to changes in how the state cigarette tax variable was 
operationalized. In the main analysis this variable described tax increases from 1996 levels for each 
state. In a sensitivity analysis we revised this variable to represent the absolute state cigarette tax 
(i.e., not set to zero in 1996 for each state). The results of this sensitivity analysis were similar to 
those of the original analysis, though with major health outcomes (total deaths averted and life-
years saved) approximately 10-20% larger in the revised analysis. Table 4.6 compares main 
analysis and sensitivity analysis for a number of major outcomes. 
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Table 4.6. Comparison of parameter estimates and major outcomes from different 
approaches to operationalizing the effect of cigarette taxes on smoking behavior* 
  Men  Women 
 
Main 
analysis 
Sensitivity 
analysis  Difference 
Main 
analysis 
Sensitivity 
analysis  Difference 
Coefficient for tax effect on 
smoking initiation  -0.056  -0.080  -0.024  0.007  -0.022  -0.029 
Coefficient for tax effect on 
smoking intensity  -0.020  -0.024  -0.004  -0.025  -0.028  -0.003 
Coefficient for tax effect on 
smoking cessation  -0.055  -0.047  0.009  -0.066  -0.065  0.001 
Reduction in smoking 
prevalence (%) by end 2012 
due to taxes  4.00  4.12  0.12  2.86  3.43  0.57 
Reduction in ever smokers (%) 
by end 2012 due to taxes  0.74  1.05  0.30  -0.10  0.23  0.34 
Reduction in every day 
smokers (%) by end 2012 due 
to taxes  0.57  0.63  0.06  0.82  0.89  0.07 
Reduction in years spent 
smoking 1996-2013 due to 
taxes (millions)  6.3  6.3  0.0  4.6  5.1  0.5 
Reduction in total deaths 
1996-2013 due to taxes 
(thousands)  14.4  16.8  2.4  13.0  14.2  1.2 
Total life-years saved 1996-
2013 due to taxes (thousands)  60.6  72.2  11.6  58.4  63.7  5.3 
* For the main analysis, the state cigarette tax variable represented any increase in taxes from 1996 
levels in each state, in 2013 constant dollars. For the sensitivity analysis, the state cigarette tax variable 
represented the absolute value of state cigarette taxes, in 2013 constant dollars. Difference represents 
value from sensitivity analysis minus value from main analysis. 
 
We also assessed the robustness of results to alternative assumptions about future smoking 
patterns. In the analysis that projects results over the next four decades, assumptions must be made 
about secular trends in smoking behavior. In the main analysis it was assumed that all 
determinants of smoking behavior were fixed at their 2013 values. In sensitivity analyses we 295 
 
allowed the changes in background smoking behaviors (as operationalized through the splines for 
time) estimated over the period 1996-2013 to be extrapolated linearly in to the future. This 
alternate set of assumptions produces lower estimates for future smoking prevalence, consistent 
with historical trends. The future benefits of the 1996-2013 tax increases is also lower with these 
alternate assumptions, with the absolute reduction in life-years spent smoking (as shown in Figure 
4.14) reduced by 8% (6, 11), total deaths reduced by 14% (12, 17) and total life-years saved 
reduced by 9% (7, 10). 
Finally, we assessed the sensitivity of elasticity estimates to a different assumption about the pass-
through of taxes to prices. For the main analysis it was assumed that taxes would be passed through 
to prices one-to-one. In this sensitivity analysis we altered this assumption to assume a pass-
through of 1.11 (i.e., that a $1.00 increase in the tax would produce a $1.11 increase in the price), 
based on analyses of interstate cigarette price variation over the period 1960-1990 by Keeler et al. 
[56]. Under these revised assumptions elasticity estimates are reduced. For changes in cigarette 
consumption by 2013, elasticity is estimated as -0.16 (-0.19,-0.13) for men, -0.12 (-0.14, -0.09) for 
women and -0.14 (-0.16, -0.11) overall. For long-run changes in cigarette consumption (calculated 
over the lifetime of a single cohort), elasticity is estimated as -0.34 (-0.44,-0.27) for men, -0.14 (-
0.22, -0.05) for women and -0.24 (-0.30, -0.17) overall. For all of these individual results, the 
revised assumption produces a reduction in the magnitude of the elasticity estimate of 11-13% 
compared to the main analysis. 
 
 Discussion  4.4.
This analysis used a novel approach to estimate the causal effect of recent increases in state 
cigarette taxes on smoking behaviors. These effects were estimated in the context of a behavioral 296 
 
model that explicitly described the different processes contributing to overall smoking prevalence, 
allowing for separate effects of taxation on smoking initiation, smoking intensity, and smoking 
cessation. Based on data from 17 rounds of BRFSS survey data, the state cigarette taxes introduced 
over the period 1996-2013 were estimated to have produced a 4% drop in overall cigarette 
consumption, compared to a counterfactual scenario that assumed no changes in state taxes over 
this period, with these behavioral effects estimated to be slightly larger for men than for women. 
While other analyses have assessed the impact of state cigarette taxes on smoking behavior, the 
specific states and time periods involved differ. For this reason the magnitude of the behavioral 
effects assessed by this and other studies can best be compared in terms of the elasticities implied 
by the results. In our study, the elasticity of demand for all adults was estimated to be -0.16 based 
on estimated differences in cigarette consumption in 2013, and -0.27 over the long-run. These 
estimates are considerably lower than the conventional understanding of the price elasticity for 
cigarettes [9], with a meta-analysis of published estimates finding a median value of -0.4 for short-
run elasticity [10]. In contrast, the relative magnitude of the different elasticities we estimate 
conforms to expectations, with elasticity estimated to be of greater magnitude for men as compared 
to women17, and over the long-run as compared to the short-run.  
Our elasticity estimates can also be compared to the other recent studies that estimate tax effects 
from cross-state variation in taxes. Using 1991-2005 data from the Youth Risk Behavior Surveys, 
                                                             
17 Our results conflict with those of Stehr [24], who finds that women are nearly twice as responsive to 
cigarette taxes as men, arguing that conventional estimates are biased due to a failure to control for 
differences in the distribution of male and female smoking participation across states. Our analysis explicitly 
allows for these inter-state differences, suggesting that the surprising findings reported by Stehr may have 
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Carpenter and Cook [15] estimate elasticities that range from -0.56 to -0.25 for youth smokers18. In 
contrast, using 1992-2002 data from the National Education Longitudinal Study DeCicca et al. 
estimate elasticities for youth smoking that are both small and statistically insignificant (ranging 
from -0.11 to 0.08) [12]. Similarly, using data from the 1997 cohort of the National Longitudinal 
Survey of Youth, Nonnemaker and Farrelly find effects of cigarette taxes on youth smoking to be 
smaller than conventional estimates and sensitive to changes in specification [16]. While much of 
the published literature on inter-state variation focusses on youth smoking, DeCicca and McLeod 
estimate outcomes for older adults, finding elasticities that range from -0.3 to -0.2 using data from 
BRFSS rounds 2000-2005 [11]. In sum, the elasticities estimated from inter-state variation in 
cigarette excise taxes are general smaller than other estimates, and our findings are consistent with 
this trend.  
One feature of the relationship between state-level cigarette prices and purchasing behavior is the 
possibility for cross-border purchasing. It is possible that, in the face of differences in cigarette 
prices between abutting states, consumers respond to tax increases (and therefore price increases) 
in one state by moving cigarette purchasing to lower tax jurisdictions. If true, this effect would 
reduce the effect of cigarette taxes relative to a scenario in which consumers faced a common price, 
or a situation where taxes were raised across all jurisdictions (as would happen with changes in the 
federal tax). Recent work by DeCicca et al. investigated the magnitude of such cross-border 
purchases using data from the TUS-CPS, and concluded that cross-border purchases account for one 
quarter of the total reduction in purchases within a state following a price increase [21]. Stehr 
reaches a similar finding by comparing BRFSS data on smoking behaviors to state-level cigarette 
sales data [58]. As a consequence of cross-border purchasing, a naïve analysis of cigarette sales 
                                                             
18 For whom elasticities are thought to be higher than the general population [10]. 298 
 
would over-estimate total changes in consumption for a state that raises its cigarette tax. This is not 
a problem for our analysis and ones like it, which use data on reported behaviors and so should not 
be affected by this bias. However, the existence of cross-border purchasing as a result of price 
differentials implies that tax changes in one jurisdiction should affect smoking behaviors in other 
jurisdictions. Such spillover effects would undermine the stable-unit treatment value assumption 
(SUTVA) that underlies the causal identification strategy for studies such as ours. If a tax hike in one 
state not only increases cigarette prices in that state but also increases effective prices for smokers 
living in abutting states, then the true benefits of state-level cigarette tax increases will be larger 
than what is estimated in our analysis, and this provides one potential explanation for lower 
elasticity estimates derived from studies of variation between U.S. states. 
In addition to estimating tax-related changes in smoking behavior over the period 1996-2013, our 
analysis compared future trends in smoking behavior with taxes maintained at their 2013 levels to 
a counterfactual scenario that assumed no new taxes since 1996. The results of this analysis must 
be viewed as more speculative than the findings reported for the 1996-2013 period, as they depend 
on assumptions about future trends in smoking behavior. This analysis also assumes that the 
responsiveness to cigarette taxes observed in the study period will be maintained in the future. The 
major finding from this part of the analysis is that estimates of smoking prevalence in these two 
scenarios continue to diverge over time, such that the reduction in total years spent smoking for the 
10 year period 2020-2029 is more than double the 11 million reduction in years spent smoking 
estimated for the 17 years 1996-2013. These long-term effects are consistent with our findings of 
long-run elasticities that are higher than those estimated for the short-run. Despite the greater 
uncertainty associated with the long-term projections, it seems clear that the behavioral outcomes 
of cigarette tax changes will continue to increase for many years after taxes are introduced.  299 
 
The analytic model used for this study directly linked changes in current smoking behavior and 
smoking history to mortality risks. As a consequence of tax-related reductions in smoking behavior, 
our analysis estimated a mortality reduction of 27,000 deaths over the period 1996-2013, 
compared to a counterfactual scenario with no state tax increases since 1996. These survival gains 
were associated with 119,000 additional life-years lived over the same period, with these benefits 
mainly accruing to older adults. These mortality reductions are relatively modest, and when 
averaged over the 17 year period 1996-2013 represent less that 0.5% of the approximately 
400,000 annual deaths attributed to smoking in the United States [35]. Even more than the changes 
in smoking prevalence, the reductions in mortality and extra years of life lived because of tax 
increases are estimated to be substantially delayed following tax introduction. In the analysis 
where outcomes were estimated for future decades, comparing 2013 tax levels to 1996 levels, 
reductions in mortality for the 10 year period 2020-2029 are more than triple the 27,400 estimate 
for total deaths averted for the 17 years 1996-2013, and the number of extra life-years lived is nine 
times the 119,000 extra life-years lived for the 1996-2013 period. While the health benefits 
estimated by this study are more substantial if future years are taken into account, these aggregate 
outcomes are still dwarfed by contemporary estimates of the total benefits of tobacco control 
measures in the U.S. Evaluating the effects of tobacco control since the surgeon general’s report on 
smoking in 1964, Holford et al. estimate 157 million life-years saved by 2012 compared to a 
counterfactual with no tobacco control [59]. Our estimate for total life-years saved for the period 
1996-2049 represents 4% of this total, despite covering a longer period (54 years vs. 49 years) and 
a larger population due to population growth. Our estimates of life expectancy gains are similarly 
small in comparison, representing 10% of the 2.3 year life expectancy gain Holford et al. estimate 
for men and 5% of the 1.6 year life expectancy gain estimated for women. These comparisons 
reinforce the relatively modest reductions in smoking behavior we estimate to have resulted from 
recent state cigarette tax increases. 300 
 
This analysis has a number of limitations in addition to those mentioned already. A key assumption 
of the identification strategy is that controlling for state-level anti-smoking sentiment (and doing so 
using the index created by DeCicca et al. [12]) removes the relationship between this and other 
unmeasured factors that otherwise confound the observed relationship between the cigarette taxes 
that states impose and the smoking behavior of their residents. If this assumption does not hold, it 
is possible that our analysis will have over-estimated the effects of state cigarette taxes on smoking 
behavior, and that the effects estimated are not truly causal. Another assumption of our analysis is 
that the smoking behavior of a state’s residents does not meaningfully influence the level of anti-
smoking sentiment, and consequently the likelihood of further tobacco control legislation being 
introduced in the future. If there is a causal relationship between smoking behavior and anti-
smoking sentiment it is likely negative, with a reduction in the number of individuals smoking 
weakening opposition to tobacco control19. What is more certain is that stronger anti-smoking 
sentiment will raise the probability of future cigarette tax hikes and other controls. If both of these 
relationships exist as described it is possible that our analysis, by ignoring the potential positive 
feedback between anti-smoking sentiment, smoking behaviors and tobacco control policies, has 
mischaracterized (and potentially underestimated) the causal effects of cigarette taxes. On a more 
concrete issue, the fact that the demographic model appears to underestimate population growth 
due to immigration means that the estimates of absolute impact (e.g., total life-years saved) will be 
modestly lower than they would be otherwise, particularly for future projections.  
                                                             
19 A major argument for this relationship is self-interest, that people will be less willing to support price 
increases and other restrictions on an activity if they are directly affected by these controls. However, this is 
only speculation, and other arguments might predict a positive relationship.  301 
 
Another limitation of this analysis is that it ignores important differences in smoking behaviors 
observed for individuals of different race, education, and income level. These differences have been 
well documented, with smoking prevalence substantially lower for those with some higher 
education, for those above the federal poverty line, and for those identifying as Asian or Hispanic 
[60]. Instead, the analysis calculates population-level averages for each subgroup of state, sex, age, 
and birth cohort. While the results will be valid for the subgroup as a whole, they may obscure 
important differences not only in general smoking behaviors but also the responsiveness to 
cigarette tax increases. The decision to average over some important individual-level predictors of 
smoking behavior was driven by concerns about model complexity, however it is possible that 
future research will allow investigation of tax effects among additional population groups and these 
stratifications are available in the BRFSS data. However, one group not included in the BRFSS is 
individuals under 18 years of age. This group was modeled for the analysis, in order to obtain 
correct estimates of overall population-level effects. The BRFSS data does provide indirect 
information on smoking initiation rates during this period, in that the aggregate effect of smoking 
initiation during the early and mid teens will need to match the smoking prevalence levels observed 
among older teens once they are eligible for the survey. Consequently, while aggregate smoking 
initiation behavior estimated for those below 18 will be correct, our results provide little insight 
into the specific timing of smoking initiation for those younger than 18. 
Finally, it is possible that choices made in determining the structure of the model influence the 
outcomes that are reported. While we believe that the model equations represent a plausible 
formalization for how cigarette taxes might influence smoking behavior and subsequent mortality, 
we accept that other equally defensible model structures are possible. The use of a mechanistic 
model of smoking behavior and population demographics allows us to report detailed estimates of 
how outcomes are distributed across time, sex, age, and state. As far as we know, the use of a 
mechanistic model for identifying the causal effects of cigarette taxation is novel, and provides new 302 
 
opportunities for understanding the relationship between taxes, behaviors and health outcomes. In 
particular, by allowing the estimation of many different quantities that can be compared to 
empirical data, we believe this approach allows natural opportunities for model refinement (for 
example, the comparison of modeled life tables to published life tables (Figure 4.10) reveals that 
more accurate long-term projections may be obtained by allowing for immigration), and allows the 
identification of misspecifications when simulated results don’t match real world data.  
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